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1 Introduction 
Diabetes mellitus has become a global concern, with over 240 million people 
suffering from this disease (IDF 2009h). The increasing prevalence of diabetes 
mellitus, severe diabetic complications, premature mortality and enormous 
economic costs are a serious socio-economic burden (Wild et al. 2004; Roglic 
et al. 2005). 
In the recent years, it was demonstrated that long-term high blood glucose 
concentrations cause oxidative stress (Robertson 2004). Chronical 
hyperglycaemia and oxidative stress result in reduced insulin action, disturbed 
β-cell function and increased β-cell apoptosis, and are involved in the 
development of long-term diabetic complications (Kaiser et al. 2003; Brownlee 
2005; Houstis et al. 2006). Studies in autopsies showed that the relative β-cell 
volume and β-cell mass in type 2 diabetic patients are significantly reduced 
compared to non-diabetics (Sakuraba et al. 2002; Butler et al. 2003). 
Animal models are essential tools to investigate the pathogenesis of diabetes 
mellitus and diabetic complications. Especially mutant mice exhibiting defined 
point mutations in diabetes-relevant genes are valuable model systems and 
are a complementary approach to so far established transgenic and knockout 
models, since the same mutations may be found in diabetic patients. Munich 
Ins2C95S and Akita mutant mice exhibit point mutations in the Ins2 gene, 
leading to the loss of the intrachain and interchain disulfide bond of insulin 2, 
respectively (Wang et al. 1999; Herbach et al. 2007). Male Munich Ins2C95S 
mutant mice exhibit a progressive diabetic phenotype, characterised by severe 
hyperglycaemia, insulin resistance, disturbed insulin secretion and profoundly 
decreased β-cell mass. Female mutant mice show a milder form of diabetes 
compared to male mutants and preserved β-cell mass, probably due to 
antioxidative effects of female sexual hormones, especially estrogen (Katalinic 
et al. 2005; Le May et al. 2006). 
Akita mice exhibit a similar diabetic phenotype as Munich Ins2C95S mutants. 
The pathogenesis of diabetes-development and β-cell loss has been 
extensively studied, and it could be demonstrated that misfolded (pro-)insulin 
accumulates in the β-cells of Akita mice, leading to ER stress and β-cell 
dysfunction (Izumi et al. 2003; Nozaki et al. 2004; Zuber et al. 2004). Several 
other studies demonstrated that misfolded and accumulated proteins can 
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induce ER stress and cell apoptosis (Xu et al. 2005; Scheuner and Kaufman 
2008).  
In the present study, the mechanisms of β-cell loss in male Munich Ins2C95S 
mutant mice were investigated. In order to examine the involvement of 
glucotoxicity and oxidative stress in the pathogenesis of β-cell destruction, one 
group of heterozygous mutant mice was treated with insulin-pellets. Placebo-
treated wild-type and mutant mice served as controls.  
The effects of insulin treatment, and therefore normalised blood glucose 
concentrations, on the endocrine pancreas were analysed using qualitative-
histological and quantitative-stereological methods. Additionally, various 
clinical parameters were determined to examine β-cell function and insulin 
sensivity, and oxidative stress in the serum and ER stress in isolated islets 
were investigated. 
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2 Literature review 
2.1 Diabetes mellitus 
2.1.1 Prevalence  
The prevalence of diabetes mellitus is increasing worldwide. About 30 million 
people were estimated to have suffered from this disease in 1985 (IDF 2009o; 
WHO 2009). In 2000, 171 million people were assumed to have diabetes (Wild 
et al. 2004; WHO 2009), and in 2007, 246 million people were affected by this 
disease, according to the IDF. Therefore, diabetes prevalence has increased 
by about 216 million in 22 years. This number is expected to increase further 
to 380 million by 2025 (IDF 2009h). Population growth, aging, urbanisation, 
unhealthy diet, obesity and sedentary lifestyle are main reasons for this 
increase in diabetes prevalence (Wild et al. 2004; IDF 2009h).  
The prevalence of diabetes is supposed to be equal in rural and urban areas 
in developed countries, whereas in developing countries, the prevalence in 
urban areas is at least 2-fold higher than in rural regions. The majority of 
people with diabetes is older than 64 years in developed countries and 45 - 64 
years of age in developing countries (Wild et al. 2004). Diabetes type 2 is the 
most common form of diabetes, which accounts for approximately 85 - 95% of 
all diabetes cases (IDF 2009o). The number of young people exhibiting type 2 
diabetes, but also of subjects suffering from type 1 diabetes is growing (IDF 
2009m, k).  
The increase in diabetes prevalence is higher in developing than in 
industrialised countries (Wild et al. 2004; IDF 2009i). The countries with the 
highest prevalence of diabetes are India, China and the USA (Wild et al. 
2004). 
2.1.2 Costs 
The economic burden of diabetes is enormous. The costs imply expenditures 
to prevent and treat diabetes, including diabetic complications, and loss of 
economic growth (IDF 2009d). 
The IDF estimated worldwide healthcare expenses of at least USD 232 billion 
for diabetes mellitus in 2007. If the prognosis of diabetes prevalence comes 
true, in 2025 these costs will rise over USD 302 billion (IDF 2009d). Health 
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care costs for diabetes range up to 15% of the annual healthcare budget 
(WHO 2009). The treatment of diabetic complications make up the largest part 
of the healthcare costs (IDF 2009n).  
Indirect costs of diabetes based on lost production caused by disability and 
mortality are estimated to be much higher than direct healthcare costs (IDF 
2009d; WHO 2009). 
2.1.3 Definition, description, classification and diagnosis of diabetes 
mellitus 
An appropriate definition and description, an uniform and functional 
classification as well as useful diagnostic criteria are essential for 
epidemiological and clinical research and clinical management, in order to 
reduce the morbidity and mortality associated with diabetes. In May 1995, an 
international expert committee, working under the sponsorship of the 
American Diabetes Association (ADA) – The expert committee on the 
diagnosis and classification of diabetes mellitus – was created to revise the old 
terminology and classification of diabetes, which was mainly based on the type 
of pharmacological treatment. In their report, diabetes is classified according 
to its aetiology and/or pathogenesis. Recommendations for diagnosing and 
screening this disease are given (The expert committee on the diagnosis and 
classification of diabetes mellitus 2002). 
2.1.3.1 Definition and description 
Diabetes mellitus is a group of different aetiological and clinical metabolic 
disorders. It is primarily defined by hyperglycaemia resulting from insulin 
resistance, disturbed insulin secretion, or both (ADA 2006). 
Marked hyperglycaemia causes typical symptoms like polyuria, polydipsia and 
weight loss. Some patients show polyphagia, blurred vision, retarded growth 
and increased susceptibility to distinct infections (ADA 2006). Uncontrolled 
hyperglycaemia can cause the two most common acute, live-threatening 
complications, diabetic ketoacidosis (DKA) and hyperglycaemic hyperosmolar 
syndrome (HHS) (Umpierrez et al. 2002; ADA 2006). 
Chronically elevated blood glucose levels are associated with the development 
of long-term complications like cardiovascular disease (CVD), nephropathy, 
retinopathy and neuropathy (ADA 2006; IDF 2009e). CVD is the major cause 
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of death in diabetes and includes angina, myocardial infarction, stroke, 
congestive heart failure and peripheral artery disease (IDF 2009b). Diabetic 
nephropathy results in renal failure and is the most common single cause of 
end stage kidney disease (IDF 2009f). Moreover, macular oedema and 
retinopathy can cause blindness in diabetic patients (IDF 2009j). 
Gastrointestinal and genitourinary dysfunction due to autonomic neuropathy is 
another complication of chronic hyperglycaemia. Loss of feeling, numbness or 
pain of different characters are caused by peripheral neuropathy, which can 
lead to Charcot joints. Peripheral neuropathy and/or peripheral artery disease 
are frequent reasons for foot ulcers and amputations in diabetics (ADA 2006; 
IDF 2009g, a). 
2.1.3.2 Classification 
According to the developing knowledge of this multifactorial disease, the 
classification for diabetes was revised several times. 
The first generally accepted systematic classification was published by the 
National Diabetes Data Group (NDDG) in 1979 (The expert committee on the 
diagnosis and classification of diabetes mellitus 2002). Based mainly on the 
treatment, diabetes was divided into four groups, insulin-dependent diabetes 
mellitus (IDDM, type 1 diabetes), non-insulin dependent diabetes mellitus 
(NIDDM, type 2 diabetes), gestational diabetes mellitus and diabetes 
associated with other conditions and syndromes (Porte et al. 2002). The 
classification was supported and developed further by the WHO expert 
committee on diabetes and later by the WHO study group on diabetes 
mellitus. They distinguished between five groups: IDDM, NIDDM, malnutrition-
related diabetes, gestational diabetes and other types. The expert committee 
on the diagnosis and classification of diabetes mellitus revised the 
NDDG/WHO classification in 1997. The classification was constantly adapted 
to the current knowledge by The expert committee on the diagnosis and 
classification of diabetes mellitus and published by the ADA (The expert 
committee on the diagnosis and classification of diabetes mellitus 2002, 2003, 
ADA 2006). Diabetes is now divided into different groups with regard to its 
aetiology and/or pathogenesis (Table 2.1). 
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 Aetiologic classification of diabetes mellitus 
I Type 1 
diabetes 
A Immune-mediated   
  B Idiopathic  
II Type 2 
diabetes 
   
III Other specific 
types 
A Genetic defects of β-cell 
function 
e.g. MODY1 - 6 
  B Genetic defects of insulin 
action 
e.g. Type A insulin 
resistance, Leprechaunism, 
Lipoatrophic diabetes 
  C Diseases of the exocrine 
pancreas 
e.g. Pancreatitis, Trauma, 
Pancreatectomy, Neoplasia, 
Cystis fibrosis 
  D Endocrinopathies e.g. Acromegaly, Cushing’s 
syndrome, Pheochromo-
cytoma, Hyperthyroidism 
  E Drug- or chemical-
induced 
Vacor, Glucocorticoids, 
Diazoxide, β-adrenergic 
agonists, Thiazides 
  F Infections e.g. Congenital Rubella, 
Cytomegalovirus 
  G Uncommon forms of 
immune-mediated 
diabetes 
e.g. “Stiff-man” syndrome, 
Anti-insulin receptor 
antibodies 
  H Other genetic syndromes 
sometimes associated 
with diabetes 
e.g. Down’s syndrome, 
Wolfram’s syndrome, 
Myotonic dystrophy 
IV Gestational 
diabetes 
mellitus (GDM) 
   
Table 2.1 Aetiologic classification of diabetes mellitus (ADA 2006) 
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2.1.3.3 Diagnosis 
The criteria for the diagnosis of diabetes were revised by The expert 
committee on the diagnosis and classification of diabetes mellitus in 1997 and 
2003 (Lehmann and Spinas 2005). 
 
Three possibilities to diagnose diabetes exist (ADA 2006): 
1. Plasma glucose concentration ≥ 200 mg/dl at any time of the day, 
independent from the time of the last meal, plus classic symptoms 
(polyuria, polydipsia, unexplained weight loss) 
2. Fasting plasma glucose (FPG) ≥ 126 mg/dl; i.e. no caloric intake for at least 
8 hours 
3. Plasma glucose 2 hours after glucose challenge during an oral glucose 
tolerance test ≥ 200 mg/dl; glucose load contains the equivalent of 75 g 
anhydrous glucose dissolved in water 
 
Positive test results should be confirmed on a subsequent day, using one of 
the 3 methods (ADA 2006). This confirmation is mainly necessary for 
individuals without diabetic symptoms. Severe infections, trauma or stress can 
lead to transient hyperglycaemia in non-diabetics (Lehmann and Spinas 
2005). 
 
Some individuals present plasma glucose levels, which are abnormally 
elevated, but lower than in diabetic patients. The fasting plasma glucose is 
impaired (impaired fasting glucose (IFG)) when fasting glucose levels range 
from 100 - 125 mg/dl. In oral glucose tolerance tests, people suffer from an 
impaired glucose tolerance (IGT), when plasma glucose levels 2 hours after 
glucose challenge, are between 140 - 199 mg/dl (ADA 2006). The values for 
normal plasma glucose (NPG, after fasting for at least 8 hours) were reduced 
from 110 mg/dl to 100 mg/dl in 2003, mainly with regard to elevated 
cardiovascular risks in individuals with blood glucose levels over 100 mg/dl 
(The expert committee on the diagnosis and classification of diabetes mellitus 
2003; Lehmann and Spinas 2005). 
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2.2 Types of diabetes mellitus 
2.2.1 Diabetes type 1 
Diabetes type 1 accounts for 5 - 10 % of all diabetes cases.  
In the majority of type 1 diabetic patients, a cellular-mediated autoimmune 
response results in the destruction of pancreatic β-cells (immune-mediated 
diabetes, diabetes type 1A). Autoantibodies to islet cells (ICA), to glutamic 
acid decarboxylase (GAD65), to tyrosine phosphatases IA-2 and IA-2β or to 
insulin (IAA) can be detected (The expert committee on the diagnosis and 
classification of diabetes mellitus 2002; Al-Mutairi et al. 2007).  
Genetic and environmental factors contribute to the development of diabetes 
type 1. More than eighteen different chromosomal regions are associated with 
the susceptibility to diabetes type 1 in humans. Several genes which are 
located in the major histocompatibility complex region on chromosome 6p21 
play a leading role in the pathogenesis of this disease (Pociot and McDermott 
2002; Al-Mutairi et al. 2007). Environmental factors e.g. virus infections 
(Coxsackie B virus, Cytomegalovirus, Epstein-Barr virus, Rubella), proteins in 
bovine milk and chemicals were assumed to induce the generation of 
autoantibodies (Kukreja and Maclaren 1999; Spinas and Lehmann 2001; Al-
Mutairi et al. 2007).  
Predominantly children and adolescents suffer from diabetes type 1, but 
individuals at any age can be affected. The rate of β-cell destruction is 
normally more rapid in younger patients than in adults (ADA 2006). When 
hyperglycaemia is diagnosed, about 80% of the β-cells are already destroyed 
(Spinas and Lehmann 2001). The onset of this disease is often abrupt in 
children and adolescents, symptoms are severe (ketoacidosis) and the 
patients are insulin-dependent (Pociot and McDermott 2002). Others show 
modest fasting hyperglycaemia which possibly changes to severe 
hyperglycaemia and/or ketoacidosis due to stress or infections. In some 
individuals, primarily in adults, residual β-cell function prevents ketoacidosis 
for a long time until they finally become insulin-dependent (ADA 2006). 
In approximately 10 - 20% of type 1 diabetics, no autoantibodies can be found 
and the aetiology remains unknown (idiopathic diabetes, diabetes type 1B). 
These individuals are prone to ketoacidosis and show insulin deficiency to 
different extents. This form of diabetes demonstrates a strong inheritance (The 
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expert committee on the diagnosis and classification of diabetes mellitus 2002; 
Al-Mutairi et al. 2007). 
2.2.2 Diabetes type 2 
Diabetes type 2 is a heterogeneous disease, based on genetic and 
environmental factors (Ahren 2005; Lehmann and Spinas 2005). The genetic 
predisposition is stronger than in patients with diabetes type 1 (ADA 2006). 
Brothers and sisters of type 2 diabetic patients present a high prevalence of 
this disease. Monozygous twins have a similar risk to develop diabetes type 2 
(Lehmann and Spinas 2005). Lacking physical activity and high caloric diet 
cause obesity, which contributes to the development of diabetes (Lehmann 
and Spinas 2005; ADA 2006). It was shown that lifestyle interventions (healthy 
diet, exercise) and weight loss reduce the incidence of diabetes in persons 
with a high risk of getting diabetic (Resnick et al. 2000; Knowler et al. 2002).  
In type 2 diabetes, hyperglycaemia results from an imbalance between 
increased insulin requirement due to reduced insulin action, and insufficient 
insulin availability (Ahren 2005). Obesity, particularly an increased amount of 
visceral fatty tissue, is associated with insulin resistance (Lehmann and 
Spinas 2005). Initially, in most of the subjects with reduced insulin action, the 
enhanced insulin demand is compensated by increased insulin secretion. 
When insulin secretion becomes inadequate in relation to the elevated 
demand, individuals present hyperglycaemia. Reduced β-cell mass, 
diminished insulin gene expression, impaired insulin processing and/or 
disturbed insulin secretion can be the reasons for insufficient insulin secretion 
(Kaiser et al. 2003; Ahren 2005). It was reported that the reduction of the 
relative β-cell volume in diabetes type 2 is caused mainly by increased 
apoptosis, not by diminished β-cell replication or islet neogenesis (Butler et al. 
2003). Glucotoxicity, lipotoxicity and aggregation of islet amyloid in humans 
seem to contribute to disturbed β-cell function and apoptosis (Ahren 2005; 
Lehmann and Spinas 2005). 
Type 2 diabetes often remains undiagnosed for several years due to the 
gradual increase of plasma glucose concentrations (ADA 2006). Associated 
complications and elevated glucose concentrations in blood or urine in 
accidentally performed tests frequently lead to the diagnosis (IDF 2009l). 
Chronically elevated blood glucose levels are responsible for the development 
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of long-term complications (ADA 2006; IDF 2009c). Diabetes type 2 is often 
associated with the metabolic syndrome. People showing central adiposity, 
elevated concentrations of triglycerides, low HDL cholesterol levels or elevated 
blood pressure have an increased risk to be affected by diabetes type 2 
(Lorenzo et al. 2003). 
2.2.3 Monogenic forms of diabetes mellitus 
About 1 - 2% of all diabetes cases are monogenic. These monogenic forms 
can be classified into two major groups: Maturity-onset diabetes of the young 
(MODY) and neonatal diabetes mellitus (NDM) (Hattersley 2005; Edghill et al. 
2008). 
2.2.3.1 Maturity-onset diabetes of the young (MODY) 
Subtypes of MODY are the most common forms of monogenic diabetes 
(Edghill et al. 2008). Autosomal dominant mutations in six genes causing 
MODY1 - 6 have been identified. These genes are encoding for the glycolytic 
enzyme glucokinase (MODY2) or for the β-cell transcription factors hepatic 
nuclear factor 4α (HNF4α, MODY1), HNF1α (MODY3), HNF1β (MODY5), 
insulin promoter factor 1 (IPF1, MODY4) and NeuroD1 (MODY6). MODY3 is 
the most common form (Hattersley 2005; ADA 2006), whereas patients rarely 
exhibit MODY4, 5 or 6 (Edghill et al. 2008). In France, UK, Spain and 
Germany, unknown MODY loci (MODYX) account for 16 - 45% of individuals 
showing typical MODY symptoms (Costa et al. 2000). Recently, insulin gene 
(INS) mutations were found in 2 MODY patients, 1 tested negative for HNF1A 
and glucokinase gene (GCK) mutations, the other tested negative for HNF1A, 
HNF4A and GCK alterations (2.2.3.3 Mutations in the insulin gene). 
MODY is usually diagnosed in children and adolescents younger than 25 
years (Vaxillaire and Froguel 2006; Edghill et al. 2008). Mutations in GCK 
(MODY2) cause mild fasting hyperglycaemia directly after birth. Due to stable 
blood glucose concentrations, pharmacological treatment is not necessary in 
most MODY2 cases. Patients exhibiting mutations in the genes of β-cell 
transcription factors (MODY1, 3, 4, 5 and 6) are normoglycaemic at birth. Their 
blood glucose levels rise continuously, leading to the diagnosis of diabetes as 
adolescents or young adults. In order to avoid long-term complications these 
patients normally require pharmacological treatment (Hattersley 2005). 
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2.2.3.2 Neonatal diabetes mellitus (NDM) 
The incidence of neonatal diabetes mellitus is 1 : 215,000 (Stanik et al. 2007) 
to 1 : 500,000 newborns (Støy et al. 2007; Polak et al. 2008). It usually 
develops within the first weeks of life (< 6 months) (Støy et al. 2007; Aguilar-
Bryan and Bryan 2008) and is characterised by mild to severe hyperglycaemia 
combined with low levels of insulin (Polak et al. 2008). NDM can be transient 
(TNDM) or permanent (PNDM). TNDM accounts for over the half of all 
neonatal diabetes cases (Polak and Cavé 2007; Aguilar-Bryan and Bryan 
2008).  
Due to similar clinical symptoms (intrauterine growth retardation, failure to 
thrive, hyperglycaemia, ketoacidosis and reduced serum insulin levels) it can 
not be distinguished between TNDM and PNDM in the neonate.  
Most patients with TNDM recover within a few months, but possibly suffer from 
persistent glucose intolerance and/or may relapse to a permanent diabetic 
state in childhood or adulthood (Polak and Cavé 2007). The most common 
forms of TNDM are based on mutations in the imprinted region on 
chromosome 6q24, whereas aberrations in the KCNJ11 and ABCC8 gene are 
less frequent (Hattersley and Pearson 2006; Aguilar-Bryan and Bryan 2008). 
These genes encode for the protein subunits Kir6.2 and SUR1 of the ATP-
sensitive potassium channel in pancreatic β-cells, respectively (Støy et al. 
2007). 
In contrast to TNDM, the deficient insulin secretion remains in patients with 
PNDM (Polak and Cavé 2007). The most frequent causes of PNDM are 
activating mutations in the KCNJ11 and ABCC8 gene (Edghill et al. 2008). 
Mutations in INS were recently described to cause PNDM (2.2.3.3 Mutations in 
the insulin gene). Inactivating homozygous mutations in the glucokinase gene 
(GCK) have been found in patients with PNDM, but are rare (Njolstad et al. 
2001; Edghill et al. 2008). Mutations in several genes (IPF1, PTF1A, FOXP3, 
GLIS3, GLUT2, TCF2, EIF2AK3) can cause PNDM and show additional non-
pancreatic features (Støy et al. 2007; Edghill et al. 2008). 
2.2.3.3 Mutations in the insulin gene 
In a recent study 16 different INS mutations were found in 227 probands with 
diabetes onset before 1 year of age (Edghill et al. 2008). Ten of these 
mutations were also described in an earlier study involving 83 patients with 
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PNDM (Støy et al. 2007). In both studies, 94% of the individuals with PNDM 
were younger than 6 months. The median age of diagnosing PNDM in the 
probands with INS mutations was 9 (Støy et al. 2007) and 11 weeks (Edghill et 
al. 2008). Patients suffered from marked hyperglycaemia including polyuria 
and polydipsia, or ketoacidosis. C-peptide levels were low or undetectable. 
Due to reduced insulin secretion in utero, the birth weights were decreased. 
The symptoms of PNDM patients with INS mutations were similar to those with 
alterations in KCNJ11 and ABCC8, apart from individuals with INS mutations 
being older at time of diagnosis and not presenting neurological aberrations. 
Neither mutations in KCNJ11 or ABCC8 nor autoantibodies could be found in 
the probands with mutated INS (Støy et al. 2007; Edghill et al. 2008).  
The 16 detected INS mutations in PNDM patients affected highly conserved 
residues within preproinsulin. Nine of the mutations created an unpaired 
cysteine residue either by substituting an existent cysteine residue within a 
disulfide bond (A7-B7 (C96Y and C96S), B19-A20 (C43G)) or by introducing a 
new cysteine residue (F48C, R89C, G90C, S101C, Y103C, Y108C), probably 
leading to incorrect processing and conformational changes of the mutated 
preproinsulin (Støy et al. 2007; Edghill et al. 2008). Mutations not involving 
cysteine residues seem to be important for correct insulin processing and 
conformation, too. Replacement of glycine residues (G32S, G32R, G47V) and 
the H29D and L35P mutations are described to disturb correct disulfide pairing 
and folding of proinsulin (Hua et al. 2006; Nakagawa et al. 2006; Støy et al. 
2007; Edghill et al. 2008). Defective cleavage of the signal peptide could be 
caused by the A24D alteration, and possibly induces endoplasmic reticulum 
(ER) stress (Støy et al. 2007). The molecular consequences of the G84R 
mutation are not completely understood (Edghill et al. 2008). 
In over 80% of the PNDM probands, the INS mutation appeared de novo, 
comparable to mutations in the KCNJ11 gene (Støy et al. 2007; Edghill et al. 
2008). Edghill et al. (2008) analysed the frequency of different mutations in 
another cohort of 279 PNDM patients diagnosed before 6 months of age. 
Eighty-seven individuals (31%) exhibited a KCNJ11 mutation. The INS gene 
was altered in 33 (12%), the ABCC8 gene in 29 patients (10.4%). Mutations in 
the GCK (4%), the EIF2AK3 (8%) and the FOXP3 (1.4%) gene were less 
common. In 108 probands (39%) no mutation was detected (Edghill et al. 
2008). 
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Polak et al. (2008) investigated 38 PNDM patients from the French neonatal 
diabetes cohort and 1 child with non-autoimmune early infancy diabetes. 
Three already known INS mutations (A24D, R89C and C96Y) were found in 4 
probands (3 PNDM patients, the 1 child with early infancy diabetes). In two 
cases (R89C mutation carriers), an autosomal dominant inheritance was 
observed. Clinical symptoms were similar to those observed by other groups 
(Stoy et al. 2007; Edghill et al. 2008). Age at diagnosis of PNDM was 4.25 
years in the child compared to 0.8, 4.8 and 8.5 months in the other 3 patients 
(Polak et al. 2008).  
 
In contrast to INS mutations in the PNDM patients, which arose mainly de 
novo, the INS mutations of 2 MODY patients were inherited and the affected 
individuals demonstrated a less severe diabetic phenotype than PNDM 
patients (Edghill et al. 2008; Molven et al. 2008). One MODY patient, as well 
as his mother and the maternal grandmother exhibited an INS mutation (R6C) 
and demonstrated a MODY-like phenotype (Edghill et al. 2008). A R46Q 
mutation was found in another MODY proband, his diabetic father and a 
paternal aunt. The three family members demonstrated a relatively mild form 
of diabetes (Molven et al. 2008). Age of diagnosis was 15 years and older in 
the described MODY patients.  
Furthermore, a L68M (Edghill et al. 2008) and a C43G (Støy et al. 2007) 
mutation in INS were found in 2 patients with type 2 diabetes. Both patients 
were diagnosed with diabetes at 30 years of age. 
 
In earlier studies, different INS mutations have already been detected. 
Affected individuals showed a mild diabetic phenotype and/or glucose 
intolerance (V92L (Nanjo et al. 1986; Nanjo et al. 1987), F48S (Haneda et al. 
1983), F49L (Tager et al. 1979; Kwok et al. 1983)) In contrast to the later 
studies described above, insulin levels were increased in all patients. 
Biological activity of insulin was stated to be diminished, leading to reduced 
clearance by receptor-mediated endocytosis and therefore to 
hyperinsulinaemia. The mutations were inherited in an autosomal dominant 
manner (Steiner et al. 1990). 
INS mutations which lead to familial hyperproinsulinaemia (R89H (Collinet et 
al. 1998), R89L (Yano et al. 1992) and H34D (Chan et al. 1987; Oohashi et al. 
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1993)) are also inherited in an autosomal dominant manner (Steiner et al. 
1990; Collinet et al. 1998). Substitution of arginine on position 65 of proinsulin 
with histidine and leucine, respectively (R89H, R89L) impairs cleavage at the 
C-peptide-A-chain junction of proinsulin, resulting in the release of type II 
proinsulin intermediates, whereas the exchange of histidine on position 10 of 
proinsulin with aspartic acid (H34D) impairs conversion of proinsulin to insulin. 
The relative proportion of proinsulin and proinsulin intermediates, respectively 
in the circulation of affected individuals was approximately 4-fold increased 
compared to control subjects (Collinet et al. 1998). Familial hyperinsulinaemia 
was considered relatively asymptomatic in earlier studies (Steiner et al. 1990), 
but subsequent studies demonstrated that with increasing age affected 
subjects became glucose intolerant (Oohashi et al. 1993; Collinet et al. 1998). 
 
The different studies indicate that INS mutations exhibit a spectrum of different 
phenotypes, ranging from mild, hyperinsulinaemic and hyperproinsulinaemic 
diabetes (Steiner et al. 1990; Collinet et al. 1998), to MODY (Edghill et al. 
2008; Molven et al. 2008) and type 2 diabetes and finally to PNDM (Støy et al. 
2007; Edghill et al. 2008). 
2.3 Animal models of diabetes mellitus 
Animal models are essential tools in order to investigate the genetics and 
pathogenesis of human diseases and to test new therapeutic strategies. Due 
to the high reproduction, practical aspects and lower expenses compared to 
larger animals like pigs and dogs, mice and rats are appropriate model 
systems (Clee and Attie 2007; Srinivasan and Ramarao 2007). Additionally, 
mice exhibit similar genome organisation, biochemical pathways and 
physiology as humans (HelmholtzCenter 2009). 
Diabetes mellitus in animals can occur spontaneously or may be induced by 
treatment with chemicals (e.g. streptozotocin (STZ), alloxan (ALX)), dietary 
methods (e.g. high fat diet), surgical manipulations (e.g. partial 
pancreatectomy) or combinations. In the recent years, transgenic animals as 
well as general and tissue specific knockout models were generated, using 
reverse genetic techniques (Srinivasan and Ramarao 2007; Aigner et al. 
2008). It can be distinguished between obese models like ob/ob mouse, 
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Zucker fatty rat, uncoupling protein 1 (UCP1) knockout mouse, and non-obese 
models (e.g. Akita mutant mouse, GK rat, STZ- or ALX-treated rodents, partial 
pancreatectomised animals, IRS-1, IRS-2 or GLUT-4 knockout mice) 
(Srinivasan and Ramarao 2007). 
2.3.1 ENU mouse mutagenesis projects 
ENU mouse mutagenesis projects existed worldwide, e.g. in Australia 
(Canberra), Canada (Toronto), USA (Texas, Maine), Japan (Yokohama), 
England (Harwell) and Germany (Neuherberg) (Aigner et al. 2008). The 
Munich ENU Mouse Mutagenesis Screen also called Munich ENU Project 
(MEP) was founded in 1997. It produced and analysed novel mouse models, 
which are important for the investigation of the genetics and pathogenesis of 
inherited human diseases (HelmholtzCenter 2009). Mutant mice were created 
large scale, using systematic, phenotype-driven methods. Random mutations 
were induced by the chemical N-ethyl-N-nitrosourea (ENU) and clinical 
relevant phenotypes were identified by distinct screening protocols. After 
proving the inheritance of the aberrant phenotype and establishing the 
corresponding mouse lines, the mutation was determined by molecular genetic 
analysis (Aigner et al. 2008).  
2.3.1.1 ENU mutagenesis 
N-ethyl-N-nitrosourea (ENU), an alkylating agent, mainly causes point 
mutations and therefore allows detailed functional analysis of genes (Stanford 
et al. 2001). ENU demonstrates strong mutagenic action on spermatogonial 
stem cells (Russell et al. 1979), leading to 1 mutation in 100,000 – 2,500,000 
bp (Concepcion et al. 2004; Augustin et al. 2005; Keays et al. 2006; Aigner et 
al. 2008). From over 1,000 mutations per animal, only few demonstrate 
phenotypic consequences. The mutants produced by ENU may exhibit 
hypomorphic (partial loss of function), loss-of-function, dominant negative or 
gain-of-function alleles of the affected genes (Aigner et al. 2008). 
2.3.1.2 Munich ENU Mouse Mutagenesis Project 
The Munich ENU Mouse Mutagenesis Project was carried out on the inbred 
strain C3HeB/FeJ (C3H), which is diabetes resistant (Clee and Attie 2007). At 
the age of 10 weeks, male C3H mice were injected intraperitoneally with ENU 
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3 times in weekly intervals. After a sterility period, ENU-treated male mice 
were bred to wild-type C3H females. As identifying of recessive mutations 
needs more time and space compared to dominant mutations, only the 
dominant breeding scheme was performed since the end of 2004. The 
aberrant phenotypes in the G1 generation were identified, using the so called 
Munich protocol. This screening protocol was created to reveal congenital 
abnormalities of mutant phenotypes, including dysmorphological 
malformations and alterations in clinical chemistry, biochemistry, immunology, 
allergy and behaviour (Aigner et al. 2008; HelmholtzCenter 2009). G1 mice 
exhibiting an aberrant phenotype were mated to C3H wild-type mice in order 
to confirm the inheritance of the mutation in the G2 offspring. Phenotypic 
mutant mice were back-crossed with C3H wild-type mice for several 
generations to reduce the amount of non-causative mutations (Keays et al. 
2006; Aigner et al. 2008). To obtain an identical genetic background and to 
avoid interactions of the ENU-induced mutations in different genotypes, it is 
necessary to back-cross mutagenised mice with wild-type mice of the same 
inbred strain (Aigner et al. 2008). 
The chromosomal position of the causative mutation was determined by 
linkage analysis. Phenotypic mutant mice were mated with wild-type mice of a 
second inbred strain. After screening for the aberrant phenotype, hybrid 
mutant G1 offspring were back-crossed to wild-type mice of the second inbred 
strain. The G2 offspring were examined again for the abnormal phenotype and 
separated into mutant and non-mutant mice. DNA samples were analysed by 
genome-wide linkage analysis in order to determine the chromosomal location 
of the causative mutation. The accurate position of the mutation within the 
identified chromosomal section was examined by further linkage and 
candidate gene analysis, including sequencing methods (Aigner et al. 2008). 
2.3.1.3 Phenotype screen for hyperglycaemic mouse lines 
Between the distinct laboratories, many variables existed which could not be 
entirely standardised. Therefore, each ENU mouse mutagenesis project had to 
determine the physiological plasma glucose concentrations of the used inbred 
strain and the cut off level to define hyperglycaemic phenotypes. In the Munich 
ENU mouse mutagenesis project, the plasma glucose concentrations of 
overnight-fasted 3-month-old male and female C3H wild-type mice were 
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determined large scale (male: 128 mg/dl, female: 123 mg/dl). Mice exhibiting 
plasma glucose concentrations over 200 mg/dl in two measurements within a 
3-week interval were defined as hyperglycaemic.  
From 15,000 G1 offspring, 12 exhibited plasma glucose levels over 200 mg/dl. 
In 4 of these non-obese G1 variants (GLS001, GLS004, GLS006, GLS007) 
the inheritance was proven, and a new hyperglycaemic mouse line (GLS008) 
seems to bequeath the mutation, too (Aigner et al. 2008).  
GLS001 and GLS006 mutants demonstrate alterations in Gck and therefore 
provide suitable animal models for MODY2 (heterozygous Gck mutation) and 
PNDM (homozygous Gck mutation) (van Bürck et al. personal 
communication). GLS004 mice exhibit a mutation in the insulin 2 gene (Ins2). 
Alterations in the insulin gene can also be found in humans (e.g. PNDM 
patients; 2.2.3.2 Neonatal diabetes mellitus (NDM)), and another mouse 
model (2.3.3 The Akita mouse).  
Hyperglycaemic mouse lines, created in other ENU mouse mutagenesis 
projects, demonstrate dominant mutations in the Gck, the insulin receptor 
(Insr) and the single-minded homolog 1 (Sim1) gene. In other diabetic mouse 
strains, the causative mutation is still unknown (Aigner et al. 2008). 
2.3.2 The Munich Ins2C95S mutant mouse  
The Munich Ins2C95S mutant mouse was generated within the Munich ENU 
Mouse Mutagenesis project. The genetic background of this non-obese 
diabetic mouse model is the inbred strain C3HeB/FeJ (C3H) (Herbach et al. 
2007; Aigner et al. 2008). Mutant mice exhibit a T→A transversion at 
nucleotide position 1903 in exon 3 of the Ins2 gene on chromosome 7. This 
point mutation results in the amino acid exchange from cysteine to serine at 
position 95 of preproinsulin (C95S), which leads to the loss of the A6-A11 
intrachain disulfide bond.  
The mutation is inherited in an autosomal dominant manner and exhibits 
complete phenotypic penetrance corresponding to the sign test after Dixon 
and Mood (Herbach et al. 2007). 
2.3.2.1 Heterozygous mutant mice 
At the age of 3 and 6 months, male heterozygous Munich Ins2C95S mutant 
mice exhibited significantly lower fasted body weights than male wild-type 
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mice, whereas female mutant and wild-type mice showed similar body 
weights. 
From 1 month of age onwards, fasted and 1.5 h postprandial blood glucose 
levels of male and female mutants were significantly higher than those of sex- 
and age-matched littermate controls. Fasted blood glucose levels of male 
mutant mice deteriorated with age, reaching nearly 400 mg/dl. Female 
mutants featured a mild diabetic phenotype with fasted blood glucose levels 
lower than 200 mg/dl. 
During oral glucose tolerance tests (OGTT) at the age of 1, 3 and 6 months, 
mutant mice of both genders exhibited significantly elevated blood glucose 
concentrations versus wild-type mice.  
At the age of 1 month, male and female mutant mice demonstrated slightly, 
but significantly reduced serum insulin levels 10 minutes after glucose 
challenge compared to age and sex-matched controls, whereas the insulin 
concentration 10 minutes after glucose challenge was largely decreased in 3- 
and 6-month-old mutants compared to age- and sex-matched wild-type-mice. 
However, no differences concerning the fasted and 1.5 h postprandial serum 
insulin levels were detected between mutants of both genders and their sex-
matched controls.  
Male and female mutant mice demonstrated a significantly lower pancreatic 
insulin content than sex-matched wild-type mice at the age of 3 and 6 months, 
whereas the insulin content in the pancreas of female mutant mice was 
significantly higher than that of male mutants.  
The HOMA of β-cell function index of 1-, 3-, and 6-month-old mutants of both 
genders was significantly reduced.  
In contrast to female mutant mice, male mutants exhibited a significantly 
higher HOMA of insulin resistance index than wild-type mice at the age of 3 
and 6 months. Four-month-old male mutant mice featured a smaller decrease 
in blood glucose levels 10 minutes after insulin injection compared to male 
wild-type mice. These findings indicate a reduced insulin sensitivity in male 
mutants at the age of 3 months and older versus male wild-type mice. 
The exocrine pancreas of 6-month-old mutant mice exhibited no gross 
morphological or histopathological changes, and no evidence of insulitis was 
found in the endocrine pancreas. Immunostaining for insulin and glucagon 
showed a disturbed islet structure: The amount of glucagon producing α-cells 
- 18 - 
was increased and non-β-cells were distributed over the islet profile. Islets of 
wild-type mice presented a typical murine structure, with few non-β-cells 
bordering a core of insulin-expressing cells. In addition, the staining intensity 
of insulin-positive cells in mutants was very weak compared to wild-type mice 
(Herbach et al. 2007). However, the described alterations were more distinct in 
male mutant mice compared to female mutants (Herbach et al. personal 
communication). 
The total islet volume, the total β-cell volume as well as the volume density of 
β-cells in the islets were significantly decreased in male, but not in female 
mutant mice compared to sex-matched wild-type mice. The volume density of 
α-cells was elevated in mutants of both genders versus wild-type animals, 
whereas only male mutant mice exhibited a significantly higher volume density 
and total volume of somatostatin expressing δ- and pancreatic polypeptide 
positive PP-cells than male wild-type mice. 
Transmission electron microscopy of β-cells of 6-month-old mutant mice 
featured several ultrastructural alterations. In male mutant mice, very few 
small insulin secretory granules were found, in contrast to wild-type mice. The 
mitochondria appeared to be swollen, the rough endoplasmic reticulum to be 
dilated as compared to male wild-type mice. Myelin figures as well as 
cytoplasmic vacuolisation were detected. In female mutants, these alterations 
were less distinct compared to male mutant mice, in particular, female mutant 
mice demonstrated more secretory granules compared to male mutants, but 
less than female wild-type mice.  
There were no signs of apoptosis such as chromatin condensation or 
apoptotic bodies (Herbach et al. 2007). 
Additional quantitative-stereological analysis of pancreata at the age of 3 
months revealed that the total β-cell volume of male mutants was only slightly, 
but not significantly reduced compared to age- and sex-matched wild-type 
mice (Herbach et al. personal communication).  
 
In conclusion, male and female heterozygous Munich Ins2C95S mutant mice 
develop diabetes mellitus. Male mutants exhibit a progressive diabetic 
phenotype with severe hyperglycaemia, insulin resistance and profound 
reduction of β-cell mass, whereas female mutants demonstrate a mild and 
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stable diabetic phenotype, no signs of insulin resistance and unaltered β-cell 
mass. 
2.3.2.2 Homozygous mutant mice 
Homozygous Munich Ins2C95S mutant mice were phenotypically unsuspicious 
until the age of 18 days, when glucosuria was detected. At the age of 21 days, 
homozygous male and female mutants suffered from severely elevated blood 
glucose levels of approximately 400 mg/dl. The body weight was reduced 
versus wild-type mice at the age of 28 days, and further decreased until time 
of death. Male and female homozygous mutant mice died at a mean age of 46 
and 52 days, respectively (Herbach et al. 2007). 
2.3.3 The Akita mouse 
The Akita mouse line arose from a spontaneous point mutation in a female 
C57BL/6 mouse (Yoshioka et al. 1997). The mutation is inherited by an 
autosomal dominant mode. A stable mouse line was established by breeding 
male heterozygous mutants with female wild-type C57BL/6J (B6) mice. The 
Akita mouse shows a G→A transversion at nucleotide position 1907 in exon 3 
of the Ins2 gene on chromosome 7. Therefore, the cysteine on position 96 in 
the A chain of preproinsulin 2 is substituted by tyrosine (C96Y), which results 
in the loss of the A7-B7 interchain disulfide bond of insulin 2 (Wang et al. 
1999). 
In humans with PNDM, the identical mutation has been found in the INS gene 
(2.2.3.2 Neonatal diabetes mellitus (NDM)). 
2.3.3.1 Heterozygous mutant mice 
At the age of 4 weeks, male and female Akita mice presented significantly 
higher randomly fed blood glucose concentrations compared to sex- and age-
matched B6 control mice (male: ~270 mg/dl vs. ~145 mg/dl; female: ~220 
mg/dl vs. ~160 mg/d). In male mutants, blood glucose levels increased until 
the age of 9 weeks and remained relatively stable afterwards (approximately 
550 - 600 mg/dl). In female mutants, blood glucose concentrations were lower 
than in male mutants (< 330 mg/dl).  
The body weight of female mutant and wild-type mice was similar during the 
investigation period. Up to an age of 18 weeks, no differences in body weight 
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between male mutant and wild-type mice were detected. Afterwards male 
mutants demonstrated no further weight gain and lost body weight from 30 
weeks of age onwards. The 50% survival rate of male mutants was less than 
half that of sex-matched wild-type mice, whereas the life expectancy of female 
mutant and wild-type mice was similar (Yoshioka et al. 1997). 
The randomly fed plasma insulin levels of 7-week-old male and female 
mutants were significantly lower than those of sex- matched wild-type mice 
(male: 193 ± 51 pmol/l vs. 471 ± 73 pmol/l; female: 248 ± 82 pmol/l vs. 379 ± 
78 pmol/l) (Yoshioka et al. 1997).  
At 2 weeks of age, the insulin content in the pancreas of Akita mice was 
approximately half as high than that of wild-type mice (178 ± 2 vs. 361 ± 2 
pmol/pancreas), whereas the glucagon content was similar in both genotypes 
(approximately 330 pmol/pancreas) (Kayo and Koizumi 1998). The insulin 
content in the pancreas of 8-week-old Akita mice was approximately 1/6 to 1/5 
of that of wild-type mice (Oyadomari et al. 2002b).  
In contrast to the reduced pancreatic insulin content, transcription of both Ins1 
and Ins2 in isolated islets of 8- to 12-week-old Akita mice was barely altered. 
Total insulin mRNA levels in isolated islets of Akita mice were slightly reduced 
compared to wild-type mice, representing 85 - 90% of the total insulin mRNA 
of wild-type mice. In the islets of wild-type and mutant mice, around 25% of the 
transcripts accounted for Ins1 and 75% for Ins2. The mutated and the wild-
type Ins2 alleles in the islets of mutant mice were transcribed in similar 
amounts (Wang et al. 1999). In contrast, Oyadomari et al. reported that insulin 
mRNA levels in the pancreas of 3-, 6- and 9- week old heterozygous mutant 
mice were higher than those of wild-type mice, probably in order to 
compensate for defective insulin secretion (Oyadomari et al. 2002b).  
In pancreas sections of 4-, 10-, 20- and 30-week-old mice, immunostained for 
glucagon and insulin, no signs of inflammation were detected. The relative 
areas (%) of islets in the pancreas of male and female mutants were similar to 
those of age- and sex-matched wild-type mice, irrespective of age at sampling. 
At the age of 4 weeks, male and female mutant mice showed a significantly 
lower proportion of insulin-positive cells in the islets than sex-matched wild-
type mice (male: 20.7 ± 4.7% vs. 71.2 ± 2.2%; female: 45.9 ± 2.7% vs. 83.1 ± 
3.1%), whereas the proportion of glucagon-positive cells was similar in male 
mutant and wild-type mice (approximately 25%). In 30-week-old male mutants, 
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the proportion of insulin positive-cells was decreased to 9.1%, whereas it 
remained stable in female mutants and wild-type mice of both genders.  
Immunofluorescence analyses using anti-insulin and anti-C-peptide 
antibodies, revealed a remarkably weaker staining intensity in most β-cells of 
8- to 12-week-old mutants compared to age- and sex-matched wild-type mice. 
Since the insulin-autoantibody only detects the wild-type and not the mutated 
insulin, the reduced insulin-staining intensity in mutant β-cells indicates a 
reduction of wild-type insulin, the reduced C-peptide staining intensity a 
reduction of wild-type and mutant proinsulin (Wang et al. 1999). 
The amount of TUNEL-positive cells in the islets of 13-week-old mutants was 
very low, but slightly increased compared to wild-type mice (0.47 vs. 0.15 
TUNEL-positive cells per islet) (Izumi et al. 2003). 
 
Electron microscopic analysis showed that the cytoplasm of β-cells of 4- to 18-
week-old wild-type mice is loaded with dense-core secretory granules (Wang 
et al. 1999; Izumi et al. 2003). The average volume and the volume density of 
secretory granules of mutant mice were severely reduced versus wild-type 
mice (Zuber et al. 2004). In addition, earlier studies stated that the number of 
secretory granules was diminished in Akita mice versus control mice (Wang et 
al. 1999; Izumi et al. 2003), however, the numerical volume density of 
secretory granules was not altered (Zuber et al. 2004). The lumina of ER-like 
organelles distended progressively with age. In older mice, enlarged 
lysosomes were detected and mitochondria were often swollen and exhibited 
disrupted crests (Izumi et al. 2003). Morphometric analysis and quantitative 
immunogold labelling of the pancreas of 8- to 12-week-old mice showed that 
proinsulin accumulates mainly in the pre-Golgi intermediates of β-cells of 
mutant mice. In β-cells of mutants, the volume density of transitional ER was 
increased 2.8-fold and that of pre-Golgi intermediates 4.5- to 5.8-fold 
compared to control mice (Zuber et al. 2004). Immunogold labelling for  
C-peptide demonstrated that the distribution of proinsulin was different in wild-
type and mutant mice: C-peptide immunoreactivity in the pre-Golgi 
intermediates of mutant mice accounted for 40% as compared to 20% in wild-
type mice. In addition, mutants showed reduced C-peptide immunoreactivity in 
the secretory granules versus wild-type mice (43% vs. 80%). These findings 
indicate that proinsulin accumulates in the pre-Golgi intermediates of Akita 
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mice (Zuber et al. 2004). The studies of Wang et al. (1999) showed similar 
results: Insulin and C-peptide immunogold labeling in wild-type mice was 
mainly detected in the secretory granules of β-cells, whereas mutant mice 
exhibited weak labelling intensity in the secretory granules (Wang et al. 1999). 
No signs of apoptosis like nuclear chromatin condensation or fragmentation 
were detected in the β-cells of mutant and wild-type mice (Izumi et al. 2003). 
 
In in vitro studies, using isolated islets of 4-week-old male mutant mice, a 
disturbed insulin secretion after incubation with 27.5 mM glucose compared to 
wild-type mice was shown (Yoshioka et al. 1997). An impaired insulin 
secretion was also detected in insulinoma cells, expressing one mutant 
Ins2C96Y allele (Nozaki et al. 2004).  
2.3.3.2 Homozygous mutant mice 
At day of birth, homozygous Akita mice demonstrated slightly elevated blood 
glucose levels and reduced body weight compared to heterozygous mutant 
and wild-type mice. Blood glucose concentrations rose rapidly, reaching 
approximately 450 mg/dl at the age of 14 days. The insulin content in the 
pancreas was severely reduced compared to wild-type mice at birth (15.6 vs. 
114.6 pmol/pancreas) and further decreased to 3.9 pmol/pancreas at the age 
of 14 days (Kayo and Koizumi 1998). 
The relative area (%) of islets in pancreas sections of 1- and 14-day-old 
homozygous mutants was less than half of that in heterozygous mutants and 
wild-type mice. The proportion of insulin-positive cells in the islets was only 
about 11%, whereas the proportion of glucagon-positive cells in the islets was 
largely increased, accounting for 51% and 41% at the age of 1 and 14 days, 
respectively. Electron microscopy of the pancreas of 14-day-old mice showed 
a decreased density of secretory granules, increased amount of ER and 
swollen mitochondria (Kayo and Koizumi 1998). 
2.3.3.3 ER stress in the Akita mouse 
It was demonstrated that the mutant proinsulin in the β-cells of Akita mice has 
an increased hydrophobicity compared to wild-type proinsulin. Therefore, 
mutant proinsulin tends to aggregate more easily than wild-type proinsulin, 
due to hydrophobic interactions between molecules. Furthermore, the free 
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cysteine residue on B7 of proinsulin can lead to incorrect disulfide bond 
formation, and the loss of the A7-B7 disulfide bond results in a reduced 
stability of mutant compared to wild-type proinsulin (Yoshinaga et al. 2005). 
Accumulation of misfolded (pro-)insulin was estimated to cause ER stress in 
the Akita mouse (Nozaki et al. 2004), which was evidenced in several studies 
(detailed information on ER stress is given in chapter 2.4 Endoplasmic 
reticulum stress (ER stress)): 
It was shown that the ER stress chaperone binding Ig protein (BiP), also called 
glucose regulated protein 78 (GRP78), was overexpressed in the pancreatic 
islets of 8- to 12-week-old mutants, and probably forms complexes with 
proinsulin (Wang et al. 1999). 
Allen et al. (2004) demonstrated that BiP and the ER-associated degradation 
(ERAD) components Hrd1 and SelIL were upregulated in the islets of Akita 
mice, and X-box binding protein 1 (XBP-1) splicing levels were elevated 
compared to wild-type mice. These findings led to the conclusion that the 
misfolded insulin is selectively ubiquitinated and degraded by a HRD1-
mediated ERAD pathway (Allen et al. 2004). 
In Ins2WT/C96Y insulinoma cells, the expression of the chaperones BiP/Grp78, 
Grp94 and oxygen-regulated protein 150 (ORP150) was induced in an ER 
stress response element (ERSE)-dependent mode. Furthermore it was shown 
that the levels of activating transcription factor 6 (ATF6) and spliced XBP-1 
were also increased in Ins2WT/C96Y insulinoma cells compared to in Ins2WT/WT 
insulinoma cells (Nozaki et al. 2004). 
Chop knockout mice expressing the mutant Ins2C96Y were created to 
investigate the involvement of C/EBP homologous protein (CHOP)/growth 
arrest and DNA damage 153 (GADD153) in the ER stress response of Akita 
mice. In 8-week-old Ins2C96Y/C96Y mice, the disruption of Chop had no influence 
on body weight, blood glucose concentration and pancreatic insulin content. In 
Ins2WT/C96Y Chop-/- mutants the onset of diabetes was delayed by 8 - 10 weeks 
compared to Ins2WT/C96Y Chop+/+ and Ins2WT/C96Y Chop-/+ mice. Additionally, it 
was demonstrated that the number of apoptotic cells in islets of 4-week-old 
Ins2WT/C96Y Chop-/- mice was significantly lower than in those of Ins2WT/C96Y 
Chop+/+ mice (Oyadomari et al. 2002b). 
Targeted disruption of the chaperone ORP150 aggravated the diabetic 
phenotype of Akita mice (Ins2WT/C96Y ORP150-/+ mice), whereas 
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overexpressing of the chaperone ORP150 improved insulin sensitivity in Akita 
mice (ORP150CAGIns2WT/C96Y mice) (Ozawa et al. 2005). 
 
In conclusion, these findings show that misfolded (pro-)insulin 2 aggregates 
and accumulates in the β-cells of Akita mice, which leads to the induction of 
the unfolded protein response (UPR), resulting in the activation of chaperones 
(e.g. BiP) and in the partial degradation of misfolded insulin via ER-associated 
degradation I (ERADI). The activation of CHOP in heterozygous Akita mice is 
involved in β-cell apoptosis and enforces the progression of diabetes mellitus 
in heterozygous Akita mice. 
2.3.4 Ins1 and Ins2 null mutant mice 
Insulin deficient (Ins1-/-, Ins2-/-) and single Ins1 or Ins2 knockout mice (Ins1-/-, 
Ins2+/+ and Ins1+/+, Ins2-/-) were created by disruption of Ins1 and/or Ins2 via 
gene targeting. For the creation of Ins2-/- mice, LacZ was inserted under the 
control of the Ins2 promoter for β-cell identification. The targeting vectors were 
transfected into D3 embryonic stem (ES) cells and recombinant D3 ES cells 
were used to create different male germ-line chimeras. Stable mouse lines 
were established by back-crossing male germ-line chimeras with female wild-
type C57BL/6J (B6) mice (Duvillie et al. 1997). 
The absence of insulin 1 and insulin 2 mRNA in the islets of single and double 
homozygous mice was proven via reverse transcriptase-PCR, the absence of 
C-peptide 1 and C-peptide 2 via immunohistochemistry (Duvillie et al. 1997; 
Leroux et al. 2001). 
2.3.4.1 Double homozygous null mutant mice 
The embryonic mortality of Ins1-/-, Ins2-/- mutant mice was not increased 
compared to wild-type and various heterozygous mutant mice. A growth-
retardation of 15 -20 % was already observed at day 18 of fetal life (Duvillie et 
al. 1997). At embryonic day 18.5 (E18.5) Ins1-/-, Ins2-/- showed similar blood 
glucose concentrations compared to Ins1-/-, Ins2-/+ mutants (56 ± 10 mg/dl vs. 
58 ± 12 mg/dl) (Duvillie et al. 2002). Soon after suckling, Ins1-/-, Ins2-/- mutants 
exhibited glucosuria and ketoacidosis. A few hours after birth, double 
homozygous mutants were around 20% lighter than wild-type and 
heterozygous mutant mice. Hepatomegaly and liver steatosis were observed. 
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The homozygous mutant pubs died at a mean age of 48 hours (Duvillie et al. 
1997).  
Ins1-/-, Ins2-/- mutant mice showed a significantly increased mean islet area 
from day E18.5 onwards compared to Ins1-/-, Ins2-/+ mutants and wild-type 
mice (Duvillie et al. 1997; Duvillie et al. 2002). The relative increase of mean 
islet size detected in Ins1-/-, Ins2-/- was probably due to a higher replication rate 
of endocrine cells within the existent islets. Additionally, the level of apoptosis 
was significantly lower in Ins1-/-, Ins2-/- compared to Ins1-/-, Ins2-/+ mutants at 
E18.5 and at birth (Duvillie et al. 2002). 
Most of the endocrine cells in the islets of all animal groups investigated were 
β-cells, as visualised by insulin immunohistochemistry or X-Gal staining 
(Duvillie et al. 1997; Duvillie et al. 2002). Morphometric analysis revealed that 
at E18.5 around 75% of the endocrine cells in the islets of Ins1-/-, Ins2-/- and 
Ins1-/-, Ins2-/+ mutants were β-cells, and 16 - 21% represented α-cells. Due to 
an increase of the mean islet area in the pancreas, both, the total estimated β-
cell and α-cell mass were increased in Ins1-/-, Ins2-/- as compared to Ins1-/-, 
Ins2-/+ and wild-type mice. The authors conclude that insulin may be a 
negative regulator of islet size in utero (Duvillie et al. 2002).  
The mRNA levels of pancreatic polypeptide and somatostatin of newborn  
Ins1-/-, Ins2-/- were severely reduced compared to wild-type mice (Duvillie et al. 
1997). 
2.3.4.2 Single homozygous null mutant mice 
It was demonstrated that compensatory mechanisms prevent single 
homozygous mutant mice from developing diabetes mellitus. Since insulin 2 is 
the major form of insulin in wild-type mice, the compensatory mechanisms 
were more pronounced in mice lacking Ins2 than in those lacking Ins1 (Leroux 
et al. 2001). 
Single homozygous null mutants for Ins1 (Ins1-/-, Ins2+/+) or Ins2 (Ins1+/+,  
Ins2-/-) were viable and fertile (Duvillie et al. 1997). Ins2-/- mice showed 
transient hyperglycaemia during the first week of life. From 1 week of age 
onwards, blood glucose concentrations of Ins1-/- and Ins2-/- mutants were 
similar to those of wild-type mice. Four- to 6-month-old Ins2-/- mice showed 
intraperitoneal glucose tolerance tests comparable to wild-type mice (Leroux 
et al. 2001).  
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In 2- to 4-month-old Ins2-/- mutants, the absence of insulin 2, which accounts 
for the major proportion of total insulin transcripts in the pancreas of wild-type 
mice, was compensated by a large increase in Ins1 transcripts. Ins2 
transcription levels of Ins1-/- mutants were comparable to those of wild-type 
mice.  
According to western blot analysis, Ins2-/- mutants seemed to exhibit a 
considerable higher insulin 1 expression in the pancreas than wild-type mice. 
In Ins1-/- mutants, the expression of insulin 2 appeared to be slightly increased 
compared to wild-type mice. 
Total insulin levels in the plasma and in the pancreas of 2- to 4-month-old wild-
type mice, Ins1-/- and Ins2-/- mutants were similar, demonstrating that the 
increased transcription of Ins1 in the pancreas of Ins2-/- mutants results in a 
quantitative compensation on the protein level (Leroux et al. 2001). 
At the age of 2 to 4 months, pancreatic sections immunostained for  
C-peptide 1, C-peptide 2, glucagon, somatostatin and pancreatic polypeptide 
exhibited normal islet morphology and unaltered distribution of the distinct 
endocrine cells in both single homozygous mutant mouse strains. In sections 
immunostained for insulin, the β-cell mass of Ins2-/- mutants was elevated 
almost 3-fold, in Ins1-/- mutants, β-cell mass was slightly but significantly 
increased as compared to wild-type mice (Leroux et al. 2001).  
 
The compensatory Ins1 transcription of Ins2 deficient β-cells was confirmed in 
in vitro studies with βIns2-/-lacZ cells. These cells showed largely elevated Ins1 
transcription levels and similar total insulin content compared to other murine 
β-cell lines, in which both Ins genes are functional. Additionally, a dose 
dependent elevation of insulin secretion after incubation of βIns2-/-lacZ cells in 
Krebs-Ringer secretion buffer with different glucose concentrations was 
observed (Leroux et al. 2003). 
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2.4 Endoplasmic reticulum stress (ER stress) 
2.4.1 The Endoplasmic reticulum 
The endoplasmic reticulum (ER) is a cell organelle which plays a crucial role in 
lipid and sterol synthesis, protein folding and post-translational modification. 
Additionally it serves as calcium store (Oyadomari et al. 2002a; Rajan et al. 
2007).  
Specific transport systems ensure that proteins are targeted to the 
endoplasmic reticulum. A signal recognition particle (SRP) binds to the signal 
sequence of a nascent protein as it emerges from the ribosome, which results 
in the formation of the SRP/ribosome-nascent-chain (RNC) complex. The 
SRP/RNC complex binds to the SRP-receptor of the ER membrane and the 
protein is translocated co- or sometimes post-translationally across the ER 
membrane via a channel mainly formed by the Sec61 protein (Walter and 
Johnson 1994; Römisch et al. 2003; Luirink and Sinning 2004). The SRP and 
SRP-receptor dissociate from each other and can enter the next targeting 
cycle. In most cases the signal sequence of the protein is cleaved by a signal 
peptidase on the luminal side of the ER membrane. In yeast also a SRP-
independent pathway was identified (Walter and Johnson 1994). 
The ER exhibits a calcium-rich and oxidative environment, essential for 
oxidative protein folding like disulfide bond formation and for post-translational 
modifications (Ma and Hendershot 2002; Xu et al. 2005). There exist several 
post-translational modifications such as acetylation, amidation, 
phosphorylation, sulfation, hydroxylation, glycosylation and disulfide bond 
formation. The most common form is glycosylation, which plays a crucial role 
for protein conformation, trafficking and function (Walsh and Jefferis 2006; 
Gabius (Ed.) 2009). Disulfide bond formation, catalysed by protein disulfide 
isomerases (PDI) and their relatives (Dsb proteins), is essential for folding, 
stability and function of proteins (Arolas et al. 2006). Lectins, e.g. the calnexin-
calreticulin cycle, protein foldases and molecular chaperones like binding Ig 
protein (BiP)/glucose regulated protein 78 (GRP78) and GRP94 are important 
for protein folding (Rajan et al. 2007).  
Properly folded proteins are transferred from the ER to the transitional ER, 
from there to the pre-Golgi intermediate, and finally to the Golgi apparatus. 
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COPII-coated vesicles derived from the transitional ER, mediate the 
anterograde trafficking from the ER to the Golgi apparatus, whereas COPI-
coated vesicles are essential for the retrograde transfer from the Golgi back to 
the ER (Fan et al. 2003; Lee et al. 2004).  
A so called “quality control” system in the ER ensures that only correctly 
folded, assembled and modified proteins are transported out of the ER, 
whereas most misfolded or unassembled proteins are retained and degraded 
(Ellgaard and Helenius 2001; Kincaid and Cooper 2007b).  
2.4.2 ER stress and the unfolded protein response (UPR) 
ER stress can be induced pharmacologically and by changes in the 
physiological environment (Ma and Hendershot 2002). Agents like 
thapsigargin, tunicamycin and dithiothreitol (DTT) are frequently used to 
activate ER stress in in vitro studies (Harding et al. 2000; Rutkowski et al. 
2006; Scheuner and Kaufman 2008). Mutations of ER chaperones, viral 
infections, metabolic disorders like glucose deprivation and 
hypercysteinaemia, aberrant Ca2+ regulation, hypoxia, changes in the redox 
status, misfolded proteins or an increased synthesis of client proteins can 
cause ER stress and induce the so called unfolded protein response (UPR) 
(Ma and Hendershot 2002; Rutkowski and Kaufman 2004; Scheuner and 
Kaufman 2008). The UPR recognises the accumulation of un- and misfolded 
proteins and activates target genes in the nucleus. These target genes have a 
consensus sequence in their promoters, the ER stress response element 
(ERSE), ERSE II and the unfolded protein response element (UPRE) 
(Oyadomari et al. 2002a; Yamamoto et al. 2004).  
At least 3 distinct mechanisms of the UPR exist to reduce ER stress and 
restore normal ER function. Transcriptional induction of ER chaperones like 
BiP, GRP94 and activation of enzymes like PDI facilitate protein folding. To 
avoid further accumulation of un- and misfolded proteins the translation of 
mRNA is attenuated by inactivation of eucaryotic initiation factor 2 alpha 
(eIF2α). Misfolded proteins are eliminated by ER-associated degradation 
(ERAD) (Oyadomari et al. 2002a; Shen et al. 2002; Laybutt et al. 2007). 
Soluble proteins are retrotranslocated to the cytosol and degraded by the 
ubiquitin-proteasome system (ubiquitin/proteasome ERAD; ERAD I). Another 
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ERAD system (autophagy/lysosome ERAD; ERAD II) was reported to degrade 
insoluble, aggregated proteins by autophagy (Fujita et al. 2007). 
When these 3 adaptive mechanisms don’t succeed in restoring normal ER 
function, severe and chronic ER stress causes apoptosis of the affected cell, 
the fourth ER stress response of the UPR (Oyadomari et al. 2002a; Liu and 
Kaufman 2003). 
2.4.2.1 Signal transduction 
The transmembrane proteins inositol requiring 1 (IRE1), double-stranded 
RNA-activated protein kinase (PKR) – like endoplasmic reticulum kinase 
(PERK) and activating transcription factor 6 (ATF6) transmit ER stress signals 
across the ER membrane (Rajan et al. 2007; Yamamoto et al. 2007). The 
chaperone BiP regulates the 3 stress transducers and therefore controls the 
expression of most ER stress target genes (Shen et al. 2002) (Figure 2.1). 
PERK and IRE1 are type-I-transmembrane serine/threonine protein kinases 
and exhibit limited homology in the amino acid sequences of the ER luminal 
domain (Liu et al. 2000). In the inactive state, the ER chaperone BiP forms a 
stable complex with the luminal domain of PERK and IRE1. ER stress induces 
the dissociation of BiP, which results in the oligomerisation of PERK and IRE1 
(Bertolotti et al. 2000). ATF6, a type II transmembrane protein, is also bound 
to BiP in its inactive state. Upon ER stress, BiP dissociates from ATF6, and 
ATF6 is translocated to the Golgi apparatus (Shen et al. 2002). 
PKR-like endoplasmic reticulum kinase (PERK) 
Oligomerised and autophosphorylated PERK phosphorylates eIF2α at serine 
51 of the α-subunit and the transcription factor Nrf2 (Oyadomari et al. 2002a; 
Cullinan et al. 2003). Phosphorylated eIF2α (PeIF2α) can not longer mediate 
the binding of the initiator Met-tRNA to the 43S ribosomal unit. Protein 
synthesis and thereby protein-folding load are reduced (Harding et al. 1999; 
Rajan et al. 2007). Although phosphorylation of eIF2α represses the 
translation of most mRNAs, it increases that of activating transcription factor 4 
(ATF4) (Vattem and Wek 2004; Rajan et al. 2007).  
ATF4 induces the transcription of chaperone BiP and transcription factor 
CHOP, the latter being involved in the regulation of apoptosis (2.4.2.2 
Apoptotic pathways) (Scheuner et al. 2001; Kojima et al. 2003; Scheuner and 
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Kaufman 2008). Furthermore, ATF4 activates genes which participate in 
amino acid transport, metabolism and assimilation, and those which are 
known to be induced by oxidative stress like heme oxygenase-1 (Hmox-1) and 
sequestosome-1/A170 (Sqsm1) (Harding et al. 2003). 
In the cytoplasm of unstressed cells, Nrf2 forms a complex with actin-binding 
protein Keap1. In response to ER stress, PERK induces the phosphorylation 
of Nrf2 and thereby the dissociation of Keap1. Nrf2 is translocated to the 
nucleus where it activates the transcription of genes involved in detoxification 
and antioxidant defence like phase II detoxifying enzymes, catalase, 
superoxide dismutase 1, γ-glutamylcysteine synthase and UDP-glucuronosyl-
transferase. Therefore Nrf2 plays an important role for cellular redox 
homeostasis and cell survival (Chan and Kan 1999; Chan et al. 2001; Cullinan 
et al. 2003). 
Inositol requiring 1 (IRE1) 
In mammalians two IRE1 proteins exist, IRE1α and IRE1β. IRE1α is broadly 
expressed, whereas IRE1β is gut-specific (Rajan et al. 2007; Yamamoto et al. 
2007). IRE1 contains serine/threonine kinase and cytoplasmic ribonuclease 
domains (Pirot 2007). Oligomerisation of IRE1 enables the 
autophosphorylation of IRE1 and the activation of its endoribonuclease 
activity. Activated IRE1 splices a small intron from the X-box binding protein-1 
(XBP-1) mRNA (Calfon et al. 2002; Lee et al. 2003). The cleaved XBP-1 
mRNA is translocated to the nucleus and induces transcription of ER resident 
chaperones, ERAD and other components of the quality control system, 
including EDEM, Derlin 1-3, and HRD1, RAMP4, PDI-P5, p58IPK, Erdj4 (Lee 
et al. 2003; Rajan et al. 2007).  
The involvement of XBP-1 in the activation of CHOP is controversially 
discussed. It was stated that cleaved XBP-1 binds to ERSE and induces 
CHOP transcription in a NF-Y dependent manner (Oyadomari and Mori 2003), 
whereas in XBP-1-/- mouse embryo fibroblasts (MEF) the induction of CHOP 
was not or only slightly impaired (Lee et al. 2003). 
IRE1 causes rapid degradation of a specific subset of mRNAs, independ from 
XBP-1, and therefore reduces the intracellular protein load (Hollien and 
Weissman 2006). 
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Furthermore, IRE1 is involved in ER stress-mediated apoptosis by activating 
c-Jun NH2 terminal kinases (JNK) and nuclear factor-κB (NF-κB) (2.4.2.2 
Apoptotic pathways). 
Activating transcription factor 6 (ATF6) 
ATF6α and ATF6β are expressed ubiquitously in mammalian cells (Yamamoto 
et al. 2007). Experiments with distinct knockout mice and mouse embryo 
fibroblasts (MEF) demonstrated that ATF6β is less important concerning the 
ER stress response than ATF6α (Lee et al. 2003; Yamamoto et al. 2007). The 
dissociation of BiP from ATF6 results in the unveiling of Golgi localisation 
signals (GLS) on ATF6. ATF6 is then translocated from the ER to the Golgi, 
where it is cleaved by site-1 and site-2 protease (S1P, S2P). The cleaved 
cytosolic fragment of ATF6 dissociates to the nucleus to activate ER stress 
target genes, encoding chaperones such as BiP, GRP94 and PDI-like folding 
enzyme P5 and Erp61 (Shen et al. 2002; Yamamoto et al. 2007). 
In in vitro studies, ATF6 was unable to bind to UPRE, in contrast to XBP-1 
(Lee et al. 2003; Yamamoto et al. 2007). However, it was stated that ATF6 can 
heterodimerise with cleaved XBP-1 from the IRE1-XBP-1 pathway in order to 
bind to UPRE and activate ERAD components like EDEM and HRD1. The 
IRE1-XBP-1 heterodimer had an 8-fold higher affinity to the UPRE than the 
XBP-1 homodimer (Yamamoto et al. 2007).  
ATF6 seems to be marginally, if at all, involved in the activation of CHOP (Ma 
et al. 2002; Okada et al. 2002; Lee et al. 2003; Yamamoto et al. 2007). 
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 Figure 2.1 ER stress signal transduction 
In the inactive state, the transmembrane proteins PERK, IRE1 and ATF6 form stable 
complexes with the chaperone BiP. Upon ER stress, BiP dissociates from PERK, IRE1 and 
ATF6, which results in the activation of PERK, IRE1 and ATF6. Homodimerised and 
autophosphorylated PERK phosphorylates eIF2α and Nrf2. Phosphorylated eIF2α (PeIF2α) 
attenuates the translation of most mRNAs and activates that of ATF4 mRNA. ATF4 regulates 
the expression of genes involved in amino acid metabolism, anti-oxidative defence, protein 
folding (chaperones) and apoptosis (CHOP). In the inactive state Nrf2 is bound to Keap1. 
Phosphorylation of Nrf2 leads to the dissociation of Keap1 and activated Nrf2 is translocated 
to the nucleus to induce the transcription of genes participating in detoxification and redox 
homeostasis. Oligomerised and autophosphorylated IRE1 splices XBP-1 mRNA, degrades a 
specific subset of mRNAs and is involved in apoptosis via activation of JNK and NF-kB. After 
BiP dissociation from ATF6, ATF6 is translocated to the Golgi, where it is cleaved by 
proteases (S1P and S2P). Spliced XBP-1 and ATF6 induce the expression of genes encoding 
for chaperones and ERAD-associated proteins. The involvement of XBP-1 and ATF6 in the 
activation of CHOP is unclear. 
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2.4.2.2 Apoptotic pathways 
When the UPR fails to resolve ER stress, affected cells undergo apoptosis. 
Three different apoptotic pathways concerning ER stress have been identified, 
the activation of CHOP, JNK and caspases 12 and 8 (Jimbo et al. 2003; Liu 
and Kaufman 2003; Rajan et al. 2007). 
C/EBP homologous protein (CHOP) 
The transcription factor CHOP, also called growth arrest and DNA damage 
153 (GADD153), is a member of the CCAAT/enhancer binding proteins 
(C/EBP) and is expressed at very low levels under physiological conditions. 
CHOP can be induced upon different adverse conditions, including ER stress 
(Oyadomari and Mori 2003). ATF4 activates CHOP, whereas the involvement 
of spliced ATF6 and XBP-1 in the induction of CHOP transcription is 
controversially discussed (2.4.2.1 Signal transduction). 
CHOP directly activates transcription of GADD34, which results in the 
dephosphorylation of PeIF2α via an eIF2α-specific phosphatase, and 
therefore results in increased client protein synthesis and protein load in the 
ER (Kojima et al. 2003; Marciniak et al. 2004). The transcription of several 
genes is regulated by CHOP, including those that are involved in apoptosis. 
Death receptor 5DR5, tribbles 3 (TRB3) and the BH3-only member protein 
Bim, for example, are upregulated by CHOP (Ohoka et al. 2005; Pirot 2007; 
Puthalakath et al. 2007; Scheuner and Kaufman 2008), whereas the anti-
apoptotic protein Bcl2 was stated to be down-regulated when CHOP is 
overexpressed (McCullough et al. 2001).  
CHOP seems also to induce oxidative stress, since increased expression of 
CHOP is associated with up-regulation of ER oxidoreductase 1 (ERO1) 
(Marciniak et al. 2004), depletion of glutathione and elevated production of 
reactive oxygen species (ROS) (McCullough et al. 2001).  
C-Jun NH2 terminal kinase (JNK) and nuclear factor-κB (NF-κB) 
JNKs are members of the mitogen-activated protein kinases (MAPK) family. 
JNK is triggered by several activators like proinflammatory cytokines, distinct 
infections and ER stress (Bogoyevitch and Kobe 2006). In response to ER 
stress the cytoplasmic domain of IRE1 binds to the adaptor protein TNF 
receptor-associated factor 2 (TRAF2) (Urano et al. 2000). IRE1 and TRAF2 
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form a complex together with apoptosis signal-regulating kinase 1 (ASK1), 
which results in the phosphorylation and activation of JNK (Nishitoh et al. 
2002). Activated JNK phosphorylates target proteins on serine and threonine 
residues, leading either to the enhancement or inhibition of their activity. Many 
of these proteins are transcription factors like c-Jun, c-Myc, TRAF2, ELK1, 
p53, STAT1; STAT3 and Pax2, others are nuclear hormone receptors like 
glucocorticoid receptor, retionic receptor RARα and RXRα and further non-
transcription factors. Some of the transcription factors activated by JNK, are 
involved in apoptosis, like c-Myc, p53 and mitochondrial transcription factors 
Bcl-xL, Bax and Bim (Bogoyevitch and Kobe 2006).  
The activation of NF-κB was reported to be involved in ER stress-mediated 
apoptosis, too. NF-κB can be activated by various endogenous and 
exogenous stimuli, like hyperglycaemia, oxidative stress, elevated free fatty 
acids, TNFα, IL-1, growth factors (Bierhaus et al. 2001) and ER stress (Hu et 
al. 2006). In the inactive state, NF-κB forms a complex with inhibitor κB (IκB). 
Activation of IκB kinase (IKK) leads to the phosphorylation and degradation of 
IκB and to the translocation of NF-κB to the nucleus. It was reported that upon 
ER stress, IRE1α forms a complex with IKK, mediated by TRAF2, resulting in 
the degradation of IκB and subsequently in the activation of NF-κB. NF-κB 
regulates the transcription of several genes including those demonstrating 
proapoptotic (e.g. Fas ligand, TNFα, TRAIL) or antiapoptotic functions (e.g. 
TRAF1, TRAF2, c-FLIP) (Hu et al. 2006). 
Caspase 12 and 8 
Caspases, a family of cysteine proteases, play a crucial role in the regulation 
of apoptosis (Degterev et al. 2003). Calcium release from the ER due to ER 
stress, activates the cytosolic protease calpain, which cleaves and activates 
the initiator caspase 12 (Tan et al. 2006). Cleaved caspase 12 in turn can 
activate caspase 9 in a cytochrome c independent manner (Morishima et al. 
2002; Tan et al. 2006).  
Upon ER stress, caspase 8 is also activated and cleaves Bid, a member of the 
Bcl-2-family. The Bid fragment is translocated to the mitochondria and 
stimulates cytochrome c release, resulting in the activation of caspase 9 
(Jimbo et al. 2003). 
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2.4.3 Diabetes mellitus and ER stress 
2.4.3.1 Pathophysiological induction of ER stress  
The main function of pancreatic β-cells is the production, storage and 
secretion of insulin. Increasing blood glucose levels, for example after meal 
intake, stimulate the biosynthesis of insulin (Andrali et al. 2008). Elouli et al. 
(2007) demonstrated that stimulation of rat islets with different glucose 
concentrations (2 - 30 mM) activates the UPR, in a protein biosynthesis 
dependent manner (Elouil et al. 2007). Elevated insulin demand in insulin 
resistant and/or hyperglycaemic diabetic individuals leads to increased 
proinsulin biosynthesis and proinsulin folding, which can induce ER stress 
(Scheuner and Kaufman 2008). 
In Type 1 diabetes, cytokines are produced during the autoimmune destruction 
of β-cells (2.2.1 Diabetes type 1). It was demonstrated that exposure of 
insulin-producing insulinoma-1E ((INS)-1E) cells to cytokines like IL-1β and 
interferon-γ (IFNγ) results in an indirect and time-dependent activation of ER 
stress, via nitric oxide (•NO) production (Kharroubi et al. 2004). Il-1β alone or 
in combination with IFNγ, but not IFNγ alone, reduced the expression of 
sarcoendoplasmic reticulum pump Ca2+ ATPase 2b (SERCA2b), which 
resulted in the depletion of ER Ca2+ and activation of ER stress (Cardozo et al. 
2005). 
Type 2 diabetes is often associated with obesity and elevated triglyceride 
levels (2.2.2 Diabetes type 2). Incubation of insulin-secreting (INS)-1E cells, 
MIN6 cells and isolated islets of obese insulin-resistant db/db mice with the 
free fatty acid (FFA) palmitate induced ER stress and caused apoptosis in a 
time-dependent mode (Kharroubi et al. 2004; Laybutt et al. 2007). After 
exposure to the FFA oleate, ER stress response and β-cell apoptosis were 
lower (Kharroubi et al. 2004) or virtually not detectable (Laybutt et al. 2007) 
compared to palmitate incubation.  
In type 2 diabetics, human islet amyloid polypeptide (hIAPP) can aggregate 
and form toxic oligomers, whereas rodent IAPP (rIAPP) doesn’t show this 
characteristic. In experiments with homozygous transgenic mice 
overexpressing either rIAPP or hIAPP, hIAPP, but not rIAPP induced ER 
stress and β-cell apoptosis, leading to the developement of diabetes mellitus. 
These findings indicate that the toxic effects of hIAPP on β-cells are mainly 
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due the propensity of hIAPP to aggregate and less due to protein 
overexpression (Huang et al. 2007).  
2.4.3.2 Gene alterations in animal models and men  
Several human diseases and animal models serve to investigate the 
relationship between ER stress and diabetes mellitus. 
PERK 
PKR-like endoplasmic reticulum kinase (PERK) is essential for reducing the 
protein folding load, for activating the expression of BiP and CHOP, for 
reducing oxidative stress and for amino acid metabolism (2.4.2.1 Signal 
transduction). 
Mutations in the EIF2AK3 gene, which encodes for PERK, were detected in 
patients suffering from the Wolcott-Rallison syndrome (WRS). This autosomal 
recessive disease shows different clinic manifestations including early-infancy 
diabetes mellitus. A slight residual enzyme activity was associated with a 
delayed onset of WRS compared to patients with complete PERK inactivation 
(Senee et al. 2004).  
PERK-/- mice were born with a normally developed endo- and exocrine 
pancreas and physiological blood glucose concentrations. Within less than 4 
weeks they showed growth retardation, severe hyperglycaemia, reduced 
insulin secretion and increased β-cell loss. In addition to the progressive 
diabetic phenotype, PERK-/- mice developed exocrine pancreas insufficiency. 
IRE1α levels were increased, indicating ER stress (Harding et al. 2001). 
ATF6 
Activating transcription factor 6 (ATF6) participates in protein folding and 
degradation under ER stress conditions (2.4.2.1 Signal transduction).  
Double knockout (ATF6α-/- and ATF6β-/-) resulted in embryonic death, 
whereas mice carrying single null mutations (ATF6α-/- or ATF6β-/-) developed 
normally (Yamamoto et al. 2007). Upon ER stress, ATF6α-/- mouse embryonic 
fibroblasts demonstrated a reduced activation of ER stress-associated 
chaperones like BiP, Grp94 as well as folding enzymes (ERp72 and P5) and a 
decreased induction of various ERAD components, resulting in diminished 
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viability of ATF6α-/- MEFs compared to ATF6α+/+ MEFs under ER stress 
conditions. 
Amino acid variants in the ATF6 gene were associated with type 2 diabetes in 
Pima Indians (Thameem et al. 2006). 
CHOP 
The transcription factor C/EBP homologous protein (CHOP) is involved in ER 
stress-mediated apoptosis (2.4.2.2 Apoptotic pathways). 
The targeted disruption of Chop reduced β-cell apoptosis in 4-week-old 
heterozygous Akita mice and delayed the onset of diabetes (2.3.3.3 ER stress 
in the Akita mouse). Song et al. (2008) reviewed distinct mouse models for 
diabetes (e.g. Lepr-/-, eIF2αS/A and STZ-treated mice) in which Chop deletion 
improved glycaemic control, β-cell function and β-cell survival upon ER stress 
(Song et al. 2008).  
Insulin gene 
Different mutations in the insulin gene were described in men and mice. 
Mutations which disturb disulfide bond formation result in a severe diabetic 
phenotype, with early onset and profound β-cell loss, as it is described in 
human patients with PNDM (2.2.3.2 Neonatal diabetes mellitus (NDM)), in the 
Munich Ins2C95S mutant mouse (2.3.2 The Munich Ins2C95S mutant mouse), 
and in the Akita mouse (2.3.3 The Akita mouse). It was demonstrated that 
misfolded (pro-)insulin 2 induces ER stress in the Akita mouse (2.3.3.3 ER 
stress in the Akita mouse). 
Wolfram syndrome 
Wolfram syndrome is a rare autosomal rezessive disorder causing juvenile 
onset diabetes mellitus, optic atrophy and often sensorineural hearing loss or 
diabetes insipidus (Fonseca et al. 2005; Ueda et al. 2005). WFS1 encodes for 
a protein located in the ER membrane and plays an important role in 
maintaining homeostasis in the ER of pancreatic β-cells. WFS1 might be 
involved in the UPR, and ER stress activates WFS1 expression. Inactivation of 
WFS1 in β-cells resulted in chronic ER stress (Fonseca et al. 2005; Ueda et al. 
2005). 
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2.4.3.3 Therapeutic strategies for reducing ER stress 
Chemical chaperones were demonstrated to stabilise protein conformation 
and increase ER folding capacity. Oral treatment of ob/ob mice with 4-phenyl 
butyric acid (PBA) or tauroursodeoxycholic acid (TUDCA) improved blood 
glucose concentrations, glucose tolerance and insulin sensitivity and reduced 
ER stress in liver and fatty tissue (Özcan et al. 2006). 
Oxidative stress can induce ER stress and vice versa, and antioxidative 
treatment reduced ER stress in vitro (2.6 Linkage between oxidative and ER 
stress). Therefore, treatment with antioxidants possibly contributes to the 
reduction of ER stress (Malhotra et al. 2008). 
CHOP is involved in apoptosis upon ER stress, and deletion of Chop delayed 
the onset of diabetes in heterozygous Akita mice. Chop-/- mice were 
phenotypically inconspicuous and presented a normal lifespan. Therefore 
specific CHOP inhibitors would be another promising therapeutic approach to 
preserve β-cells mass upon ER stress (Scheuner and Kaufman 2008). 
2.5 Glucotoxicity and oxidative stress 
Chronically elevated blood glucose concentrations over months and years 
have adverse effects on pancreatic β-cell function and viability, can disturb 
insulin signalling and lead to the development of long-term diabetic 
complications like retinopathy, nephropathy, neuropathy and cardiovascular 
disease (Evans et al. 2002; Kaiser et al. 2003; Robertson 2004; Robertson 
and Harmon 2006; Tsuboi et al. 2006; Shah et al. 2007). 
Several pathways have been identified, demonstrating how long-term 
hyperglycaemia results in these adverse effects: glucose autoxidation 
(Robertson 2004; Ahmed 2005), polyol pathway (Chung et al. 2003), 
hexosamine pathway (Du et al. 2000; Brownlee 2005), protein kinase C (PKC) 
activation (Koya and King 1998; Ohshiro et al. 2006), production of advanced 
glycation endproducts (AGEs) (Schmidt and Stern 2000; Ahmed 2005), and 
increased oxidative phosphorylation (Korshunov et al. 1997; Nishikawa et al. 
2000; Brownlee 2005). All these pathways lead to the generation of free 
radicals, which cause chronic oxidative stress (Robertson 2004).  
Additionally, in type 1 diabetes, the autoimmune response results in 
inflammation and increased oxidative stress, e.g. due to superoxide (•O2-) 
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release from monocytes and production of reactive oxygen species (ROS) by 
cytokines (Devaraj et al. 2006; Robertson and Harmon 2006). 
2.5.1 Free radicals and oxidative stress 
Free radicals have both, beneficial and deleterious effects. 
In physiological concentrations, free radicals like nitric oxide (•NO) and •O2- 
support reactions like vasodilation (Beckman et al. 2003), immune response 
and other physiological pathways. Several ROS-mediated reactions even 
maintain redox homeostasis (Valko et al. 2007). 
A disturbed equilibrium between generation of free radicals and antioxidant 
capacity, due to increased production of free radicals, reduced antioxidant 
defence mechanism or both, results in oxidative stress (Betteridge 2000; 
Maritim et al. 2003). Oxidative stress is involved in aging and is associated 
with several diseases like cancer, cardiovascular disease, Alzheimer’s 
disease, Parkinson’s disease, rheumathoid arthritis and diabetes mellitus 
(Valko et al. 2007). Due to low levels of antioxidant enzymes, pancreatic  
β-cells are very susceptible to oxidative stress (Lenzen et al. 1996; Tiedge et 
al. 1997; Shah et al. 2007). 
Oxygen free radicals are produced at low levels during several physiological 
reactions via reduction of oxygen (Betteridge 2000; Chong et al. 2005). It can 
be distinguished between reactive oxgen species (ROS) like •O2-, hydroxyl 
(•HO), peroxyl (•RO2), and hydroxyperoxyl (•HO2-) radicals, hydrogen peroxide 
(H2O2) and hydrochlorus acid (HOCl), and reactive nitrogen species (RNS) like 
•NO, nitrogen dioxide (•NO2-), peroxynitrite (OONO-), and nitrous oxide (HNO2) 
(Evans et al. 2002). 
The most common free radical is •O2- (Chong et al. 2005). •O2- is produced in 
the mitochondria during oxidative phosohorylation. Under physiological 
conditions, 0.4 - 4% of the consumed oxygen is converted into •O2-. The 
mitochondrial manganese superoxide dismutase (MnSOD) transforms •O2- into 
H2O2, which in turn is converted into H20 and O2, either by glutathione 
peroxidase (GSH-Px) in the mitochondria or by catalase (CAT) in cytosolic 
peroxisomes. •O2- can also be generated by xanthine oxidase, NADPH 
oxidase, cycloxygenase and lipoxygenase. In the presence of transition metals 
like copper (Cu) or iron (Fe), H2O2 can be transformed to highly reactive •HO 
and OH- by the so called Fenton reaction (Evans et al. 2002; Valko et al. 
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2007). Furthermore, •O2- can react with •NO to OONO- (Pfeiffer et al. 2001) 
(Figure 2.2). 
Several studies demonstrated that in diabetic animals and humans, oxidative 
stress is increased, as evidenced by various oxidative stress markers (2.5.4.2 
Measurement of oxidative stress). 
 
 
Figure 2.2 Radical generation and detoxification 
Superoxide (•O2-) is generated during the oxidative phosphorylation in mitochondria and during 
several other reactions. •O2- is converted to H20 and O2 via the endogenous antioxidant 
enzymes superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and/or catalase 
(CAT). Exaggerated •O2- production, for example due to chronic hyperglycaemia, results in the 
generation of reactive oxygen (and nitrogen) species. •O2- can react with nitric oxide (•NO) to 
peroxynitrite (OONO-). In the presence of transition metals like copper (Cu2+) and iron (Fe2+), 
hydrogen peroxide (H2O2) is transformed to highly reactive hydrogen peroxide (•OH) (Fenton 
reaction). 
 
2.5.2 Adverse effects of hyperglycaemia-induced oxidative stress 
Free radicals are highly reactive and can cause tissue damage by directly 
reacting with lipids, proteins and DNA, leading to lipid peroxidation 
(Kalaivanam et al. 2006; Ramakrishna and Jailkhani 2007; Song et al. 2007), 
DNA damage (Song et al. 2007) and protein alteration (Palmeira et al. 2007; 
Ramakrishna and Jailkhani 2007; Bonnard et al. 2008). Furthermore, reaction 
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of •O2- with •NO to OONO- reduces •NO concentrations, which results in 
impaired vasodilation (Cai and Harrison 2000). 
 
Adverse effects of hyperglycaemia-induced oxidative stress can also be 
indirect by induction of several pathways like JNK, p38 MAPK, and NF-κB 
(Evans et al. 2002).  
C-Jun NH2 terminal kinase (JNK) and p38 mitogen-activated protein 
kinase (p38 MAPK) 
JNK and p38 MAPK, also called stress activated protein kinases 1 and 2 
(SAPK 1 and 2), are members of the MAPK family, and are activated by 
similar stimuli like oxidative stress, hypoxia, and various cytokines (e.g. TNFα, 
IL-1) (Roux and Blenis 2004). Additionally, JNK can be activated by ER stress 
(2.4.2.2 Apoptotic pathways). 
 
Several studies showed that JNK, is activated by hyperglycaemia-induced 
oxidative stress (Evans et al. 2002; Kaneto et al. 2004). 
JNK activation is associated with reduced insulin sensitivity, disturbed β-cell 
function and increased β-cell apoptosis (2.5.3 Insulin resistance, β-cell 
dysfunction and β-cell apoptosis). 
p38 MAPK plays an essential role in inflammation, immunity, cell growth and 
apoptosis (Evans et al. 2002; Roux and Blenis 2004). Exposure to high 
glucose concentrations activated p38 MAPK in vascular smooth muscle cells 
(Begum and Ragolia 2000), and treatment with H2O2 caused p38 MAPK 
induction in rat glomeruli (Dunlop and Muggli 2000). 
H2O2 incubation of isolated rat islets induced JNK and p38 MAPK, leading to 
decreased Ins expression, which could be preserved by inhibition of JNK but 
not by inhibition of p38 MAPK (Kaneto et al. 2002).  
Nuclear factor-κB (NF-κB) 
NF-κB is activated by various stimuli including oxidative stress and regulates 
the transcription of several genes involved in inflammation (e.g. TNFα, IL-1, 
IFNγ), immune response, cell adhesion (e.g. vascular cell adhesion molecule 1 
(VCAM1)), cell growth control (e.g. vascular endothelial growth factor (VEGF)) 
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and apoptosis (2.4.2.2 Apoptotic pathways) (Baldwin 2001; Evans et al. 2002; 
Hu et al. 2006). 
Different studies demonstrated that hyperglycaemia and oxidative stress 
activate NF-κB in several cells, like bovine vascular endothelial cells 
(Nishikawa 2000) and mononuclear blood cells of peripheral blood (Hofmann 
1999). Reduction of oxidative stress via blocking the mitochondrial electron 
transport chain (Nishikawa 2000) or antioxidant treatment, for example with  
α-lipoic acid (LA) (Hofmann 1999) reduced NF-κB activation in these 
endothelial and blood cells, respectively. However, incubation of isolated rat 
islets for 1 - 7 days in 30 mM glucose or treatment with H202 over night did not 
affect NF-κB activity (Elouil et al. 2005). 
 
These findings show that, different pathways can be activated by 
hyperglycaemia-induced oxidative stress in several tissues. However, the JNK 
pathway seems to be the most important concerning β-cell function and β-cell 
apoptosis.  
2.5.3 Insulin resistance, β-cell dysfunction and β-cell apoptosis 
Chronic hyperglycaemia and oxidative stress lead to reduced insulin 
sensitivity, disturbed β-cell function and β-cell apoptosis, which in turn results 
in further elevation of blood glucose concentration and therefore in further 
deterioration of insulin action, β-cell function and β-cell viability (Kaiser et al. 
2003; Robertson 2006). 
2.5.3.1 Insulin resistance 
Physiologically, insulin binds to the insulin receptor (IR), which is expressed on 
the surface of several cell types, like myocytes, adipocytes, hepatocytes and 
β-cells, resulting in the autophosphorylation of IR. Phosphorylation of IR 
enables the binding of the insulin receptor substrates (IRS) IRS1 and 2 as well 
as Gab1 and Shc to the IR. The tyrosine kinase activity of the IR then 
activates IRS by phosphorylation of several tyrosine residues of IRS. Tyrosine-
phosphorylation promotes the binding of IRS to the src homology 2 (SH2) 
domain of several downstream proteins like phosphatidylinositol 3-kinase (PI3-
kinase), Grb2 and others. IRS1 and 2 activate PI3-kinase, which in turn 
activates the serine/threonine kinase Akt (also called protein kinase B (PKB)) 
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and atypical forms of PKC (PKCγ and ζ), resulting in increased glycogen 
synthesis, inhibition of gluconeogenesis, elevated lipid synthesis and 
increased glucose uptake in adipocytes and myocytes by GLUT4 translocation 
to the plasma membrane. Phosphorylation of the IRS Gab1 and Shc leads to 
the binding of Grb2, which recruits SOS, resulting in the induction of the MAPK 
pathway, mediating proliferative effects of insulin (Biddinger and Kahn 2006) 
(Figure 2.3). 
 
 
Figure 2.3 Insulin signalling 
Binding of insulin (I) to the insulin receptor (IR) results in the autophosphorylation of IR and 
subsequently to the activation of insulin receptor substrates (IRS1, IRS2, Gab1, Shc). IRS1 
and 2 activate phosphatidylinositol 3-kinase (PI3-kinase) which in turn activates Akt/PKB, 
PKCγ and ζ, resulting in synthesis of glycogen and lipids, in inhibition of gluconeogenesis and 
in glucose uptake in myocytes and adipocytes. Phosphorylation of Gab1 and Shc activates 
Grb2 which finally induces the MAPK pathway, realising the proliferative effects of insulin.  
 
Oxidative stress leads to impaired insulin signalling, probably due to serine 
(Ser) and threonine (Thr) phosphorylation of IRS1 and 2, which disturbs 
binding of IRS to the IR and therefore impairs the phosphorylation of IRS on 
tyrosine (Tyr) residues. IRS, phosphorylated on Thr or Ser instead of Tyr, 
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shows impaired interaction with downstream target molecules, resulting in 
disturbed insulin action (Paz et al. 1997; Evans et al. 2002). JNK might be 
involved in reduced insulin action, since phosphorylation of IRS1 on serine 
307 in Chinese hamster ovarian (CHO) cells was probably mediated by JNK 
(Aguirre et al. 2000).  
The negative effect of oxidative stress on insulin sensitivity of adipocytes and 
muscle cells was demonstrated in different studies. 
Treatment of 3T3-L1 adipocytes, either with TNFα or dexamethasone for 
several days, led to upregulation of ROS-related genes, increased ROS 
production and reduced insulin sensitivity compared to non-treated 3T3-L1 
adipocytes, and insulin sensitivity was ameliorated by antioxidant treatment or 
overexpression of antioxidant enzymes (Houstis et al. 2006). 
H2O2, generated by incubation with the enzyme glucose oxygenase and its 
substrate glucose, only slightly reduced basal glucose uptake in rat L6 muscle 
cells, overexpressing GLUT4 (L6 GLUT4 cells), whereas insulin-stimulated 
glucose transport was almost abolished. Pre-treatment with the antioxidant LA 
for 18 hours prevented insulin-stimulated glucose uptake. It was assumed that 
serine and/or threonine phosphorylation of IRS induced by H2O2 resulted in 
the impaired insulin action (Maddux et al. 2001).  
2.5.3.2 β-cell dysfunction 
Several in vitro and in vivo studies showed that chronically high glucose levels 
and oxidative stress reduce DNA binding activity of the transcription factors 
PDX-1 and MafA in β-cells, alter the expression of several β-cell genes like 
GLUT2, GCK and INS and lead to disturbed glucose-stimulated insulin 
secretion (GSIS) (Kaiser et al. 2003; Robertson and Harmon 2006). 
 
PDX-1, which  binds to the A3 element of the insulin promoter in β-cells, is 
essential for pancreas development, β-cell differentiation, regeneration and 
function by regulating the expression of several genes encoding for, for 
example, somatostatin, glucokinase, GLUT2 and insulin (McKinnon and 
Docherty 2001; Holland et al. 2002; Miyazaki et al. 2004; Andrali et al. 2008). 
MafA binds to the RIPE3b/C1 element on the insulin promoter and is involved 
in the regulation of pancreatic β-cell function and GSIS (Zhang et al. 2005; 
Kondo et al. 2009).  
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Chronic incubation of HIT-T15 cells in 11.1 mM glucose resulted in diminished 
MafA and PDX-1 binding activity to the insulin promoter, reduced insulin 
mRNA content, decreased insulin concentrations and reduced GSIS. 
Treatment with the antioxidants N-acetyl cysteine (NAC) or aminoguanidine 
(AG) at least partially prevented these adverse effects of high glucose levels 
(Tanaka 1999). A more recent study, in which HIT-T15 cells were also 
incubated in 11.1 mM glucose for long-term, demonstrated that reduced MafA 
binding activity to the insulin promoter is caused by largely diminished MafA 
protein concentrations, whereas mRNA levels were unaltered (Harmon 2005). 
Incubation of isolated rat islets in H2O2 for 48 hours caused activation of JNK, 
reduced binding activity of PDX-1 to the insulin promoter and diminished 
insulin mRNA levels. Adenovirus-mediated expression of dominant-negative 
JNK or treatment with NAC preserved insulin gene expression in islets 
incubated in H2O2. Furthermore, overexpression of JNK in isolated islets 
resulted in reduced PDX-1 DNA binding activity and decreased insulin gene 
expression. These findings led to the assumption that activation of JNK 
reduces Ins expression by decreasing binding activity of PDX-1 to the insulin 
promoter (Kaneto et al. 2002). 
 
One week after 85-95% pancreatectomy (Px), Sprague-Dawley rats developed 
mild to severe hyperglycaemia. Four weeks after pancreatectomy, islets of Px 
rats with blood glucose concentrations of 150 mg/dl and higher demonstrated 
reduced expression of several genes involved in β-cell development, 
differentiation and glucose metabolism (e.g. Pdx-1, Ins, Glut2, Gck, Kir6.2, Pc 
(pyruvate carboxylase)) compared to islets of shamPx rats. A relation between 
different degrees of hyperglycaemia and altered gene expression was 
detected. Treatment of severely hyperglycaemic rats for 4 weeks with 
phlorizin, which rapidly normalised blood glucose concentrations, reversed the 
alterations of gene expression (Jonas et al. 1999). Incubation of isolated rat 
islets in 30 mM glucose for 48 hours reduced mRNA expression of Glut2 and 
Gck and resulted in disturbed GSIS compared to islets incubated in 10 mM 
glucose (Tsuboi et al. 2006). The reduced expression of Glut2 and Gck was 
also analysed on the protein level via immuno blot analysis. Incubation of 
MIN6N8 cells, a mouse pancreatic β-cell line, in 33.3 mM glucose for 4 days 
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reduced GLUT2 and glucokinase content and impaired ATP production after 
glucose stimulation (Kim et al. 2005).  
 
The findings of the different studies demonstrate that chronic hyperglycaemia 
and oxidative stress result in disturbed β-cell function by altering the 
expression of various genes. Reduced DNA binding activity of PDX-1 seem to 
play a major role in this context, since PDX-1 regulates the expression of 
several genes involved in glucose metabolism and β-cell function and the 
expression of these genes was reduced in various studies.  
2.5.3.3 β-cell apoptosis 
Chronic hyperglycaemia and oxidative stress reduce functional β-cell mass 
and lead to β-cell apoptosis. Several pathways were described demonstrating 
the molecular mechanisms underlying β-cell apoptosis via glucotoxicity (Kaiser 
et al. 2003). 
JNK 
JNK can be activated by high glucose levels and chronic oxidative stress 
(2.5.2 Adverse effects of hyperglycaemia-induced oxidative stress). 
Human islets, incubated for 4 days with 33.3 mM glucose exhibited increased 
JNK activation, elevated mRNA levels of c-Fos, c-Myc and caspase 1, largely 
decreased insulin content and increased β-cell apoptosis compared to islets 
incubated in 5.5 mM glucose. Co-incubation with dominant inhibitor JNK-
binding domain of IB1/JIP-1 (JNKi) reduced JNK activity and partially 
prevented the described alterations (Maedler et al. 2008). 
Fas  
Human pancreatic islets physiologically express Fas-ligand (FasL), but not 
Fas receptor (Fas) (Maedler et al. 2001). FasL binding to Fas results in the 
recruitment of adaptor proteins like Fas-associated via death domain (FADD), 
which in turn recruits caspase 8 (or 10), forming the death-inducing signal 
complex (DISC). Subsequently, caspase 8 (or 10) are activated by 
autoproteolysis and dissociate from Fas and FADD. Activation of caspase 8 
(or 10) results in the cleavage and activation of caspase 3 and 7, which in turn 
cleave cellular substrates, leading to structural changes within the cell and 
finally to apoptosis (Movassagh and Foo 2008).  
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It was stated that caspase 3 and 7 also increase Bax translocation to the 
mitochondria, resulting in cytochrome c release, and connecting extrinsic and 
intrinsic apoptotic pathways (Lakhani et al. 2006). 
Exposure of islets of dead, but heart-beating non-diabetic donors to high 
glucose concentrations (11.1 and 33.3 mM) for 5 days resulted in a dose-
dependent increase in apoptosis compared to islets incubated in 5.5 mM 
glucose. The islets treated with 33.3 mM glucose demonstrated increased 
expression of Fas receptor and activation of caspase 8 and 3 (Maedler et al. 
2001). 
Mitochondrial pathway  
Bcl-2 family members act pro-apoptotic (e.g. “multidomain” proteins Bax and 
Bak, as well as “BH3-only” proteins Bid, Bad and Bim) or anti-apoptotic (e.g 
Bcl-2, Bcl-xL, MCL-1). It is assumed that “BH3 only” proteins activate 
“multidomain” proteins Bax and Bak, leading to the permeabilisation of the 
outer mitochondrial membrane and to the release of cytochrome c into the 
cytosol, which in turn results in mitochondrial remodelling and dysfunction. In 
the “post-mitochondrial pathway” cytochrome c forms a complex with Apaf-1 
and caspase-9, the so called “apoptosome”, resulting in the activation of 
initiator caspase 9, which in turn activates caspase 3 and 7 (Scorrano and 
Korsmeyer 2003).  
Incubation of human islets in 16.7 mM glucose for 5 days altered the balance 
of pro- and anti-apoptotic proteins and increased β-cell apoptosis compared to 
islets cultured in 5.5 mM glucose. Expression of Bad and Bid was increased, 
that of Bcl-xL decreased, as evidenced by RT-PCR and western blot analysis 
(Federici et al. 2001). 
The treatment of MIN6N8 cells with high glucose concentrations resulted in 
the activation of the mitochondrial and the Fas-associated apoptosis pathway. 
Exposure of MIN6N8 cells to high glucose concentrations (33.3 mM) increased 
β-cell apoptosis and caspase 3-cleavage in a time-dependent mode. The 
expression of Bcl-2 and Bcl-xL was decreased, that of Bax, Fas and p53 
increased compared to cells incubated in 5.5 mM glucose. Cytochrome c 
release from the mitochondria was increased, mediated by the translocation of 
Bax to the mitochondrial outer membrane (Kim et al. 2005).  
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In conclusion, long-term high blood glucose levels and oxidative stress result 
in decreased insulin action in insulin-sensitive tissues like muscle and fatty 
tissue, and in disturbed β-cell function and insulin secretion, especially in 
response to glucose. Apoptosis of β-cells, mediated by extrinsic and intrinsic 
apoptotic pathways, lead to reduced functional β-cell mass. All these adverse 
alterations aggravate the diabetic phenotype. 
2.5.4 Antioxidants 
2.5.4.1 Antioxidative defence 
Organisms possess an endogenous antioxidant defence system in order to 
reduce oxidative stress (Chong et al. 2005; Rahimi et al. 2005). This system 
includes antioxidative enzymes like mitochondrial manganese superoxide 
dismutase (MnSOD/SOD2), cytosolic copper/zinc superoxide dismutase 
(Cu/ZnSOD/SOD1), glutathione peroxidase (GSH-Px), glutathione reductase 
(GR) and catalase (CAT), and nonenzymatic antioxidants like glutathione, 
vitamins E, A and C, α-lipoic acid (LA), antioxidant minerals (copper, zinc, 
manganese and selenium), several bioflavonids, coenzyme Q10 (CoQ10), and 
cofactors (folic acid, B vitamins) (Maritim et al. 2003; Chong et al. 2005; 
Ramakrishna and Jailkhani 2007). 
SOD, GSH-Px and/or CAT convert •O2- to H2O and O2 (2.5.1 Free radicals and 
oxidative stress). GSH-Px oxidises reduced glutathione (GSH) to oxidised 
glutathione (GSSG), which in turn is reduced to GSH by GR, leading to the 
oxidation of NADPH to NADP+ (Shah et al. 2007; Lu 2009) (Figure 2.4 (B)). 
Vitamins A and E are lipophilic radical scavengers. Vitamin E, whose most 
active form in humans is α-tocopherol, directly reacts with •O2-, •RO2 and 
singlet oxygen, and protects membranes from lipid peroxidation. Vitamin C is 
hydrophilic and scavens radicals, like H2O2 (Berg et al. 2003; Maritim et al. 
2003; Johansen et al. 2005).  
Vitamins interact in recycling processes to regenerate the reduced form of 
vitamins, which can act as antioxidant. Vitamin C reduces the oxidised  
α-tocopherol radical to α-tocopherol, and is thereby converted to 
dehydroascorbic acid (DHA). GSH in turn reduces DHA to vitamin C (Maritim 
et al. 2003; Rahimi et al. 2005) (Figure 2.4 (A)). GSH can also reduce  
α-tocopherol radical to α-tocopherol. GSSG can be transformed to GSH via 
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GR or dihydrolipoic acid (DHLA) (Figure 2.4 (B), (C)). DHLA and LA are 
powerful antioxidants that scaven free radicals, regenerate vitamin C and GSH 
(Figure 2.4 (C)) and chelate metals. Furthermore LA is a coenzyme in the 
pyruvate dehydrogenase and α-ketoglutarate dehydrogenase mitochondrial 
enzyme complex and therefore plays an important role in generating energy 
from glucose (Evans and Goldfine 2000; Rahimi et al. 2005). CoQ10 is a 
lipophilic antioxidant and acts as an electron carrier in the mitochondrial 
electron transport chain (Johansen et al. 2005). 
 
(A) 
 
  
(B) (C) 
  
Figure 2.4 Recycling processes of endogenous antioxidants 
Vitamins and other antioxidants like α-lipoic acid (LA) or glutathione (GSH) interact in recycling 
processes to regenerate the reduced and active form of the antioxidant.  
(A) α-tocopherol, the most active form of vitamin E, directly reacts with radicals (•R) and 
thereby is converted to α-tocopherol radical. Vitamin C reduces the α-tocopherol radical to  
α-tocopherol, being transformed to dehydroascorbic acid (DHA). Reduced glutathione (GSH) 
can regenerate vitamin C and is thereby oxidised to GSSG. (B) During the conversion of H2O2 
to H2O by glutathione peroxidase (GSH-Px), GSH is oxidised to GSSG. Regeneration of GSH 
by glutathione reductase (GR) leads to the oxidation of NADPH to NADP+. (C) Dihydrolipoic 
acid (DHLA) can reduce DHA to vitamin C and GSSG to GSH. 
ox: oxidation, red: reduction  
 
2.5.4.2 Measurement of oxidative stress 
The measurement of oxidative stress is necessary to examine the involvement 
of oxidative stress in the pathogenesis of diabetes mellitus and to investigate 
the effect of antioxidant treatment in vitro and in vivo. 
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Oxidative stress can be analysed be determining concentrations of MnSOD, 
Cu/ZnSOD, CAT, GR, GSH-Px, xanthine oxidase and NADPH oxidase 
(Maritim et al. 2003; Shah et al. 2007). Other biomarkers result from the 
oxidative damage on lipids, proteins and DNA. Lipid peroxidation can be 
determined by analysing malondialdehyde (MDA) and thiobarbituric active 
reactive substances (TBARS) levels (Kalaivanam et al. 2006; Ramakrishna 
and Jailkhani 2007; Song et al. 2007). DNA damage may be determined by 
measuring oxidised base 8-OHdG (8-hydroxy-2-deoxy-guanosine) levels or by 
comet assay (Sigfrid et al. 2004; Song et al. 2007), and protein alteration by 
investigating protein carbonylation (Palmeira et al. 2007; Ramakrishna and 
Jailkhani 2007; Bonnard et al. 2008). Further methods exist to examine 
oxidative stress like determination of F2-isoprostane levels, glutathione 
concentrations or analysing the antioxidant capacity (Rahimi et al. 2005; Shah 
et al. 2007).  
However, different statements exist concerning the alteration of these 
parameters upon oxidative stress, especially the activity of SOD, CAT and 
GSH-Px (Maritim et al. 2003). STZ-induced diabetic Wistar rats showed 
decreased SOD, CAT and GSH-Px activities in the kidneys (Kedziora-
Kornatowska et al. 2003) and reduced SOD and CAT activity in the liver 
compared to control rats (Elmalí et al. 2004). In another study using STZ-
induced diabetic rats, elevated MnSOD levels were determined in liver, 
kidneys and pancreas compared to control rats. The GSH-Px concentrations 
in liver mitochondria were decreased, whereas mitochondria in pancreas and 
kidneys of diabetic rats showed elevated GSH-Px levels (Jang et al. 2000). In 
the liver of diabetic mice increased CAT concentrations were found after STZ 
treatment (Caballero et al. 2000).  
In contrast to conflicting data on enzyme activities, the findings concerning 
other oxidative stress parameters are more consistent. Several studies 
showed that diabetic animals and humans regularly exhibit elevated TBARS 
levels and decreased glutathione concentrations (Kedziora-Kornatowska et al. 
2003; Maritim et al. 2003). DNA damage (Ramakrishna and Jailkhani 2007) 
and glycated proteins (Jang et al. 2000) were also increased in diabetics.  
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2.5.4.3 Antioxidative treatment 
Many studies demonstrated that oxidative stress plays a major role in the 
development of diabetes mellitus including long-term complications. Therefore 
treatment with antioxidants could play an important role for improvement and 
management of diabetes and diabetes-associated complications (Rahimi et al. 
2005). 
Several antioxidants were used in in vivo and in vitro studies to investigate 
their beneficial effects on diabetes and long-term complications. The 
antioxidative potential of vitamins A, E and C, LA, phytochemicals 
(Chanwitheesuk et al. 2005), zinc, selenium, melatonin, CoQ10 (Hodgson et al. 
2002), taurine, nicotinamide and drugs like NAC (Kaneto et al. 1999; 
Fiordaliso et al. 2004), aspirin (Caballero et al. 2000), allopurinol (Desco et al. 
2002), angiotensine convertase inhibitors (Kedziora-Kornatowska et al. 2000) 
and angiotensin receptor blockers were examined (Maritim et al. 2003; Rahimi 
et al. 2005). Some drugs used in diabetic therapy like metformin (Ouslimani et 
al. 2005), repaglinide (Gumieniczek et al. 2005) and sulphonylureas (glipizide, 
glibenclamide (Elmalí et al. 2004)) seem to have antioxidative effects, too 
(reviewed in Rahimi et al. 2005). 
 
Examples of the use of antioxidants in in vitro studies are described above 
(e.g. 2.5.3 Insulin resistance, β-cell dysfunction and β-cell apoptosis). The 
beneficial effects of antioxidants detected in in vitro experiments were partly 
confirmed in vivo. 
Treatment of diabetic C57BL/KsJ-db/db mice with NAC, Vitamins C and E, or 
with all 3 antioxidants demonstrated that NAC improved blood glucose 
concentrations, glucose tolerance, pancreatic insulin mRNA and insulin 
content compared to non-treated diabetic mice, whereas treatment with 
vitamins E and C didn’t improve β-cell function (Kaneto et al. 1999). Oral 
application of vitamin E or C reduced renal lipid peroxidation, kidney weight, 
glomerular basement membrane thickness and urinary albumin excretion in 
STZ-induced diabetic Wistar rats, but didn’t improve blood glucose levels 
compared to non-treated diabetic rats (Kedziora-Kornatowska et al. 2003).  
LA treatment showed beneficial effects in several studies and therefore 
attracted considerable attention as an antioxidant (Johansen et al. 2005). For 
example, treatment of STZ-induced diabetic rats with LA improved blood 
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glucose concentrations, plasma insulin levels and lipid peroxidation compared 
to non-treated diabetic rats, and reversed hypertension (Kocak et al. 2000).  
 
Clinical trials with humans were mainly carried out using vitamin C and E and 
LA (Johansen et al. 2005).  
Oral treatment with vitamin E and C reduced the urinary albumin excretion rate 
in type 2 diabetic patients with persistent albuminuria (Gæde et al. 2001) and 
improved endothelium-dependent vaso-relaxation in type 1 diabetics, but not 
in type 2 diabetics (Beckman et al. 2003). Intravenous infusion of LA for  
3 weeks, reduced symptoms of peripheral neuropathy in the ALADIN I (Ziegler 
et al. 1995) and SYDNEY trial (Ametov et al. 2003), whereas i.v. treatment for 
3 weeks and subsequent oral LA administration showed no significant effect in 
the ALADIN III trial (Ziegler et al. 1999). 
 
In conclusion, experimental studies with animal models and clinical trials 
showed that antioxidant treatment may have beneficial effects on diabetes and 
its long-term complications. However, the results of different studies were 
variable, which could be due to different type and duration of treatment 
protocols. Furthermore, treatment design in clinical trials is limited compared 
to investigations using animal models, since experiments with animals can be 
standardised and tissue samples of several organs can be analysed. 
2.6 Linkage between oxidative and ER stress  
Oxidative stress, protein misfolding and ER stress are interrelated. ER stress 
can result in oxidative stress and vice versa (Scheuner and Kaufman 2008).  
2.6.1 Oxidative protein folding 
The ER exhibits an environment optimised for oxidative protein folding. Many 
secretory proteins exhibit disulfide bonds, which are necessary for protein 
maturation, stability and function (Tu and Weissman 2004). Insulin, for 
example, contains 3 disulfide bonds (A7-B7, A20-B19, A6-A11). 
Thiol-disulfide oxidoreductases like protein disulfide isomerase (PDI), catalyse 
disulfide bond formation, isomerisation and reduction of several substrates. 
PDI is reduced by oxidising disulfide bonds in proteins. Reduced PDI is 
regenerated by oxidation through the thiol-reductase ER oxidoreductase 1 
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(ERO1), which results in the production of low amounts of H2O2  (Tu and 
Weissman 2002; Tu and Weissman 2004; Scheuner and Kaufman 2008).  
The oxidoreductases thioredoxin (Trx) and glutaredoxins (Grx) are members 
of the thioredoxin family and are involved in protein folding. Trx and Grx 
reduce protein disulfides to thiols, promote disulfide bond formation and 
interact with PDI and chaperones. Regeneration of reduced Grx is dependent 
on GSH (Berndt et al. 2008). 
GSH reduces improperly paired disulfide bonds, and NADPH is necessary for 
the regeneration of GSH (Scheuner and Kaufman 2008). 
Additionally, chaperones are also involved in protein folding, thereby 
consuming energy in form of ATP (Scheuner and Kaufman 2008). 
2.6.2 ER stress induces oxidative stress and vice versa 
As described above, oxidative protein folding produces little amounts of H2O2 
and consumes GSH, which is a potential antioxidant. Therefore, high protein 
load and remodelling of disulfide bonds within misfolded proteins leads to 
oxidative stress by production of ROS and reduction of GSH levels (Kincaid 
and Cooper 2007a; Scheuner and Kaufman 2008).  
On the other hand, oxidative stress depletes GSH, which is essential for 
disulfide bond formation. Furthermore, the reduction of glucose to sorbitol in 
the sorbitol pathways converts NADPH to NADP+, which results in decreased 
regeneration of GSH (Chung et al. 2003). ROS are highly reactive and can 
interact directly with proteins and inactivate chaperones, leading to impaired 
protein folding (Scheuner and Kaufman 2008). 
 
The close link between oxidative and ER stress was demonstrated by 
Malhotra et al. (2008). Coagulation factor VIII (FVIII) is expressed at very low 
levels in vivo and forms high molecular weight aggregates, which results in the 
activation of the UPR. Chinese hamster ovarian (CHO) cells expressing wild-
type human FVIII in response to sodium butyrate (NaB) were generated. NaB 
incubation of these CHO-FVIII cells resulted in increased wtFVIII mRNA and 
wtFVIII protein levels, and led to apoptosis in approximately 16% of the wtFVIII 
expressing cells. Most of wtFVIII was not secreted, but aggregated within the 
ER lumen, resulting in UPR activation. ROS concentrations were increased 
more than 100-fold in wtFVIII expressing CHO cells, compared to control CHO 
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cells. Co-incubation of CHO-FVIII cells with NaB and the antioxidant butylated 
hydroxyanisole (BHA) significantly reduced ROS production and apoptosis, 
increased wtFVIII secretion and thereby reduced intracellular wtFVIII 
accumulation (Malhotra et al. 2008).  
These findings indicate that reducing oxidative stress, which was produced by 
accumulation of misfolded protein, via antioxidant treatment, could decrease 
ER stress and improve cell survival in diseases of protein misfolding (Malhotra 
et al. 2008). 
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3 Research design and methods 
3.1 Treated male Munich Ins2C95S mutant and wild-type mice 
3.1.1 Animals 
Munich Ins2C95S mutant mice were generated within the Munich N-ethyl-N-
nitrosurea (ENU) mouse mutagenesis project. Male heterozygous mutants 
were bred onto a C3HeB/FeJ genetic background (Herbach et al. 2007). 
Animals received standard rodent diet (Altromin C1324, Germany) and tap 
water ad libitum. They were housed in a temperature- and light-controlled 
room (21 - 23°C, 55 ± 3% relative humidity, 12 hours light : 12 hours dark 
cycle). At the age of 21 days, mice were weaned, separated depending on 
sex, and marked by ear perforation. Tail tip biopsies for genotyping were 
taken, and blood glucose concentrations were measured. Twenty-two male 
heterozygous mutant mice were treated with subcutaneous sustained release 
insulin-pellets (Linshin, Canada; mt, ins), 21 male heterozygous mutant and 22 
male wild-type mice were provided with hypodermic placebo-pellets, also 
called blank-pellets (Linshin, Canada; mt, pl and wt, pl, respectively). 
Treatment with insulin- or placebo-pellets started at 32 days of age. Body 
weight and randomly fed blood glucose concentrations were determined 
weekly in order to control therapy. 
Regular clinical examinations were carried out starting with 12 wild-type, 12 
insulin-treated and 12 placebo-treated mutant mice. Intraperitoneal insulin 
tolerance tests (ipITTs) were performed at the age of 50, 100 and 150 days. A 
placebo-intraperitoneal insulin tolerance test (placebo-ipITT) was 
accomplished with 150-day-old mice. At the age of 45, 85, 110 and 150 days, 
oral glucose tolerance tests (OGTTs) were carried out, and serum C-peptide 
levels were determined before and 10 minutes after glucose challenge. The 
serum of 140-day-old mice was examined concerning thiobarbituric acid 
reactive substances (TBARS). During the investigation period (21 - 160 days 
of age), 1 insulin-treated and 3 placebo-treated mutants died. The 32 
remaining animals were sacrificed at the age of 160 days for examination of 
organ weights. Twelve mice (4 per investigation group) were used for 
qualitative-histological and quantitative-stereological analyses of the pancreas. 
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Additional 29 mice (10 wt, pl; 10 mt, ins; 9 mt, pl) were killed at the age of 100 
days. The islets of 12 of these animals (4 per group) were isolated and 
assayed in respect of ER stress via western blot analyses. The remaining 17 
mice (6 wt, pl; 6 mt, ins; 5 mt, pl) were killed by exsanguination under general 
anesthesia in order to examine pancreatic C-peptide levels as well as serum 
TBARS and serum glucagon concentrations. 
All tests were performed with randomly fed mice, in order to avoid 
hypoglycaemia of the mutant mice treated with insulin-pellets. The number of 
animals used in the distinct examinations is stated in table 3.1.  
 
All experiments were performed under the approval and in accordance with 
the guidelines of the responsible animal welfare authority (AZ 55.2-1-54-2531-
94-07). 
 
Number of animals investigated in distinct tests 
Group 1 Group 2  
wt, pl mt, ins mt, pl wt, pl mt, ins mt, pl 
genotyping 12 12 12 10 10 9 
body weight  12 11-12* 9-12* 10 10 9 
blood glucose  12 11-12* 9-12* 10 10 9 
OGTT 
  45 d 
  85 d 
110 d 
150 d 
 
7 
8 
12 
12 
 
7 
7 
11* 
11* 
 
7 
7 
11* 
9* 
   
ipITT 
  50 d 
100 d 
150 d 
 
12 
12 
12 
 
12 
9* 
11* 
 
12 
11* 
9* 
   
placebo-ipITT 
150 d 6 6 6    
C-peptide, serum 
  45 d 
  85 d 
110 d 
150 d 
 
7 
8 
12 
12 
 
7 
7 
9* 
11* 
 
7 
7 
8* 
9* 
   
C-peptide, 
pancreas 
100 d 
 
 
 
 
 
 
 
 
 
 
 
6 
 
 
6 
 
 
5 
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glucagon, serum 
100 d    6 6 5 
TBARS, serum  
100 d 
140 d 
 
 
6 
 
 
6 
 
 
6 
 
6 
 
 
6 
 
 
5 
 
ER stress, islets 
100 d    4 4 3
# 
organ weights 
160 d 6 6 5    
pancreas, LM, 
morphometry 
160 d 
4 4 4    
pancreas, TEM 
160 d 5 5 5    
Table 3.1: Number of animals investigated in distinct tests  
Group 1: sacrifice at 160 days of age; Group 2: sacrifice at 100 days of age;  
wt, pl: wild-type mice; mt, ins: insulin-treated mutant mice; mt, pl: placebo-treated mutant mice; 
*: 1 mt, ins and 3 mt, pl died during the investigation period;  
#: in 1 of 4 mt, pl not enough islets for western blot analysis could be obtained 
d, days of age; OGTT: oral glucose tolerance test; ipITT: intraperitoneal insulin tolerance test; 
TBARS: thiobarbituric acid reactive substances; ER: endoplasmic reticulum; LM: light 
microscopy; TEM: transmission electron microscopy 
 
3.1.2 Genotyping 
The genotype of mice was determined by a restriction fragment length 
polymorphism (RFLP) based method as previously described (Herbach et al. 
2007). The missense mutation in Ins2 creates a new Hpy 188I restriction site 
which is used for the allelic differentiation of Ins2. After DNA amplification with 
the primers Ins2_5for and Ins2_6rev, which are specific for Ins2, and digestion 
of the 529 bp PCR amplificates, wild-type mice show a 521 bp fragment, 
heterozygous Munich Ins2C95S mutant mice show both the 473 bp and the 521 
bp fragment, and homozygous mutants demonstrate the 473 bp fragment (Fig. 
3.1). 
Tail tip biopsies of approximately 0.4 cm length were taken at weaning and 
stored at -80°C until assayed. For DNA extraction, the tail tip was incubated in 
400 μl master mix over night in a heating block at 55°C. Thereafter, 
undigested components were separated by centrifugation for two minutes at 
15,000 rpm. The supernatant was poured into another Eppendorf cup, and 
400 μl isopropanol (neoLab, Germany) were added to precipitate DNA. The 
DNA pellet was washed twice with 900 μl 70% EtOH (Merck, Germany), the 
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liquid phase was discarded and the DNA pellet was dried at room 
temperature. DNA was suspended in 100 - 200 μl TE buffer, according to the 
size of the pellet when dried. To make sure that the DNA was dissolved 
completely, it was stored at 4°C for at least 24h before proceeding with the 
PCR. 
Nineteen μl of the PCR master mix and 1 μl of the suspended DNA were 
mixed carefully in PCR analysis cups (Eppendorf, Germany), which were then 
placed into a Mastergradient thermocycler (Eppendorf, Germany) and the 
program was run. PCR-H2O served as quality control. If needed, PCR samples 
were stored at -20°C until further use. Enzymatic digestion took place in a 
thermocycler (Eppendorf; 37°C, 30 minutes), using 9 μl of the amplified DNA 
sample, and 11 µl of restriction enzyme master mix. After enzymatic digestion, 
4 μl of loading dye were added to each sample. Then the samples were 
transferred into the sample wells of a 2% agarose gel, which was positioned in 
an Easy Cast™ gel chamber (PeqLab, Germany) filled with TAE (1x) running 
buffer. At the beginning of the row 12 μl pUC Mix Marker 8 (MBI Fermentas, 
Germany) were placed in a well in order to allow estimation of amplified 
fragment size. Electrophoresis was run at 65 volt for the first 15 minutes, 
afterwards at 110 volt for about 80 minutes (PowerPac 300, Bio-Rad, USA). 
The gel was stained in ethidium bromide solution (Roth, Germany) for 20 
minutes. The amplified products were visualised (Universal Hood, Bio-Rad, 
USA) under UV light (306 nm), and a digital picture was taken to document the 
result. 
Materials: 
Reagents were stored at room temperature if not stated differently. 
 
Master mix for DNA isolation: 
 Cutting Buffer: 375 μl 
 20% SDS (Roth, Germany): 20 μl 
 Proteinase K (20 mg/ml): 5 μl 
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Cutting buffer:  
 Tris/HCl 1 M, pH 7.5 (Roth, Germany): 2.5 ml 
 EDTA 0.5 M, pH 8.0 (Sigma, Germany): 5.0 ml 
 NaCl 5 M (AppliChem, Germany): 1.0 ml 
 Dithiothreitol (DTT) 1 M (Roth, Germany): 250 µl  
 Spermidine (500 mg/ml; Sigma, Germany): 127 µl 
 ad 50 ml distilled water 
 stored at 4°C 
 
Proteinase K (Roche, Germany): 
 20 mg/ml diluted in distilled water, stored at -20°C 
 
TE buffer: 
 Tris/HCl 10 mM, pH 8.0 (Roth, Germany) 
 EDTA 1 mM (Sigma, Germany) 
 
PCR master mix: 
 Taq PCR Master Mix Kit (Quiagen, Germany) 
 10x Buffer: 2 µl
 MgCl2: 1.25 µl 
 Q-solution: 4 µl 
 Taq polymerase: 0.1 µl 
 
 Redistilled water: 8.65 µl 
 
 dNTP 1 mM (Eppendorf, Germany):  1 µl 
 
 Primer sense (Ins2_5for): 1 µl 
 Primer antisense (Ins2_6rev): 1 µl 
 Primer concentration 2 µM each  
 (Genzentrum/DNSynthese, Germany; primer sequences: 
 Ins2_5for: 5’-TGA CCT TCA GAC CTT GGC AC-3’ 
 Ins2_6rev: 5’-TAG CTG CCA TCA CCC ATG CC-3’) 
 all reagents stored at -20°C 
 
Restriction enzyme master mix: 
 Restriction enzyme Hpy 188I  
 (New England BioLabs, UK): 0.8 µl 
 NEBuffer 4 (New England BioLabs, UK): 2.0 µl 
 Redistilled water: 8.2 µl 
 stored at -20°C 
 
Loading dye 6x: 
 Glycerine (Merck, Germany): 3 ml 
 Bromphenol blue (Merck, Germany): spatula tip  
 Redistilled water: 7 ml 
 stored at 4°C 
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Agarose gel, 2%: 
 Agarose (Roth, Germany): 4 g 
 dissolved in boiling TAE (1x) buffer: 200 ml 
 
Marker: 
 100 bp DNA Ladder (New England BioLabs, UK): 25 µl 
 Loadind dye 6x: 25 µl 
 Redistilled water: 100 µl 
 stored at 4°C 
 
Ethidium bromide solution: 
 Ethidium bromide 1% (Roth, Germany): 100 µl 
 TAE (1x): 1,000 ml 
 
EDTA 0.5 M pH 8.0, stock solution: 
 EDTA (Roth, Germany): 14.89 g 
 Distilled water: 80 ml 
 adjust to pH 8.0 with NaOH 5 M (Merck, Germany) 
 
TRIS 1 M: 
 Tris base (Roth, Germany): 6.057 g 
 ad 50 ml distilled water 
 adjust to pH 8.0 with 37% HCl (Merck, Germany) 
 
TAE 50x: 
 Tris base (Roth, Germany):  242 g 
 Glacial acetic acid (Merck, Germany): 57.1 ml 
 EDTA 0.5 M, pH 8.0: 100 ml 
  ad 1,000 ml distilled water  
 
 
Program for DNA amplification: 
1. 94°C, 5 minutes (denaturation, initiation)  
2. 94°C, 45 seconds (denaturation) 
3. 62°C, 45 seconds (primer annealing) 
4. 72°C, 90 seconds (elongation) 
 
34 cycles 
5. 72°C, 10 minutes (final extension)  
hold on 4°C  
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Figure 3.1: Genotyping via polymerase chain reaction (PCR) and restriction fragment 
length polymorphism (RFLP) 
M 1 2 3 4 5 6 7 8 9 10
After PCR and RFLP analysis, wild-type mice (3, 7, 9) present DNA fragments of 521 base 
pairs (bp), heterozygous mutant mice (1, 2, 4, 6) exhibit fragments of 473 bp and 521 bp, 
homozygous mutants (5, 8) possess fragments of 473 bp. Due to incomplete digestion of the 
amplified DNA fragment, homozygous mutants show a weak band at 521 bp. 
10: PCR-H2O; M: marker; visible marker bands represent fragment sizes of 1118, 881, 692, 
501, 489, 404, 331, 242, 190 and 147 base pairs (from top to bottom) 
 
3.1.3 Treatment with insulin- and placebo-pellets  
Sustained release insulin- and placebo-pellets (Linbits®, Linshin, Canada) 
weigh 13 mg and measure 2 mm in diameter and 3 mm in length. Insulin-
pellets contain insulin and micro-recrystallised palmitic acid, and deliver 0.1 
units insulin per day for about 30 days, according to the manufacturer. The 
placebo-pellets only contain micro-recrystallised palmitic acid. 
Treatment was started with one subcutaneous pellet, as soon as male 
heterozygous mutant mice showed randomly fed blood glucose levels over 
200 mg/dl, which occurred at a mean age of 32 days. Heterozygous mutant 
mice were treated with insulin-pellets (mt, ins), placebo-treated heterozygous 
mutant mice (mt, pl), and wild-type mice (wt, pl) served as controls. Body 
weight and blood glucose concentrations were controlled weekly. As soon as 
blood glucose levels of insulin-treated heterozygous mutants reached more 
than 180 mg/dl, another insulin- or placebo-pellet was applied, according to 
the treatment group. 
Pellet application: 
For analgesia after pellet application, each mouse received 10 µl of Metacam® 
solution (15 mg/ml Meloxicam, Boehringer, Germany) per os, using a pipette. 
An anaesthetic mixture of Medetomidine (0.5 mg/kg body weight, Domitor®, 
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Pfizer, Germany), Midazolam (5 mg/kg body weight, Midazolam-ratiopharm®, 
Ratiopharm, Germany) and Fentanyl (0.05 mg/kg body weight, Fentanyl 
DeltaSelect®, Delta Select, Germany) was injected intraperitoneally with a  
30-gauge needle. A dexpanthenol containing ointment (Bepanthen®, Bayer, 
Germany) was applied into both eyes. Approximately 15 minutes after the 
injection, an area of 1 cm2 in the mid dorsal region of the mouse was shaved 
using an electric shaver. The skin was cleaned and disinfected with a 10% 
povidone-iodine solution (Braunol® 10%, B.Braun, USA). A 16-gauge needle, 
a 12-gauge trocar, and a stylet were placed into a container filled with a 2% 
povidone-iodine solution (Braunol® 10%, diluted 1:5 in distilled water) for 
disinfection. The pellets were submerged in the 2% povidone-iodine solution 
for about 5 seconds and inserted into the cone end of the 12-gauge trocar. 
The shaved and disinfected skin was penetrated with the 16-gauge needle to 
create a small hole, and the trocar containing the pellet was pushed through 
the skin orifice. Using the stylet, the pellet was placed under the skin 
approximately 1 cm away from the orifice. The injection site was covered with 
a Chlorhexidine healing powder (Riemser, Germany). Finally, an antagonist 
mixture of Atipamezole (2.5 mg/kg body weight, Antisedan®, Pfizer, Germany), 
Flumazenil (0.5 mg/kg body weight, Anexate®, Roche, Germany) and 
Naloxone (1.2 mg/kg body weight, Naloxon DeltaSelect®, DeltaSelect, 
Germany) was injected subcutaneously to end anaesthesia. 
In order to avoid hypothermia, an infrared lamp was used during anaesthesia 
until the mice recovered. 
3.1.4 Body weight 
Body weights of randomly fed mice were determined weekly during the 
investigation period to the nearest 0.1 g, using a precision balance (KERN, 
Germany). 
3.1.5 Blood glucose concentration 
From 21 days of age onwards, blood glucose levels were measured weekly at 
11 am. Blood samples were taken from the nicked tail tip with a 10 µl open-
end capillary (HITADO, Germany) by softly massaging the tail. The capillary 
was placed into a tube filled with 500 µl hemolysis solution (glucapil®, 
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HITADO, Germany), and blood glucose concentration was determined, using 
the blood glucose analyser SUPER GL® (HITADO, Germany). 
Blood glucose levels during oral glucose tolerance tests and intraperitoneal 
insulin tolerance tests were evaluated in an analogue way. 
Additionally, the glucose concentration in blood collected from the retroorbital 
plexus of 100-day-old mice was determined, as described above. 
3.1.6 Oral glucose tolerance test (OGTT) 
At the age of 45, 85, 110 and 150 days, oral glucose tolerance tests were 
performed. To avoid hypoglycaemia of insulin-treated mutants, mice were not 
fasted over night. 
At 10 am, each mouse was placed into an individual cage with tap water 
access ad libitum. The tail tip was nicked, and blood samples were collected to 
analyse basal blood glucose and serum C-peptide concentrations. The mice 
received 11.1 µl of a 1 M glucose solution per gram body weight (α-D-
Glucose, Sigma, Germany; diluted in tap water) into the stomach via gavage 
tube. Ten minutes after glucose administration, further blood samples for 
determination of blood glucose and serum C-peptide levels were taken. At 20, 
30, 60, 90 and 120 minutes, samples for analysing the blood glucose 
concentrations were collected. Blood glucose levels were measured 
immediately as described above (3.1.5 Blood glucose concentration). The 
area under the glucose curve was calculated using the program GraphPad 
Prism 3.0 (GraphPad Software, USA). 
To assay the serum C-peptide concentrations, about 100 - 120 µl blood were 
collected from the tail tip using a 75 µl capillary tube (Hirschmann, Germany). 
After centrifugation (1K15 centrifuge, Sigma, Germany; 10 minutes, 10,000 
rpm), the serum was removed and stored at -80°C until assayed.  
3.1.7 Insulin tolerance test and placebo-insulin tolerance test 
3.1.7.1 Intraperitoneal insulin tolerance test (ipITT) 
Intraperitoneal insulin tolerance tests (ipITTs) were carried out at the age of 
50, 100 and 150 days. 
Each mouse was placed into a separate cage with tap water access ad 
libitum. At 2 pm, blood samples were collected from the nicked tail tip to 
determine basal blood glucose levels. Subsequently, 0.75 I.U. insulin per 
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kilogramme body weight (40 U/ml, Insuman® Rapid, Aventis, Germany; diluted 
1:247 in 0.9 % NaCl; 120 µl injection volume) were administered 
intraperitoneally, using a 30G x ½” cannula. Further blood samples were taken 
10, 20, 30, 60 and 90 minutes after insulin application. Blood glucose 
concentrations were measured immediately as described above (3.1.5 Blood 
glucose concentration). 
3.1.7.2 Placebo-intraperitoneal insulin tolerance test (placebo-ipITT) 
At the age of 150 days, a placebo-insulin tolerance test was accomplished to 
investigate the influence of the pellet-insulin in insulin-treated mutant mice on 
the ipITT. Instead of insulin, the mice were injected 120 µl 0.9% NaCl 
intraperitoneally. The test procedure was otherwise identical to the ipITT. In 
the placebo-ipITT 6 mice per investigation group were analysed and compared 
to the ipITT of the identical animals at the age of 150 days.  
3.1.8 C-peptide concentration in serum and pancreas 
3.1.8.1 Serum C-peptide concentration 
During the oral glucose tolerance tests at the age of 45, 85, 110 and 150 days 
(3.1.6 Oral glucose tolerance test (OGTT)), the serum C-peptide 
concentrations were determined from randomly fed mice (0 minutes), and 10 
minutes after oral glucose challenge, using a Rat C-Peptide RIA Kit (Linco 
Research, USA). This radioimmunoassay fully cross-reacts with murine  
C-peptide. 
Due to small sample volumes (55 - 70 µl serum), the assay was performed 
using the half amount of sample and assay reagents as denoted in the 
instruction sheet. The exact procedure of the RIA Kit is described in the 
Appendix (10.2.1.1 C-peptide). 
Additionally, the difference between the C-peptide levels 10 minutes after 
glucose application and basal values (0 minutes) were calculated. 
3.1.8.2 Pancreatic C-peptide content 
At the age of 100 days, 17 randomly fed mice (6 wild-type, 6 insulin- and 5 
placebo-treated mutant mice) were anaesthetised by intraperitoneal injection 
of 200 µl of a ketamine/xylazine mixture, and euthanised by exsanguination. 
The serum was separated from cellular components via centrifugation (1K15 
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centrifuge, Sigma, Germany; 10 minutes, 10,000 rpm) and stored at -80°C 
until assayed. The pancreas was separated carefully from the adjacent 
tissues, and homogenised for 1 minute in 4 ml acetic acid (2 M), using a 
Polytron PT 1200 E tissue homogeniser (Kinematic AG, Switzerland). After 
boiling the homogenate for 5 minutes in water bath (GFL, Germany), it was 
centrifuged for 15 minutes at 15,000 x g (4K15C centrifuge, Sigma, 4°C). 
Samples were aliquoted and stored at -80°C until assayed. 
 
Pancreatic C-peptide levels were analysed by the same radioimmunoassay 
used to determine serum C-peptide concentrations (3.1.8.1 Serum C-peptide 
concentration). Pancreas homogenate was diluted 1:1,000 (wild-type mice), 
1:400 (insulin-treated mutant mice) and 1:100 (placebo-treated mutant mice) 
in PBS. 
The protein content in the pancreas homogenate was measured, using a 
spectrophotometer (NanoDrop ND-1000, peqlab, Germany). C-peptide levels 
were expressed as C-peptide-to-protein-ratio. 
Materials: 
Anaesthetic: 
 Ketamine 10% (Selectavet, Germany): 1 ml 
 Xylazine 2% (Rompun 2%, Bayer, Germany): 0.25 ml 
 NaCl 0.9%: 5 ml 
 
Acetic acid 2 M: 
 Glacial acetic acid (Merck, Germany): 11.9 ml 
 Distilled water: 88.1 ml 
 
Phosphate buffered saline (PBS): 
 NaCl (AppliChem, Germany): 7.95 g 
 Na2HPO4 (Roth, Germany): 1.15 g 
 KCl (Merck, Germany): 0.20 g 
 KH2PO 4 (AppliChem, Germany): 0.20 g 
 ad 1,000 ml distilled water 
 adjust to pH 7.4  
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3.1.9 Serum glucagon concentration 
The serum glucagon levels of 100-day-old mice (see 3.1.8.2) were 
determined, using a Glucagon RIA KIT (Linco Research, USA) which fully 
cross-reacts with murine glucagon. 
The assay was performed according to the manufacturer’s protocol, using half 
the reaction batch volumes (10.2.1.2 Glucagon). 
3.1.10 Serum lipid peroxidation 
Lipid peroxidation in the serum of 100- and 140-day-old mice was examined, 
using a TBARS Assay Kit® (Cayman, USA), according to the manufacturer’s 
protocol (10.2.3 Thiobarbituric Acid Reactive Substances (TBARS)). Serum 
was diluted 1:1 in HPLC grade water (Applichem, Germany).  
Serum samples were obtained from the nicked tail tip (140 days; see 3.1.6) or 
the retroorbital plexus (100 days; see 3.1.8.2). Additionally, the corresponding 
blood glucose concentrations were determined (3.1.5 Blood glucose 
concentration).  
3.1.11 Western blot analysis of isolated islets 
Isolated islets of 100-day-old mice (4 wild-type, 4 insulin- and 4 placebo-
treated mutant mice) were examined with regard to the endoplasmic reticulum 
stress markers BiP/Grp78 (Binding Ig protein/Glucose regulated protein 78), 
PeIF2α (phosphorylated eukaryotic initiation factor 2α), and GADD153/CHOP 
(Growth arrest and DNA damage 153/C/EBP homologous protein). Actin was 
used as loading control. The optical density of BiP, PeIF2α and CHOP was 
determined, using ImageJ 1.41o (NIH 2004) and divided by the optical density 
of actin.  
3.1.11.1 Islet isolation 
The 12 mice were anaesthetised by intraperitoneal injection of 200 µl of 
ketamine/ xylazine mixture, and killed by cervical dislocation. The bowel was 
placed to the right side of the mouse in order to expose the pancreas and the 
bile duct. The bile duct was ligated near the liver with a thin string. The small 
intestine was clamped with a compressor on each side of the bile duct orifice. 
Using a winged infusion set (Venofix®, B.Braun, Germany), the bile duct was 
cannulated via the small intestine, and 2 ml collagenase solution (Sigma, 
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Germany) were injected into the pancreas. The bloated pancreas was 
cautiously removed from the adjacent tissue and placed into a screw-cap tube, 
filled with 3.75 ml perfusion solution and 1.5 ml collagenase solution. 
Pancreatic tissue was digested for at least 20 minutes in a water bath (GFL, 
Germany; 37°C). The tube was gently shaken occasionally. The digested 
pancreas was transferred into a petri dish filled with ice cold HANK’s with 0.3% 
BSA to stop digestion. Islets were hand picked on ice with a pipette under a 
stereomicroscope (Stemi DV4, Zeiss, Germany; magnification x 32), and 
transferred into a 1.5 ml Eppendorf tube. After all visible islets were collected, 
tubes were centrifuged (1 minute, 1,000 rpm), the supernatant was discarded, 
and 30-50 µl of protein extraction buffer were added to the islets. Cell 
membranes were destroyed by freezing at -80°C, thawing on ice for 30 
minutes, followed by sonication (B15, Branson, USA), and lysing on ice for 
another 30 minutes. After centrifugation (1K15 centrifuge, Sigma, Germany; 5 
minutes, 5,000 rpm), the supernatant was separated, and stored at -20°C until 
assayed. 
Materials 
Anaesthetic: 
 described above (3.1.8.2) 
 
Collagenase solution: 
 Perfusion solution: 20 ml 
 Collagenase type 1 (C0130, Sigma, Germany): 40 mg 
 on ice  
 
Perfusion solution: 
 HANK’s 1x: 40 ml 
 CaCl2 1 M (Merck, Germany): 94 µl  
 Hepes 1 M (Sigma, Germany): 1 ml 
 on ice 
 
HANK’s 1x:  
 HANK’s 4x: 250 ml 
 α-D-Glucose (Sigma, Germany): 0.40 g  
 Distilled water: 750 ml  
 adjust to pH 7.25 
 on ice 
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HANK’s 4x: 
 NaCl (Applichem, Germany):  8.0 g 
 Hepes (Sigma, Germany): 2.38 g 
 KCl (Roth, Germany): 400 mg 
 NaHCO3  (Merck, Germany): 350 mg 
 KH2PO4 (Roth, Germany): 60 mg 
 Na2HPO4 (Roth, Germany): 60 mg 
 MgSO4 (Merck, Germany): 200 mg
 CaCl2 (Merck, Germany): 185 mg
 Distilled water: 250 ml 
 stored at 4°C 
 
HANK’s 1x with 0.3% BSA: 
 HANK’s 1x: 960 ml 
 Bovine serum albumin (BSA; Sigma, Germany): 2.88 g 
 
Protein extraction buffer: 
 20 mmol/l Tris/HCl pH 7.6 (Roth, Germany) 
 0.5% Ipegal CA 630 (MP Biomedicals, USA) 
 250 mmol/l NaCl (AppliChem, Germany) 
 3 mmol/l EDTA  
 3 mmol/l EGTA 
 1 mmol/l phenylmethylsulfonyl fluoride (PMSF) 
 2 mmol/l sodium-orthovanadate 
 1 mmol/l DTT (dithiothreitol, Roth, Gerrmany) 
 Complete (Roche, Germany)  
 
Sodium-orthovanadate stock solution (200 mmol/l): 
1. dissolve 0.92 g sodium-orthovanadate (MP Biomedicals, USA) in 20 ml 
distilled water on a magnetic stirrer 
2. adjust to pH 10 with 1 N NaOH or 1 N HCl until solution turns yellow 
3. boil for approximately 10 minutes until solution clears 
4. cool down, using an ice bath 
5. repeat step 2 - 4 until solution stays clear and pH 10 stabilises 
6. fill up to 22.5 ml with distilled water 
7. store aliquots of 1 ml at -20°C 
Thaw before use by heating to 90 - 100°C in order to dissolve crystals. 
 
PMSF 100x:  
 PMSF (Sigma, Germany): 17.4 mg 
 ad 1 ml isopropanol 
 store at -20°C  
 
EDTA 0.3 M, 100x: 
 EDTA (Sigma, Germany): 1.116 g 
 ad 10 ml distilled water 
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EGTA 0.3 M, 100x: 
 EGTA (Sigma, Germany): 1.141 g 
 ad 10 ml distilled water 
 
Complete, 25x (Roche, Germany): 
Dissolve 1 pellet in 2 ml distilled water, aliquot and store at 4°C (stable for 1 - 
2 weeks) or freeze at -20°C (stable for 12 weeks) 
 
3.1.11.2 Islet protein content  
The protein content in isolated islets was analysed via Bradford method. A 
protein standard was produced by dissolving 10 mg of bovine serum albumin 
(BSA, Sigma, Germany) in 1 ml phosphate buffered saline (PBS). The 
standard concentrations 250, 125, 62.5, 31.3, 15.6, 7.8, 3.9, 2.0 μg/ml were 
produced by serial dilution in a 96-well plate. One µl of the sample was added 
to 199 µl PBS in one well of the 96-well plate, and diluted 1:2 in PBS in the 
adjacent well. Subsequently, 100 µl of a 40% Bradford reagent (Bio-Rad, 
Germany) was added to all wells. After incubation for 5 minutes, the protein 
content was determined photometrically at 595 nm, using a plate reader 
(SUNRISE, Tecan, Germany) and the program Magellan 2 (Tecan, Germany). 
Materials: 
PBS: 
 described above (3.1.8.2) 
 
Bradford reagent: 
 Bio-Rad Protein Assay 100% (Bio-Rad, Germany): 2 ml 
 Distilled water: 5 ml 
 protected from light and stored at 4°C 
 
3.1.11.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
A 10%-SDS gel was poured in a gel casting chamber (Mini-Protean III®, Bio-
Rad, Germany) and covered with isopropanol. After polymerisation for about 
45 minutes, the isopropanol was drained, and the stacking gel was casted 
onto the 10% separation gel. A comb was immediately placed into the still fluid 
stacking gel in order to create sample wells. After polymerisation of the 
stacking gel (approximately after 40 minutes), the comb was removed 
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carefully, and the gel was set into an electrophoresis cell (Protean III®, Bio-
Rad, Germany). The inner cell of the electrophoresis chamber was filled to the 
top, the outer cell was filled about 3 cm with running buffer.  
The islet samples were diluted to a protein content of 12 µg/20 µl, but at least 
1:2 in sample buffer. Denaturation of proteins took place in a thermoblock 
(TB1, Biometra, Germany; 10 minutes, 100°C).  
A molecular weight standard (Precision Plus ProteinTM, Bio-Rad, Germany) 
was pipetted into the first well of the gel, samples were loaded into the other 
wells. Gel electrophoresis was run at 200 volt for 50 minutes (Power PAC 300, 
Bio-Rad, Germany). 
Materials: 
Reducing sample buffer: 
 Sample buffer, stock solution: 475 µl 
 β-mercaptoethanol (Sigma, Germany): 25 µl 
 
Sample buffer, stock solution: 
 Tris/HCl 0.5 M, pH 6.8: 1.2 ml 
 SDS 10% (Sigma, Germany): 2 ml 
 Glycerol (Merck, Germany): 1 ml 
 Bromphenol blue 0.05% (Merck, Germany): 0.6 ml
 Distilled water: 4.8 ml 
 
10%-SDS polyacrylamide gel: 
 Distilled water: 2.085 ml 
 Tris/HCl 1.5 M, pH 8.8: 1.25 ml 
 SDS 10% (Sigma, Germany): 50 µl 
 Acrylamide 30% (Roti Phenol®, Roth, Germany): 1.665 ml 
 Ammonium persulfate (APS) 10% (Bio-Rad, Germany): 25 µl 
 Tetraethylethylenediamine (TEMED) (Roth, Germany): 5 µl 
 
Stacking gel: 
 Distilled water: 1.525 ml 
 Tris/HCl 0.5 M, pH 6.8: 0.625 ml 
 SDS 10% (Sigma, Germany): 25 µl 
 Acrylamide 30% (Roti Phenol®, Roth, Germany): 0.325 ml 
 Ammonium Persulfate (APS) 10% (Bio-Rad, Germany): 25 µl 
 Tetraethylethylenediamine (TEMED) (Roth, Germany): 5 µl 
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Tris/HCl 0.5 M, pH 6.8: 
 Tris base (Roth, Germany): 6.057 g 
 ad 100 ml distilled water 
 adjust to pH 6.8 with HCl 37% (Merck, Germany) 
 
Tris/HCl 1.5 M, pH 8.8: 
 Tris base (Roth, Germany): 18.5 g 
 ad 100 ml distilled water 
 adjust to pH 8.8 with HCl 37% (Merck, Germany) 
 
Running buffer, ready to use: 
 Stock solution: 40 ml 
 SDS 10% (Sigma, Germany): 4 ml 
 ad 400 ml distilled water 
 
Running buffer, stock solution: 
 Tris base (Roth, Germany): 30.3 g 
 Glycine (Merck, Germany): 144 g 
 ad 1,000 ml distilled water 
 
3.1.11.4 Western blot analysis 
Two fibre pads, 6 absorbent papers and 1 nitrocellulose membrane 
(Schleicher & Schuell, Germany) were cut approximately to the gel size and 
moistened in Towbin buffer. After electrophoresis, gels were placed on the 
pre-wetted nitrocellulose membrane (Schleicher & Schuell, Germany) between 
three layers of absorbent paper, and fibre pads each side, and the sandwich 
was set in the gel holder cassette. Two cassettes were placed into the 
electrode module, which was then inserted in the buffer tank along with a 
frozen cooling unit (Mini Trans-Blot Cell, Biorad, Germany), and a magnetic 
stir bar. The tank was set into a styrofoam box which was filled with crushed 
ice for cooling. After filling the tank with cold (4°C) Towbin buffer, the transfer 
was run for 90 minutes at 100 volt on a magnetic stirrer (IKA, Germany). The 
nitrocellulose membrane was marked at one edge and washed in Tris buffered 
saline-Tween (TBS-T). 
Silver staining of the gel was performed to demonstrate blotting success 
(3.1.11.5 Silver staining and drying). 
 
For immunostaining, a tumbling shaker (Heidolph, Germany) was used while 
washing and incubating the nitrocellulose membrane. Washing was carried out 
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3 times for 5 minutes with TBS-Tween (TBS-T) if not stated differently. All 
antibodies were diluted in 10 ml of 1% BSA in TBS-T. 
To avoid non-specific binding of the used antibodies, the membrane was 
blocked in 1% bovine serum albumin (BSA) in TBS (1 hour, room 
temperature). After washing, the membrane was simultaneously incubated in 
polyclonal rabbit anti-Grp78 (Stressgen, Canada; 1:10,000), monoclonal rabbit 
anti-PeIF2α (Cell Signaling, USA; 1:1,000), and polyclonal rabbit anti-
GADD153 (Santa Cruz Biotechnology, USA; 1:500) antibodies over night at 
4°C.  
The next day, the membrane was washed and incubated with a horseradish 
peroxidase conjugated anti-rabbit antibody (Cell signalling, 1:10,000) for  
1 hour at room temperature. After another washing step, the membrane was 
covered with Luminol Reagent (Santa Cruz Biotechnology, USA) for 1 minute. 
Afterwards, the membrane was placed into a film cassette (Ortho Fine, AGFA, 
Germany), and covered with a plastic transparency to avoid dehydration. In a 
darkroom, an Amersham Hyperfilm ECL (GE Healthcare, Germany) was laid 
upon the covered membrane and exposed for about 2 minutes. The film was 
developed (Kodak professional developer, Kodak, USA), shortly rinsed in a 
12% acetic acid solution, fixed (Kodak professional fixer, Kodak, USA), rinsed 
thoroughly with tap water, and dried. The membrane was removed from the 
film cassette, washed for 5 minutes in TBS-T, incubated for 10 minutes in 
stripping buffer, washed for 2 x 10 minutes in PBS and for 2 x 5 minutes in 
TBS-T (mild stripping protocol according to Abcam, UK). After blocking in  
1% BSA in TBS (1 hour, room temperature) and washing, the membrane  
was incubated with a monoclonal mouse anti-actin antibody (Chemicon 
international, Germany; 1:10,000, over night, 4°C). The membrane was 
washed, and a horseradish peroxidase rabbit anti-mouse antibody was added 
(DAKO, Germany; 1:10,000). Detection of immunoreactivity was performed as 
described.  
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Materials: 
Towbin buffer: 
 Tris base (Roth, Germany): 3.03 g  
 Glycine (Merck, Germany): 14.4 g 
 Methanol (neoLab, Germany): 200 ml 
 Distilled water: 800 ml 
 stored at 4°C 
 
Tris buffered saline (TBS), ready to use: 
 TBS, stock solution: 500 ml 
 Distilled water: 4,500 ml 
 
Tris buffered saline (TBS), stock solution x10: 
 Tris base (Roth, Germany): 60.6 g 
 NaCl (AppliChem, Germany): 87.6 g 
 ad 1,000 ml distilled water 
 adjust to pH 7.4 with HCl 37% (Merck, Germany) 
 
TBS-T: 
 TBS, stock solution x10: 50 ml 
 Distilled water: 450 ml 
 Tween 20 (Merck, Germany): 250 µl 
 
Luminol Reagent (Santa Cruz Biotechnology, USA): 
 Solution A: 5 ml 
 Solution B: 5 ml 
 
Developer: 
 Kodak professional developer (Kodak, USA): 7.8 g 
 Distilled water: 50 ml 
 
Fixer:  
 Kodak professional fixer (Kodak, USA): 9.2 g 
 Distilled water: 50 ml 
 
Stripping buffer: 
 Glycine (neoLab, Germany): 15 g 
 SDS 10% (Sigma, Germany): 1 g 
 Tween 20 (Merck, Germany): 10 ml 
 ad 1,000 ml distilled water 
 adjust to pH 2.2 with 37% HCl (Merck, Germany) 
 
3.1.11.5 Silver staining and drying 
The 10%-SDS gel was incubated for 30 minutes in fixation solution. 
Subsequently, it was washed 3 times for 20 minutes with 50% ethanol (Merck, 
- 74 - 
Germany). After pre-treating the gel for 1 minute in sodium thiosulfate solution, 
it was rinsed with distilled water (3 x 20 seconds). The gel was impregnated 
for 20 minutes and washed (2 x 20 seconds) with distilled water. Development 
was performed under visual control until bands could be seen. After rinsing the 
gel in distilled water (20 seconds), the procedure was stopped with EDTA 
solution. The gel was washed 3 times for 2 minutes with distilled water and 
incubated in drying solution on a tumbling shaker (over night, 4°C). The next 
day, two sheets of cellophane (DryEase Mini Cellophane, Novex, Germany) 
were moistened in drying solution for 30 seconds. One part of the DryEase gel 
drying frame (Novex, Germany) was placed on a dryer base (DryEaseMini-Gel 
Drying Base, Novex) and covered with one of the cellophane films. The gel 
was laid in the centre of the film and the other cellophane sheet was placed 
onto the gel. Air blisters and wrinkles were carefully removed. The 
gel/cellophane sandwich was closed with the other part of the frame, using 5 
plastic clamps. The gel was set in an upright position and let dry for 36 hours 
in a draft-protected place. Finally, the dried gel was taken out of the frame and 
placed under a heavy book for straightening. 
Materials  
Fixation solution: 
 Ethanol 100% (Merck, Germany): 500 ml 
 Glacial acetic acid (Merck, Germany): 120 ml 
 Formaldehyde 37% (SAV-LP, Germany): 0.5 ml 
 ad 1,000 ml distilled water 
 
Pre-treating solution: 
 (Na2S2O3 ) x 5 H2O (Merck, Germany): 50 mg 
 Distilled water: 50 ml 
 
Impregnation solution: 
 AgNO3 (AppliChem, Germany): 50 mg 
 Distilled water: 50 ml
 Formaldehyde 37% (SAV-LP, Germany): 35 µl 
 
Development solution: 
 Na2CO3 (Merck, Germany): 1.5 g 
 (Na2S2O3 ) x 5 H2O (Merck, Germany): 0.1 mg 
 Distilled water: 100 ml 
 Formaldehyde 37% (SAV-LP, Germany): 50 µl 
 
- 75 - 
Stop solution: 
 EDTA 0.1 M, pH 8.0 (Sigma, Germany): 14.8 g 
 Distilled water: 400 ml 
 
Drying solution: 
 Methanol 15% 
 Glycerol 3% 
 diluted in distilled water 
 
3.1.12 Organ preparation and weighing 
3.1.12.1 Perfusion 
At the age of 160 days, 17 animals (6 wild-type, 6 insulin- and 5 placebo-
treated mutant mice) were sacrificed for determining organ weights and for 
qualitative-histological and quantitative-stereological analyses of the pancreas. 
About 90 minutes before perfusion, 300 µl of a 10 mM 5-Bromo-2’-deoxy-
uridine (BrdU) solution (Roche, Germany) were injected intraperitoneally, for 
later determination of islet-cell replication. Each mouse was anaesthetised by 
ketamine/xylazine application (see 3.1.8.2), and killed by cervical dislocation. 
Tissue was fixed for histology via orthograde vascular perfusion. A 15-gauge 
needle connected with perfusion tubes was inserted into the left heart 
ventricle. The vena cava inferior was transsected directly after the beginning of 
the perfusion to enable the fluids to drain off. First, the vasculature was pre-
flushed with 2 ml Lidocaine (Lidocainehydrochloride 2%, bela-pharm, 
Germany) in order to dilate the blood vessels, followed by perfusion with about 
40 - 50 ml PBS (pH 7.4, 37°C) to wash the blood out of circulation. Then, 
perfusion with warm (37°C) 4% paraformaldehyde in 0.05 M cacodylate buffer 
was performed for 5 minutes.  
The PBS buffer and the fixative were filled in open bottles which hang about 
1.7 metres above the bottom in order to create a constant pressure  
(60 mmHg) for perfusion.  
Materials:  
5-Bromo-2’-deoxy-uridine (BrdU)-solution (10 mM): 
 5-Bromo2’-deoxy-uridine crystals (Roche, Germany): 10 mg 
 Distilled water: 3.256 ml 
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PBS:  
 described above (3.1.8.2) 
 
Paraformaldehyde 4% in 0.05 M cacodylate buffer  
 
Cacodylate buffer 0.05 M:  
 Sodium Cacodylate Trihydrate (Fluka, Germany): 10.7 g 
 Paraformaldehyde (Merck, Germany): 40 g 
 Calciumchloride-dihydrate (Merck, Germany): 0.735 g 
 ad 1,000 ml distilled water  
 clear solution with NaOH 1 N (Roth, Germany) 
 adjust to pH 7.2 with HCl 37% ( Merck, Germany) 
 
Dilute sodium cacodylate trihydrate in 500 ml distilled water (room 
temperature), adjust to pH 7.2 with HCl 37% and heat up to 80°C. 
Subsequently, add paraformaldehyde and calciumchloride-dihydrate. Clear the 
solution with 1 N NaOH. Add 500 ml distilled water, let cool down and adjust to 
pH 7.2 with HCl 37%. 
 
3.1.12.2 Organ weight 
After perfusion and removal of the pancreas, the animals were post-fixed in 
4% paraformaldehyde in cacodylate buffer for one week at room temperature. 
Organs (lung, heart, thymus, liver, spleen, stomach, intestine, kidneys, 
mesenterial lymph node, testes, epididymes) and abdominal fat were carefully 
removed from the adjacent tissues, blotted dry on cellulose paper, and 
weighed to the nearest mg, using a BP 61S scale (Satorius, Germany). 
The gastrointestinal tract was weighed filled with ingesta, and after emptying.  
Abdominal fatty tissue consisted of mesentery (without lymph node), and 
residual fatty tissue from the abdominal and pelvic cave. 
3.1.12.3 Pancreas preparation  
The pancreas was separated from the adjacent tissue immediately after 
perfusion. It was blotted dry and weighed to the nearest mg. The specific 
weight of the pancreas (1.10 mg/mm3) was determined by the submersion 
method (Scherle 1970). 
A piece of approximately 6 mm3 was cut off the splenic end of the pancreas, in 
order to prepare samples for transmission electron microscopy (TEM). The 
remaining pancreas was placed into a plastic tissue capsule (Engelbrecht, 
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Germany) on a biopsy pad (Bio-optica, Italy) to avoid distorsion, and was post-
fixed in 4% paraformaldehyde in cacodylate buffer. 
The next day, the pancreas was embedded in agar (BactoTM Agar, 
Becton&Dickinson, USA) to alleviate its later slicing, put into a tissue capsule, 
dehydrated and embedded in paraffin (Histomaster, Bavimed, Germany). 
The following day, the pancreas was cut perpendicular to its longitudinal axis 
into parallel slices of 1 mm thickness, with the first cut positioned randomly 
within an interval of 1 mm length at the splenic end of the pancreas. The slices 
were positioned with the right cut surface facing downwards, and paraffin 
embedding (SAV-LP, Germany) was finished.  
Approximately 4 µm thick sections were cut, using a HM 315 microtome 
(Microm GmbH, Germany) and mounted on 3-aminopropyltriethoxy-silane-
treated glass slides (Starfrost® microscope slides, Light Labs, USA). 
Subsequently, the sections were dried and stored in a heating cabinet (37°C). 
3.1.13 Immunohistochemistry of the pancreas 
Immunohistochemical staining for insulin, glucagon, somatostatin, and 
pancreatic polypeptide producing cells was performed, using the indirect 
immunoperoxidase method. 
For the determination of replicating and apoptotic β-cells, co-staining for 
insulin and BrdU or insulin and TUNEL was performed, using the indirect 
immunoperoxidase and alkaline phosphatase method. 
All incubations were carried out at room temperature in a humidity chamber. 
Normal serum and antibodies were diluted in Tris buffered saline (TBS,  
pH 7.4). TBS was used for washing if not stated differently. 
3.1.13.1 Glucagon, somatostatin and pancreatic polypeptide 
The antibodies used were purchased from DAKO® (Germany). 
Pancreas sections were deparaffinised in xylene (20 minutes), rehydrated in a 
descending alcohol series (2 x 100%, 2 x 96%, 1 x 70% ethanol), and rinsed in 
distilled water. Endogenous peroxidase activity of tissue sections was blocked 
by incubation in 1% hydrogen peroxide solution for 15 minutes. After washing 
for 10 minutes, sections were pre-treated with normal swine serum (MP 
Biomedicals, USA; dilution 1:10, 30 minutes) to reduce non-specific binding. 
Subsequently, an antibody cocktail containing polyclonal rabbit anti-human 
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glucagon (dilution 1:50), polyclonal rabbit anti-human somatostatin (dilution 
1:100), and polyclonal rabbit anti-human pancreatic polypeptide (dilution: 
1:500) was applied for 2 hours. The tissue sections were rinsed for 10 
minutes, and incubated with a horseradish peroxidase conjugated porcine 
anti-rabbit IgG (1:50, containing 5% mouse serum) for 1 hour. After washing 
(10 minutes), immunoreactivity was visualised using 3,3’-diaminobenzidine 
tetrahydrochloride dihydrate (DAB, KEM-EN-TEC, Denmark) as chromogen. 
Slides were washed in tap water for 5 minutes, counterstained with Mayer’s 
Hemalaun (Applichem, Germany) and washed with running tap water (5 
minutes). Subsequently, the sections were dehydrated via an ascending 
alcohol series, cleared in xylene, and mounted under glass coverslips, using 
Roti® Histokitt II (Roth, Germany). 
Materials: 
TBS:  
 described above (3.1.11.4) 
 
Hydrogen peroxide 1%: 
 H2O2 30% (neoLab, Germany): 6 ml 
 Distilled water: 194 ml 
 
3,3’-diaminobenzidine tetrahydrochloride dihydrate (DAB): 
 DAB pellets (KEM-EN-TEC, Denmark): 1 piece 
 Distilled water: 10 ml 
Let the pellet dissolve for about 1 hour protected from light, filter the solution 
and add 1 µl H2O2 30% (neoLab, Germany) per 1 ml DAB solution directly 
before use. 
 
3.1.13.2 Insulin 
For qualitative-histological investigations and for the determination of the total 
volume of isolated β-cells in the pancreas, an immunohistochemistry for insulin 
was performed. The staining procedure was similar to that demonstrating α-, 
δ- and PP-cells (3.1.13.1 Glucagon, somatostatin and pancreatic polypeptide). 
To reduce non-specific binding, normal rabbit serum (MP Biomedicals, USA; 
dilution 1:10) was used. Sections were incubated with polyclonal guinea pig 
anti-porcine insulin (dilution 1:500, 2 hours). Horseradish peroxidase 
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conjugated rabbit anti-guinea pig IgG (dilution 1:50, 5% mouse serum, 1 hour) 
served as second antibody. 
3.1.13.3 Replicating cells (BrdU) 
Ninety minutes before sacrifice 300 µl of a 5-Bromo-2’-deoxy-uridine solution 
were injected intraperitoneally (see 3.1.12.1). A double immunohistochemistry 
revealing insulin- and BrdU-positive cells was accomplished in order to survey 
the rate of replicating β-cells. 
 
Tissue sections were deparaffinised, rehydrated and washed as described. 
Antigen retrieval was performed by pre-treatment with Target Retrieval 
Solution (DAKO, Germany) for 20 minutes at 95°C. After cooling to room 
temperature (approximately 20 minutes), sections were washed (2 x 2 
minutes), and endogenous peroxidase activity was blocked by incubation in 
1% hydrogen peroxide solution for 10 minutes. Slices were washed (10 
minutes) and normal goat serum (MP Biomedicals, USA; dilution 1:10) was 
applied for 30 minutes. Subsequently, a polyclonal guinea pig anti-porcine 
insulin antibody was added (DAKO, Germany; dilution 1:1,000) for 1 hour. The 
tissue sections were washed (10 minutes) and incubated with an alkaline 
phosphatase conjugated goat anti-guinea pig IgG for 1 hour (Southern 
Biotech, USA; dilution 1:100). After washing for 10 minutes, immunoreactivity 
was visualised, using fuchsin substrate-chromogen (DAKO, Germany). The 
slides were shortly rinsed with distilled water, washed 2 x 2 minutes and 
incubated with normal rabbit serum (MP Biomedicals, USA; dilution 1:10, 30 
minutes). Subsequently, the sections were washed (2 x 2 minutes) and a rat 
anti-human BrdU antibody was added (Anti-Bromodeoxyuridine-Peroxidase, 
Roche, Germany; dilution 1: 50) for 1 hour. After washing (3 x 2 minutes), the 
sections were incubated with a horseradish peroxidase conjugated rabbit anti-
rat antibody (DAKO, dilution 1:50) for 30 minutes. Slides were rinsed 3 x 2 
minutes, and immunoreactivity was visualised, using DAB (KEM-EN-TEC, 
Denmark). After rinsing with distilled water, slides were counterstained with 
Mayer’s Hemalaun (Applichem, Germany), and washed with running tap water 
for approximately 5 minutes. The sections were air-dried, and mounted under 
glass coverslips, using Aquatex® (Merck, Germany). 
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Materials: 
5-Bromo-2’-deoxy-uridine (BrdU)-solution (10 mM): 
 described above (3.1.12.1) 
 
Target Retrieval Solution, ready to use: 
 Target Retrieval Solution (DAKO, Germany):  20 ml 
 Distilled water: 180 ml 
 
Hydrogen peroxide 1%:  
 described above (3.1.13.1) 
 
Fuchsin substrate-chromogen solution: 
 DAKO® Fuchsin Substrate-Chromogen System: 
 Fuchsin chromogen: 120 µl 
 Activating reagent: 120 µl 
 Substrate: 1.76 ml 
Mix 120 µl of fuchsin chromogen with 120 µl of activating reagent. Incubate for 
1 minute and add 1.76 ml substrate. 
 
DAB:  
 described above (3.1.13.1) 
 
3.1.13.4 Apoptotic cells (TUNEL) 
Apoptotic β-cells were demonstrated via combined insulin and TUNEL 
staining, the latter using the Apop Tag® Plus Peroxidase In Situ Apoptosis 
Detection Kit (Chemicon, USA).  
Pancreas sections were deparaffinised, rehydrated and washed as described. 
After being rinsed for 5 minutes, antigen retrieval was performed, using 
proteinase K solution (DAKO, Germany; 10 minutes, 37°C). The slides were 
rinsed 2 times for 2 minutes in distilled water, and endogenous peroxidase 
activity was blocked by applying 3% hydrogen peroxide for 5 minutes. 
Afterwards, the tissue sections were stained for insulin as described above 
(see 3.1.13.3). The washed slides were covered with equilibration buffer for 2 
minutes. After carefully removing excess liquid, slides were incubated with 
working strength TdT enzyme for 1 hour at 37°C. Attaching of nucleotides to 
DNA fragments was stopped by applying stop/wash buffer for 10 minutes. The 
slides were washed (3 x 2 minutes), and anti-digoxigenin conjugate was 
applied for 30 minutes. 
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Sections were rinsed (3 x 3 minutes) and DAB was added for 5 minutes to 
demonstrate immunoreactivity. After washing with distilled water (5 minutes), 
sections were counterstained with Mayer’s Hemalaun (Applichem, Germany), 
rinsed with running tap water (5 minutes), air-dried, and mounted under glass 
coverslips, using Aquatex® (Merck, Germany). 
Materials: 
Hydrogen peroxide 3%: 
 H2O2 30% (neoLab, Germany): 18 ml 
 Distilled water: 180 ml 
 
DAB: 
 described above (3.1.13.1) 
 
Following materials were components of the assay kit: 
 
Equilibration buffer: 
 ready to use 
 
Working strength TdT enzyme: 
 TdT enzyme: 22.5 µl 
 Reaction buffer solution: 52.5 µl 
  
Stop/wash buffer: 
 Stop/wash Buffer: 1 ml 
 Distilled water: 34 ml 
 
Anti-digoxigenin conjugate: 
 ready to use 
 
Kit was stored at -20°C. After the first use, TdT enzyme was stored at -20°C, 
the other reagents at 4°C. 
Reagents were warmed up to room temperature before use. Plastic coverslips 
were used for incubations. 
 
3.1.14 Quantitative-stereological analyses  
The pancreas of 160-day-old mice was investigated, using state-of-the-art 
quantitative-stereological methods as previously described (Wanke et al. 
1994; Herbach et al. 2007). 
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3.1.14.1 Pancreas volume 
To determine the pancreas volume (Vpan), the complete cut surface of 
pancreas sections was photographed at a final magnification of x16 (M 400 
photomacroscope, Wild, Switzerland). An object micrometer (Zeiss-Kontron, 
Germany) was photographed at the same magnification for calibration. All 
photographs were printed under equal conditions. 
Point-counting was performed, using a point-counting grid, photocopied onto a 
plastic transparency. The sum of points (∑P) hitting pancreatic tissue 
(endocrine and exocrine pancreas including connective tissue of the pancreas; 
∑Ppan), and the sum of points hitting the whole section (including extra 
pancreatic fatty tissue, lymphatic tissue, nerves, intestinal tissue and vessels; 
∑Psection) were determined separately. To calculate the volume fraction of 
pancreatic tissue in the section (Vv(pan/section)), ∑Ppan was divided by ∑Psection. 
The total volume of the pancreas (Vpan) before embedding was calculated by 
dividing the pancreas weight by the specific weight of the pancreas (see 
3.1.12.3) and by multiplying by Vv(pan/section). 
 
The area corresponding to one point was determined using the Videoplan® 
image analysis system (Zeiss-Kontron, Germany) after calibration with the 
printed object micrometer. One point equalled 0.1474 mm2 on the point 
counting grid. The sum of cross-sectional areas of the pancreas (∑Apan) was 
obtained by multiplying ∑Ppan by 0.1474 mm2. 
3.1.14.2 Volume density and total volume of islets, β-cells, non-β-cells 
and capillaries  
Evaluations were performed on sections simultaneously immunostained for 
glucagon, somatostatin and pancreatic polypeptide. All islets within the 
pancreas sections were photographed with a Leica DFC 320 camera, 
connected to a microscope (Leica Microsystems, Germany), using a x25 
objective. An object micrometer (Zeiss-Kontron, Germany) was photographed 
at the same magnification for calibration. All photographs were printed under 
the same conditions on a colour laser printer (HP, Germany). Using point 
counting morphometry, the sum of points hitting islets (∑Pislets), non-β-cells 
(∑Pnon-β-cells), and capillaries (∑Pcapillaries) were analysed separately (Figure 
3.2). The sum of points hitting β-cells (∑Pβ-cells) was calculated by subtracting 
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the sum of points hitting non-β-cells and capillaries from ∑Pislets. The area 
corresponding to 1 point was determined as described above (3.1.14.1) and 
equalled 181.8 µm2. 
The sum of cross-sectional areas of islets, β-cells, non-β-cells, and capillaries 
(∑Aislets, ∑Aβ-cells, ∑Anon-β-cells, and ∑Acapillaries, respectively) was attained by 
multiplying the sum of points hitting the respective compartment by 181.8 µm2. 
 
 
Figure 3.2 Point counting grid placed on an islet immunostained for glucagon, 
somatostatin and pancreatic polypeptide 
A point counting grid was used in order to count the sum of points hitting islet tissue, 
capillaries and non-β-cells.  
1: capillary, 2: non-β-cell, 3: β-cell 
 
The volume density of islets in the pancreas (Vv(islets/pan)) was calculated by 
dividing ∑Aislets by ∑Apan, the volume density of the endocrine compartment in 
the pancreas (Vv(endo/pan)) by dividing ∑Aβ-cells plus ∑Anon-β-cells by ∑Apan  
((∑Aβ-cells + ∑Anon-β-cells) / ∑Apan). The total volume of islets in the pancreas 
V(islets,pan) was attained by multiplying Vv(islets/pan) by Vpan. 
Due to perfusion fixation, around one fourth of the islet profile consisted of 
capillary volumina. Therefore, the volume density of β- and non-β-cells in the 
endocrine compartment of the islets (Vv(β-cells/endo) and Vv(non-β-cells/endo)) was 
determined by dividing ∑Pβ-cells, and ∑Pnon-β-cells by the ∑P hitting the endocrine 
compartment (∑Pislets - ∑Pcapillaries), respectively.  
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The volume density of β-cells, non-β-cells, and capillaries in the islets  
(Vv(β-cells/islets), Vv(non-β-cells/islets), Vv(capillaries/islets)) was calculated by dividing  
∑Pβ-cells,  ∑Pnon-β-cells or ∑Pcapillaries by the ∑Pislets.  
The total volume of β-cells (V(β-cells,islets)) and the total volume of non-β-cells 
(V(non-β-cells,islets)) in the islets were obtained by multiplying Vv(β-cells/islets) and 
Vv(non-β-cells/islets) by V(islets,pan), which is identical with multiplying Vv(β-cells/endo) and 
Vv(non-β-cells/endo) by V(endo,pan). The total volume of capillaries in the islets 
(V(capillaries,islets)) was calculated by multiplying Vv(capillaries,islets) by V(islets,pan). 
3.1.14.3 Volume density and total volume of isolated β-cells 
Isolated β-cells, an indicator for neogenesis of pancreatic islets (Bonner-Weir 
et al. 2008; Inada et al. 2008), were defined as single β-cells and small 
clusters of β-cells of up to 4 nuclear profiles that were not contained within 
established islets. The area of isolated β-cell profiles was determined 
planimetrically, using the Videoplan® image analysing system (Zeiss-Kontron, 
Germany). Images from sections immunostained for insulin were displayed on 
a colour monitor at an 850x final magnification. The sum of cross-sectional 
areas of isolated β-cell profiles (∑Aisolated β-cells) was quantified by circling their 
contours with a cursor on the digitising tablet of the image analysis system. 
The volume density of isolated β-cells in the pancreas (Vv(isolated-β-cells/pan)) was 
calculated by dividing ∑Aisolated β-cells by ∑Apan. The total volume of isolated  
β-cells (V(isolated-β-cells,pan)) was obtained multiplying Vv(isolated-β-cells,pan) by Vpan. 
3.1.14.4 β-cell replication  
β-cell replication was determined on pancreas sections double-stained for 
insulin and BrdU.  
The number of nuclear endocrine-cell profiles of 30 islets (10 islets per 
investigated group) were counted and the area that corresponds to one 
endocrine cell (Aendo) was calculated by dividing the corresponding cross-
sectional areas of the endocrine compartment of those islets by the number of 
nuclear profiles. The area corresponding to 1 endocrine-cell profile equalled 
102.6 µm2. 
The number of all nuclear β-cell profiles in the pancreas sections was 
calculated dividing ∑Aβ-cells (3.1.14.2 Volume density and total volume of islets, 
β-cells, non-β-cells3.1.16.2) by 102.6 µm2. BrdU positive nuclear β-cell profiles 
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in the islets were counted and divided by the number of nuclear β-cell profiles. 
Data are expressed as BrdU positive β-cells per 100,000 β-cells. 
3.1.14.5 β-cell apoptosis 
Apoptotic β-cells were determined on pancreas sections double-stained for 
insulin and TUNEL. Calculations were performed analogous to replicating  
β-cells and data are expressed as TUNEL positive β-cells per 100,000 β-cells. 
3.1.15 Transmisson Electron Microscopy (TEM) 
Pancreatic islets of 160-day-old mice were investigated electron 
microscopically. 
A piece of 6 mm3 from the splenic end of the pancreas (3.1.12.3 Pancreas 
preparation) was placed into a 0.5 ml Eppendorf cup, containing 4% 
paraformaldehyde in 0.05 M cacodylate buffer as fixative. After one hour, the 
pancreas piece for TEM was cut into 5 - 6 equal cubes and post-fixed for at 
least 24 hours at 4°C on a tumbling shaker. Samples were washed in 
cacodylate buffer (3 hours, room temperature) and post-fixed in a solution 
consisting to 1 part of 2% osmium tetroxide and to 1 part of 0.05 M cacodylate 
buffer (2 hours, 4°C). Subsequently, the pancreas samples were washed in 
cacodylate buffer (3 x 2 minutes) and dehydrated by an ascending acetone 
series (Roth, Germany). Pancreatic tissue was incubated in a solution 
containing equal amounts of 100% acetone and Glycid ether 100 (Serva, 
Germany) for 1 hour at room temperature, followed by incubation in Glycid 
ether 100 (2 x 30 minutes, room temperature). Samples were embedded in 
glycidether embedding mixture in dried gelatine capsules (Plano, Germany). 
Polymerisation was carried out at 60°C for 48 hours. 
Epon blocks were trimmed, using a Reichert-Jung TM60 milling machine 
(Leica, Germany). Semi-thin sections (0.5 µm) were produced with a Reichert-
Jung Ultracut E microtome (Leica, Germany), and stained with Toluidine  
blue O and Safranin O. After identifying the islets within the semi-thin sections 
via light microscopy, and marking their positions in a drawing, the areas of the 
Epon blocks containing islets were trimmed further, and ultra-thin sections  
(70 - 80 nm) were prepared (Reichert-Jung Ultracut E, Leica, Germany). The 
sections were mounted on coated copper rings, contrasted with uranyl acetate 
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and lead citrate (Reynolds 1963), and examined using an EM 10 electron 
microscope (Zeiss, Germany). 
Materials: 
Cacodylate buffer 0.05 M, paraformaldehyde 4% in 0.05 M cacodylate buffer: 
 described above (3.1.12.1) 
 
Ascending acetone series (Roth, Germany): 
 Acetone 50%: 3 x 2 minutes, 4°C 
 Acetone 70%: 2 x 10 minutes, 4°C 
 Acetone 90%: 2 x 10 minutes, 4°C 
 Acetone 100%: 2 x 20 min, 4°C 
 Acetone 100%: 1 x 20 min, room temperature 
 
Osmium tetroxide 2%: 
 Osmium tetroxide (OsO4, Merck, Germany): 1 g 
 Distilled water: 50 ml 
 
Glycidether embedding mixture: 
 Solution A: 70 ml 
 Solution B: 130 ml 
 2,4,6-tris-(dimethylaminomethyl) phenol (Serva, Germany):3 ml 
 
Solution A: 
 Glycid ether 100 (Serva, Germany): 62 ml 
 2-dodecenyl succinicacid anhydride (Serva, Germany): 100 ml 
 
Solution B: 
 Glycid ether 100 (Serva, Germany): 100 ml 
 Methylnadic anhydride (Serva, Germany): 89 ml 
Staining protocol: semi-thin sections: Toluidine blue O and Safranin O  
Toluidine blue O: 
 Di-sodiumtetraborate (Borax, Merck, Germany): 1 g 
 Toluidine blue O (Roth, Germany): 1 g 
 Distilled water: 100 ml 
 
Dissolve Borax in distilled water, add Toluidine blue 0 and stir for 
approximately 2 hours. Filter before use. Stain sections for 45 - 60 seconds on 
a heating plate (Meditel, Germany; 55°C), rinse with distilled water and let dry. 
 
Safranin O: 
 Di-sodiumtetraborate (Borax, Merck, Germany): 1 g 
 Safranin O (Chroma, Germany): 1 g 
 Saccharose (Merck, Germany): 40 g 
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 Formaldehyde 37% ( Roth, Germany): 2-3 drops 
 Distilled water: 100 ml 
 
Dissolve Borax in distilled water, add Safranin O and saccharose and stir for 
approximately 2 hours. The next day, add formaldehyde. Filter before use. 
Stain sections for 15 seconds on a heating plate (Meditel, Germany, 55°C), 
rinse with distilled water and let dry. Cover the sections with coverslips 
(Menzel GmbH & Co KG, Germany) using Histofluid (Superior®, Germany). 
Contrasting ultra-thin sections with uranyl acetate and lead citrate 
(Reynolds 1963) 
Uranyl acetate (Reynolds): 
 Uranyl acetate (Merck, Germany): 1 g 
 Redistilled water: 50 ml 
 
Swing carefully, don’t stir. Filter before use. 
Stain sections for 30 minutes at room temperature. 
 
Lead acetate (Reynolds): 
 Sodium citrate 1 M (Merck, Germany): 6 ml 
 Lead nitrate solution 1 M (Merck, Germany): 4 ml 
 Sodium hydrate solution 1 M (Merck, Germany): 8 ml 
 Redistilled water: 32 ml 
 
Mix sodium citrate with redistilled water while gently stirring. Add lead nitrate 
drop by drop, the solution gets milky (precipitation). Use sodium hydrate to 
clear the solution. Filter before use. Stain sections for 10 minutes at room 
temperature. 
 
3.2 C-peptide II concentration in serum and pancreas of 
untreated male and female Munich Ins2C95S mutant and wild-
type mice 
In order to determine the expression and secretion of the mutant insulin 2,  
C-peptide II concentrations were analysed in the pancreas and serum of 31 
untreated mice (4 male and 5 female wild-type mice, 6 heterozygous mutant 
and 5 homozygous mutant mice of both genders). 
Due to the short lifespan of homozygous mutants (31 - 76 days; Herbach et al. 
2007), mice were sacrificed at the age of 21 days. The animals were 
anaesthetised by intraperitoneal ketamine/xylazine injection (80 µl per mouse), 
and blood was collected from the retroorbital plexus (see 3.1.8.2). Afterwards 
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the mice were killed by cervical dislocation. The pancreas was removed and 
homogenised in 0.5 ml of 2 M acetic acid (see 3.1.8.2). Blood glucose 
concentrations were determined immediately, and serum was prepared as 
described (3.1.8.2). 
Pancreas samples were diluted 1:20 (wild-type mice) and 1:10 (heterozygous 
and homozygous mutants) in distilled water. C-peptide II concentrations in the 
serum and the pancreas were analysed using a Mouse C-Peptide II ELISA 
(KAMIYA, USA) according to the manufacturer’s protocol. The exact 
procedure of the Mouse C-Peptide II ELISA is described in the Appendix 
(10.2.2 C-peptide II ELISA). Protein contents in the pancreas homogenates 
were determined using a spectrophotometer (NanoDrop ND-1000, peqlab, 
Germany), and C-peptide II concentrations were expressed as C-peptide II-to-
protein-ratio. 
3.3 Additional investigations of untreated male and female 
Munich Ins2C95S mutant and wild-type mice 
3.3.1 Animals 
Additional tests were performed with 9 male and 8 female heterozygous 
Munich Ins2C95S mutant mice as well as 10 male and 10 female wild-type mice. 
One male mutant died during the investigation period. Housing conditions, 
weaning age, earmarking and genotyping was carried out as described above 
(3.1.1 Animals). These animals were not treated with insulin- or placebo-
pellets. At the age of 230 days, the mice were killed by exsanguination under 
general anaesthesia (see 3.1.8.2). 
3.3.2 Randomly fed body weight and blood glucose concentration 
Body weight and blood glucose concentrations of randomly fed animals were 
measured at the age of weaning (21 days) and in 30, 90 and 180-day-old mice 
(3.1.4 Body weight, 3.1.5 Blood glucose concentration). 
In addition, blood glucose levels were analysed at 200 and 230 days of age.  
3.3.3 Intraperitoneal insulin tolerance test (ipITT) 
The insulin sensitivity of Munich Ins2C95S mutant mice of different age-groups 
was previously examined via homeostasis model assessment of insulin 
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resistance index (HOMA IR (%)). Intraperitoneal insulin tolerance tests 
(ipITTs) were accomplished in male heterozygous mutant and male wild-type 
mice at the age of 4 months (Herbach et al. 2007). 
Since the HOMA IR is not designed for mice, insulin sensitivity was to be 
further assessed in different age-groups (21, 30, 90 and 180 days) and both 
genders of Munich Ins2C95S mutants and wild-type mice (n≥8 per age, sex and 
genetic group), via intraperitoneal insulin tolerance test (3.1.7.1 Intraperitoneal 
insulin tolerance test (ipITT)). 
3.3.4 Serum glucagon concentration 
The serum glucagon levels of 20 mice (5 mice per sex and genetic group) 
were determined (3.1.9 Serum glucagon concentration) randomly fed (T0) and 
10 minutes after intraperitoneal insulin injection (T10) at the age of 200 days. 
Insulin was applied as described above (3.1.7.1 Intraperitoneal insulin 
tolerance test (ipITT)). At 230 days of age, the glucagon concentrations of the 
same animals were analysed after a 15-hour fasting period (T0) and 10 
minutes after oral glucose challenge (T10) (3.1.6 Oral glucose tolerance test 
(OGTT)). 
Additionally, the differences of glucagon concentrations between T10 and T0 
were calculated. 
3.4 Statistical analysis and data presentation 
Data were analysed using a two-tailed Student’s t-test (MS Excel, Microsoft®, 
USA). P values < 0.05 were considered significant. Data are presented as 
means and either standard deviations (SD) or standard error of means (SEM), 
as indicated. 
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4 Results 
4.1 Treated male Munich Ins2C95S mutant and wild-type mice 
4.1.1 Body weight 
From the age of 21 days onwards, the body weights of randomly fed animals 
were measured weekly. No significant differences between insulin-treated 
mutants, wild-type mice and placebo-treated mutants existed until 100 days of 
age. Placebo-treated mutant mice were significantly lighter than wild-type mice 
at the age of 160 days (27.5 ± 1.4 g vs. 29.6 ± 2.1 g) (Figure 4.1). 
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Figure 4.1: Randomly fed body weights 
Body weights of insulin-treated mutants (mt, ins) are similar to those of wild-type (wt, pl) and 
placebo-treated mutant mice (mt, pl). At the age of 160 days, placebo-treated mutant mice are 
lower in body weight than wild-type mice. 
Data are means ± SEM; b): wt, pl vs. mt, pl; p<0.05; (n): number of animals investigated 
 
4.1.2 Blood glucose concentration 
In order to control and manage insulin therapy, randomly fed blood glucose 
concentrations were controlled weekly, starting with weaning at the age of 21 
days until time of sacrifice at 160 days of age. 
In general, insulin-treated mutant mice aged 60 days and older showed blood 
glucose concentrations similar to wild-type mice, ranging from approximately 
100 to 140 mg/dl. Only shortly before the next pellet injection, blood glucose 
levels of insulin-treated mutants were higher than those of wild-type mice, but 
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were never over 200 mg/dl (not shown). Blood glucose levels of wild-type mice 
remained stable during the investigation period (≤ 134 ± 10 mg/dl). From 31 
days of age onwards, placebo-treated mutant mice exhibited a progressive 
diabetic phenotype with increasing blood glucose levels, reaching 582 ± 165 
mg/dl at 160 days of age (Figure 4.2). 
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Figure 4.2: Randomly fed blood glucose levels between 21 and 160 days of age 
Blood glucose concentrations of insulin-treated mutant mice (mt, ins) from 60 days of age 
onwards don’t differ from those of wild-type mice (wt, pl). Placebo-treated mutant mice (mt, pl) 
demonstrate a progressive diabetic phenotype. 
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl; 
p<0.05; ↓: beginning of therapy (32 days of age); (n): number of animals investigated 
 
4.1.3 Oral glucose tolerance test (OGTT) 
At the age of 45, 85, 110 and 150 days, oral glucose tolerance tests were 
performed.  
During all OGTTs, placebo-treated mutant mice featured significantly elevated 
blood glucose concentrations compared to wild-type mice and insulin-treated 
mutants. Therefore, the corresponding areas under blood glucose curve 
(AUCblood glucose) were also increased (3.0- to 4.3-fold vs. wt, pl; 3.5- to 7.0-fold 
vs. mt, ins). The AUCblood glucose of insulin-treated mutants was similar to that of 
wild-type mice at 45, 85 and 150 days of age (Figure 4.3 (A2)-(D2)). 
Blood glucose levels of insulin-treated mutant mice started to decline between 
20 and 30 minutes after oral glucose application, those of placebo-treated 
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mutants between 30 and 60 minutes. In wild-type mice blood glucose values 
already declined between 10 and 20 minutes after glucose challenge. One 
hundred and twenty minutes after glucose challenge, the blood glucose levels 
of mutant mice treated with placebo-pellets were 29% (range 14% - 54%) 
higher, and those of wild-type mice were 19% (range 13% - 30%) higher than 
basal blood glucose concentrations. Due to the exogenous insulin delivered by 
the pellets, insulin-treated mutant mice presented 38% (range 22% - 59%) 
lower blood glucose concentrations at the end of the test than before glucose 
application (Figure 4.3 (A1)-(D1)).  
These results demonstrate that placebo-treated Munich Ins2C95S mutant mice 
exhibit a diminished glucose tolerance, whereas insulin treatment partially 
normalises glucose tolerance in male mutants.  
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Figure 4.3 (A)-(D): OGTT at the age of 45 (A), 85 (B), 110 (C) and 150 (D) days 
(A1)-(D1): Course of blood glucose concentrations 
Placebo-treated mutant mice (mt, pl) present elevated blood glucose levels at all time points of 
the OGTT, irrespective of age at sampling. Blood glucose concentrations of insulin-treated 
mutants (mt, ins) decline later than those of wild-type mice (wt, pl), but earlier than those of 
placebo-treated mutants. One hundred and twenty minutes after glucose challenge, blood 
glucose levels are 29% and 19% higher than basal values (T0) in mutants with placebo-pellets 
and wild-type mice, respectively. Due to the insulin therapy, insulin-treated mutants show 38% 
lower blood glucose concentrations at the end of the OGTT compared to T0. 
 
(A2)-(D2): Area under blood glucose curve (AUCblood glucose) 
The AUCblood glucose is significantly increased in placebo-treated mutant mice (mt, pl) during the 
OGTTs, irrespective of age at sampling. At the age of 45, 85 and 150 days, insulin-treated 
mutant (mt, ins) and wild-type mice (wt, pl) feature similar AUCblood glucose. 
 
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl;  
p<0.05; (n): number of animals investigated 
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4.1.4 Insulin tolerance test and placebo-insulin tolerance test 
4.1.4.1 Intraperitoneal insulin tolerance test (ipITT) 
The insulin sensitivity was investigated at the age of 50, 100 and 150 days via 
intraperitoneal insulin tolerance test (ipITT). 
The percentaged decrease of the blood glucose concentration from basal 
value (T0=100%) after insulin injection was determined at different time points 
(T10, T20, T30, T60 and T90; data not shown). The corresponding area under 
the blood glucose curve (AUCblood glucose) was calculated. At the age of 50 
days, no significant differences between placebo-treated mutant and wild-type 
mice, regarding the AUCblood glucose were detected. One hundred- and 150-day-
old placebo-treated mutants exhibited a significantly higher AUCblood glucose than 
wild-type mice and insulin-treated mutants. Due to the additional exogenous 
insulin released by the pellets, insulin-treated mutant mice showed lower 
AUCblood glucose compared to wild-type mice, irrespective of age at testing 
(Figure 4.4 (A)-(C)). 
These data indicate that placebo-treated mutants become insulin resistant, 
whereas insulin treatment normalises insulin sensitivity. 
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Figure 4.4 (A)-(C): Area under the curve of the percentaged blood glucose decrease 
from basal value (AUCblood glucose) of the ipITT at the age of 50 (A), 100 (B) and 150 (C) 
days  
The AUCblood glucose of mutant mice treated with insulin-pellets (mt, ins) are lower than those of 
wild-type mice (wt, pl). Placebo-treated mutant mice (mt, pl) feature a significantly elevated 
AUCblood glucose at the age of 100 and 150 days, compared to wild-type and insulin-treated 
mutant mice.  
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl 
p<0.05; (n): number of animals investigated 
 
4.1.4.2 Comparison between intraperitoneal insulin tolerance test 
(ipITT) and placebo-intraperitoneal insulin tolerance test (placebo-ipITT)  
To investigate the influence of the insulin released by the pellets of insulin-
treated mutant mice during the ipITT, a placebo-ipITT with 0.9% NaCl was 
carried out at the age of 150 days. The results of the placebo-ipITT were 
compared to the corresponding values of the ipITT. 
During the ipITT (Figure 4.5 (A)), the percentaged blood glucose 
concentrations of placebo-treated mutants only slightly decreased, despite of 
insulin application (T90: 80% ± 33% compared to T0: 100%). Due to the 
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therapy, insulin-treated mutants demonstrated a stronger decline of the 
percentaged blood glucose levels than wild-type mice (T90: mt, ins: 32% ± 8% 
vs. wt, pl: 64% ± 20%).  
In the placebo-ipITT (Figure 4.5 (B)), the percentaged blood glucose 
concentrations of placebo-treated mutant and wild-type mice decreased little 
after 0.9% NaCl injection (T90: mt, pl: 87% ± 12%; wt, pl: 98% ± 3%). Although 
insulin-treated mutant mice featured a considerable blood glucose decrease 
from basal during the placebo-ipITT (T90: 54% ± 10%), the decrease was 
significantly weaker than that in the ipITT. 
The AUCblood glucose of the ipITT and the placebo-ipITT were similar in placebo-
treated mutants. Insulin-treated mutant and wild-type mice exhibited a 
significantly lower AUCblood glucose in the ipITT than in the placebo-ipITT (Figure 
4.6). 
These results demonstrate that insulin-treated mutants don’t become insulin 
resistant in contrast to placebo-treated mutants. 
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Figure 4.5 (A)/(B): Percentaged blood glucose decrease from basal value during the 
ipITT (A) and the placebo-ipITT (B) at 150 days of age 
The percentaged blood glucose concentrations of placebo-treated mutant mice (mt, pl) only 
decrease little after insulin injection, compared to wild-type (wt, pl) and insulin-treated mutant 
mice (mt, ins) (A). During the placebo-ipITT (B) placebo-treated mutant and wild-type mice 
demonstrate almost no decline of the percentaged blood glucose values. Due to the insulin 
released by the pellets, the percentaged blood glucose concentrations of insulin-treated 
mutants decrease during the placebo-ipITT, but not as marked as during the ipITT. 
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl  
p<0.05; (n): number of animals investigated 
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Figure 4.6: Comparison of the AUCblood glucose between the ipITT and the placebo-ipITT at 
the age of 150 days 
Insulin-treated mutants (mt, ins) and wild-type mice (wt, pl) exhibit a significantly lower 
AUCblood glucose after insulin injection (ipITT) than after administration of 0.9% NaCl (placebo-
ipITT). Placebo-treated mutant mice (mt, pl) show a similar AUCblood glucose in the ipITT and the 
placebo-ipITT. 
Data are means ± SEM; *: ipITT vs. placebo-ipITT; p<0.05; 
(n): number of animals investigated 
 
4.1.5 Serum C-peptide concentration 
To examine the endogenous insulin secretion, without the influence of the 
insulin delivered by the pellets, serum C-peptide concentrations were 
determined at 45, 85, 110 and 150 days of age during the OGTT. C-peptide is 
known to be secreted with insulin in equimolar concentrations. 
Randomly fed (T0) C-peptide levels of insulin-treated mutant mice were 69 - 
87% and 35 - 76% lower compared to wild-type mice and placebo-treated 
mutants, respectively. Placebo-treated mutants exhibited a 43 - 53% lower  
C-peptide concentration than wild-type mice. 
Ten minutes after oral glucose challenge (T10), C-peptide concentrations of 
insulin-treated mutants were 91 - 96% and 43 - 75% lower versus wild-type 
mice and placebo-treated mutants, respectively. Compared to wild-type mice, 
placebo-treated mutants exhibited a 76 - 86% lower C-peptide concentration 
(Table 4.1). 
Ten minutes after oral glucose application, serum C-peptide levels of insulin-
treated mutants declined 0.7- to 0.9-fold. C-peptide concentrations of wild-type 
mice increased 1.5- to 3.6-fold. In placebo-treated mutant mice, the C-peptide 
concentrations decreased 0.6- to 0.9-fold after glucose application at the age 
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of 45, 85 and 110 days and slightly increased at the age of 150 days (Figure 
4.7). 
The analysed C-peptide levels show that insulin-treated and placebo-treated 
Munich Ins2C95Smutant mice suffer from a disturbed insulin secretion. 
 
  age (days) 
time group 
(n ≥7) 45 85 110 150 
T0 wt, pl  827 ± 140 639 ± 301 636 ± 290  525 ± 237  
 mt, ins  156 ± 105 a 126 ± 49 a 82 ± 66 a 161 ± 107 a 
 mt, pl 473 ± 145 b,c 328 ± 61 b,c 347 ± 100 b,c 247 ± 93 b 
T10 wt, pl  1225 ± 458  1576 ± 340  1480 ± 482  1870 ± 307  
 mt, ins 113 ± 62 a 93 ± 50 a 61 ± 46 a 147 ± 79 a 
 mt, pl 295 ± 61 b,c 291 ± 96 b,c 245 ± 91 b,c 257 ± 87 b,c 
Table 4.1: C-peptide concentrations (pM) in the serum of randomly fed (T0) mice and 10 
minutes after oral glucose challenge (T10) 
Randomly fed and 10 minutes after oral glucose application, insulin-treated mutants (mt, ins) 
show lower C-peptide levels compared to wild-type mice (wt, pl) and placebo-treated mutant 
mice (mt, pl). The C-peptide concentrations of placebo-treated mutants are significantly lower 
than those of wild-type mice. 
Data are means ± SD; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl  
p<0.05; (n): number of animals investigated 
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Figure 4.7: Changes in C-peptide concentrations 10 minutes after oral glucose 
challenge 
In insulin-treated mutant mice the C-peptide levels decline 10 minutes after glucose 
administration. Placebo-treated mutants feature a decline of C-peptide concentrations at 45, 
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85 and 110 days of age, and a slight incline at the age of 150 days. In wild-type mice (wt, pl) 
the C-peptide levels increase 10 minutes after glucose administration.  
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl;  
p<0.05; (n): number of animals investigated 
 
4.1.6 Pancreatic C-peptide content 
C-peptide levels in the pancreas of 100-day-old mice were determined, and 
were related to the pancreatic protein content. 
Insulin-treated mutant mice exhibited a 59% lower C-peptide/protein level in 
the pancreas compared to wild-type mice. The C-peptide/protein content in the 
pancreas of placebo-treated mutants was 91% and 78% lower than that of 
wild-type and insulin-treated mutant mice, respectively (2.9 ± 0.8 nM/mg vs. 
31.6 ± 17.6 nM/mg vs. 13.1 ± 4.2 nM/mg; Figure 4.8).  
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Figure 4.8: C-peptide/protein concentrations in the pancreas of 100-day-old mice 
Insulin-treated mutant mice (mt, ins) present a significantly higher C-peptide/protein content in 
the pancreas than placebo-treated mutants (mt, pl). The C-peptide/protein concentration of 
wild-type mice (wt, pl) is significantly higher than that of mutant mice. 
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl;  
p<0.05; (n): number of animals investigated 
 
4.1.7 Serum glucagon concentration 
Randomly fed serum glucagon concentrations of 100-day-old insulin-treated 
mutants and wild-type mice were equal. Despite of severe hyperglycaemia, 
placebo-treated mutant mice demonstrated 1.5-fold (p<0.05) higher glucagon 
levels in the serum compared to wild-type and insulin-treated mutant mice 
(Table 4.2). 
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 group (n) glucagon (pg/ml) blood glucose (mg/dl) 
wt, pl (6) 87 ± 17  145 ± 13  
mt, ins (6) 87 ± 27  158 ± 61  
mt, pl (5) 127 ± 21 b,c 571 ± 39 b,c 
Table 4.2: Serum glucagon levels and corresponding blood glucose concentrations at 
the age of 100 days 
Placebo-treated mutant mice (mt, pl) show significantly higher serum glucagon concentrations 
compared to wild-type (wt, pl) and insulin-treated mutant mice (mt, ins), despite of elevated 
blood glucose levels. 
Data are means ± SD; b,c: b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl; p<0.05;  
(n): number of animals investigated 
 
4.1.8 Serum lipid peroxidation 
The amount of thiobarbituric acid reactive substances (TBARS) in the serum 
of 100- and 140-day-old animals was determined. TBARS, a product of lipid 
peroxidation due to oxygen stress, are presented in malondialdehyde (MDA) 
equivalents. 
Insulin-treated mutant and wild-type mice showed a similar extent of lipid 
peroxidation in the serum (17 - 20 µM MDA), irrespective of age at sampling. 
Placebo-treated mutant mice exhibited 3.6- and 3.3-fold elevated MDA values 
versus wild-type and insulin-treated mutant mice, respectively at the age of 
100 days, as well as 4.4- and 4.0-fold higher MDA concentrations versus wild-
type and insulin-treated mutant mice, respectively at the age of 140 days. 
One hundred-day-old placebo-treated mutant mice presented significantly 
elevated blood glucose values compared to wild-type (3.9-fold) and insulin-
treated mutant mice (3.6-fold). At the age of 140 days, placebo-treated 
mutants featured 4.5-fold (vs. wt, pl) and 3.6-fold (vs. mt, ins) higher blood 
glucose concentrations (Table 4.3). 
Blood glucose levels correlated with lipid peroxidation in the serum (Figure 
4.9).  
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  age (days) 
 100 140 
group (n) MDA (µM) blood glucose (mg/dl) 
MDA (µM) blood glucose 
(mg/dl) 
wt, pl (6) 17.6 ± 2.9  145 ± 13  16.7 ± 1.7  126 ± 12  
mt, ins (6) 19.5 ± 5.3  158 ± 61  18.4 ± 3.4  157 ± 33  
mt, pl (5/6)* 63.6 ± 10.2 b,c 571 ± 39 b, c 74.0 ± 12.3 b,c 568 ± 63 b,c 
Table 4.3: Serum lipid peroxidation expressed in malondialdehyde (MDA) equivalents 
and corresponding blood glucose concentrations  
Insulin-treated mutant mice (mt, ins) exhibit similar serum MDA and blood glucose levels as 
wild-type mice (wt, pl), irrespective of age at sampling. The serum MDA and blood glucose 
concentrations of placebo-treated mutant mice (mt, pl) are at least 3.3-fold higher compared to 
wild-type mice and insulin-treated mutants.  
Data are means ± SD; b,c: b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl p<0.05; 
(n): number of animals investigated; *100 days: n=5, 140 days: n=6 
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Figure 4.9 (A)/(B): Correlation of blood glucose concentrations and serum lipid 
peroxidation expressed in MDA equivalents at the age of 100 (A) and 140 (B) days 
The blood glucose concentrations and serum MDA equivalents in the examined groups 
correlate by r = 0.98, irrespective of age at testing (p<0.01). 
 
4.1.9 Western blot analysis of isolated islets 
Islets of 100-day-old mice were isolated for examination of the ER stress 
markers BiP, PeIF2α and CHOP/GADD153 via western blot analysis. Islets of 
wild-type mice were easily detected under the stereomicroscope, appearing 
round to oval shaped with a smooth surface, and endocrine cells within the 
islets being smaller than the cells of the exocrine pancreas. Using reflected 
light microscopy and a black background, wild-type islets appeared brighter 
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than exocrine tissue clusters. In transmitted light, the islets appeared brownish 
versus whitish exocrine pancreas. Islets of placebo-treated mutant mice were 
sparse, and most of them appeared as irregularly shaped clusters of 
endocrine cells, suggesting fragmentation of islets. With reflected light 
microscopy, islets of placebo-treated mutants appeared more transparent than 
islets of wild-type mice or exocrine tissue clusters, using transmitted light, 
islets of placebo-treated mutants could not be identified. Islets of insulin-
treated mutants, could not be identified as easily as wild-type islets, but easier 
than islets of placebo-treated mutants. In transmitted light, only few of the 
islets could be detected, exhibiting a slightly brown colour. Using reflected light 
microscopy, more islets were detectable, the islets were not as bright 
compared to those of wild-type mice, but less transparent versus islets of 
placebo-treated mutants. Some islets exhibited an irregular shape, others 
were shaped similar to those of wild-type mice. About 100 - 150, 40 - 60, and 
30 - 40 islets per animal could be harvested within 1.5 hours from pancreata of 
wild-type mice, insulin-treated and placebo-treated mutants, respectively. 
Isolated islets of wild-type mice were at least 90% pure, whereas isolates of 
insulin-treated mutants were contaminated with approximately 15 - 25%, those 
of placebo-treated mutant mice with approximately 30 - 40% exocrine 
pancreas tissue fragments.  
In 1 placebo-treated mutant, the actin band was missing despite sufficient total 
protein content in the sample, as evidenced by Bradford method. This 
suggests degradation of proteins in the sample. 
The molecular weights of the different ER stress markers were 78 kDa for BiP, 
40 kDa for PeIF2α, and 25 kDa for CHOP. The optical density of bands of the 
ER stress markers was determined, and referred to that of actin (45 kDa). 
4.1.9.1 BiP/actin 
Insulin-treated mutants showed a similar optical density of BiP/actin in the 
islets compared to wild-type mice and a slightly higher optical density of 
BiP/actin than placebo-treated mutants (1.33 ± 0.54 vs. 1.21 ± 0.22 vs. 0.98 ± 
0.30; n.s.; Figure 4.10).  
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Figure 4.10: Optical density of BiP/actin in isolated islets at the age of 100 days 
In insulin-treated mutants (mt, ins) the optical density of BiP/actin is similar compared to wild-
type mice (wt, pl), and marginally higher than in placebo-treated mutant mice (mt, pl). 
Data are means ± SEM; (n): number of animals investigated 
 
4.1.9.2 PeIF2α/actin 
The optical density of PeIF2α/actin was higher in the islets of insulin-treated 
mutants as compared to wild-type and placebo-treated mutant mice (1.25 ± 
0.42 vs. 0.85 ± 0.34 vs. 0.85 ± 0.36; n.s.; Figure 4.11). 
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Figure 4.11: Optical density of PeIF2α/actin in isolated islets at the age of 100 days 
Insulin-treated mutants (mt, ins) demonstrate a higher optical density of PeIF2α/actin in the 
islets than wild-type mice (wt, pl), and placebo-treated mutants (mt, pl).  
Data are means ± SEM; (n): number of animals investigated 
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4.1.9.3 CHOP/actin 
Insulin-treated mutants featured a significantly higher optical density of 
CHOP/actin than wild-type mice (p<0.01) and a higher optical density of 
CHOP/actin versus placebo-treated mutant mice (1.30 ± 0.32 vs. 0.49 ± 0.19 
vs. 0.84 ± 0.33; Figure 4.12).  
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Figure 4.12: Optical density of CHOP/actin in isolated islets at the age of 100 days 
The optical density of CHOP/actin in the islets of insulin-treated mutants (mt, ins) is 
significantly higher than that of wild-type mice (wt, pl). Placebo-treated mutants (mt, pl) exhibit 
an over 1.5-fold higher optical density of CHOP/actin in the islets than wild-type mice. 
Data are means ± SEM; a): wt, pl vs. mt, ins; p<0.05; (n): number of animals investigated 
 
4.1.10 Organ weight 
Five to six mice per group were selected randomly for the determination of the 
organ weights at 160 days of age. In these selected mice, no significant 
differences concerning the body weight existed (compare to 4.1.1 Body 
weight). Placebo-treated mutants exhibited more contents in the 
gastrointestinal tract (GIT) than wild-type mice (p=0.052) and insulin-treated 
mutants (p<0.05). When the GIT contents were subtracted from the entire 
body weight, placebo-treated mutants were lighter than wild-type mice 
(p=0.06) and insulin-treated mutants (p<0.05). The emptied GIT of placebo-
treated mutants was significantly heavier than that of wild-type and insulin-
treated mutant mice. Mutant mice treated with insulin-pellets possessed less 
abdominal fatty tissue (mesenterial and residual fatty tissue from the 
abdominal and pelvic cave) than wild-type mice, but more than placebo-
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treated mutants. The kidney and liver weights of insulin-treated mutants and 
wild-type mice were similar, whereas placebo-treated mutant mice featured 
elevated kidney and liver weights (Figure 4.13, Table 4.4). Placebo-treated 
mutants showed significantly lighter testes than wild-type mice. With regard to 
the weight of pancreas, heart and spleen, no significant differences between 
the examined groups were found (Table 4.4). 
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Figure 4.13: Organ weights of 160-day-old mice 
Insulin-treated mutant (mt, ins) and wild-type mice (wt, pl) exhibit lower gastrointestinal tract 
(GIT) contents, liver and kidney weights than placebo-treated mutants (mt, pl). The abdominal 
fatty tissue of insulin-treated mutant mice is lighter than that of wild-type mice but heavier 
compared to placebo-treated mutants. 
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl; 
p<0.05; (n): number of animals investigated 
 
 
group (n) body body - 
GIT 
contents 
GIT 
empty 
pancreas heart spleen testes 
 g g g mg mg mg mg 
wt, pl (6) 29.1 
± 2.5 
27.1 
± 1.8 
2.95 
± 0.50  
379 
± 69 
160 
± 14 
164 
± 48 
157 
± 6  
mt, ins (6) 28.1 
± 0.8 
26.6 
± 0.9  
2.99 
± 0.37  
362 
± 64 
152 
± 13 
129 
± 42 
154 
± 17 
mt, pl (5) 27.2 
± 1.4 
24.9 
± 1.3 c 
4.21 
± 0.37 b, c
375 
± 44 
145 
± 15 
121 
± 20 
142 
± 8 b 
Table 4.4: Organ weights at the age of 160 days 
No significant differences concerning body, pancreas, heart and spleen weights are detected 
among the investigation groups. Placebo-treated mutant mice (mt, pl) feature higher contents 
in the gastrointestinal tract (GIT), and lower body weight minus GIT contents compared to 
insulin-treated mutant (mt, ins) and wild-type mice (wt, pl). The emptied GIT is significantly 
heavier and the testes are lighter in placebo-treated mutants than in wild-type and insulin-
treated mutant mice.  
Data are means ± SD; b,c: b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl;  
(n): number of animals investigated 
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4.1.11 Qualitative-histological findings of the pancreas 
4.1.11.1 Exocrine pancreas and pancreatic islets 
Qualitative findings of the exocrine pancreas of 160-day-old mice did not 
reveal any pathological changes, and there were no signs of insulitis.  
The amount of large islet profiles in the pancreas of insulin- and placebo-
treated mutants appeared to be slightly lower compared to wild-type mice. In 
insulin-treated mutant mice, the average size of islet profiles seemed larger 
than those of placebo-treated mutants.  
In sections immunostained for insulin, insulin-treated mutant mice presented 
less insulin-positive islet-cells than wild-type mice, but more than placebo-
treated mutants. 
In placebo-treated mutant mice, many of the β-cells demonstrated only weak 
staining intensity, indicating low insulin content. Some of the insulin-positive 
cells of insulin-treated mutants were stained almost as strong as those of wild-
type mice, whereas other β-cells exhibited a reduced staining intensity 
compared to wild-type mice (Figure 4.14). 
Immunohistochemistry for glucagon, somatostatin and pancreatic polypeptide 
demonstrated that placebo-treated mutants possessed a higher proportion of 
α-, δ- and PP-cells than wild-type mice. The islet structure was altered in 
placebo-treated mutants with non-β-cells being dispersed all over the islet 
profile. In insulin-treated mutant mice these alterations were not as distinct. 
Wild-type mice exhibited a typical murine islet composition with basically 
insulin-positive β-cells in the centre, surrounded by a ring of non-β-cells 
(Figure 4.15). 
In a few islets of placebo-treated mutant mice, the endocrine cells were 
displaced by exocrine pancreas, and the islet structure was destroyed. This 
phenomenon was not observed in wild-type or insulin-treated mutant mice 
(Figure 4.16). 
- 107 - 
   
Figure 4.14 (A)-(C): Pancreas sections immunostained for insulin. Representative islet 
profiles of 160-day-old mice 
Islet profiles of insulin-treated mutant mice (B) show a higher proportion of insulin-positive 
cells with stronger staining intensity than placebo-treated mutants (C). Most of the cells in the 
islet profiles of wild-type mice (A) are β-cells, which are stained intensively for insulin.  
Bar: 50 μm 
 
   
Figure 4.15 (A)-(C): Pancreas sections simultaneously immunostained for glucagon, 
somatostatin and pancreatic polypeptide. Representative islet profiles of 160-day-old 
mice 
Islet structure and composition in placebo-treated mutant mice (C) are altered, with the 
proportion of non-β-cells being increased and non-β-cells being distributed all over the islet 
profile. These changes are less obvious in insulin-treated mutants (B). Wild-type mice (A) 
show a typical islet structure, characterised by few non-β-cells, surrounding a core of β-cells.  
Bar: 50 μm 
 
 
Figure 4.16: Pancreas section simultaneously immunostained for glucagon, 
somatostatin and pancreatic polypeptide. Islet profile of a 160-day-old placebo-treated 
mutant mouse 
In placebo-treated mutant mice, a few islets feature a destroyed structure with endocrine cells 
being displaced by exocrine pancreas; Bar: 50 μm 
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4.1.11.2 Isolated β-cells 
Single insulin-positive cells and β-cell clusters of up to 4 nuclear profiles were 
identified as isolated β-cells, which are interpreted as sign of islet neogenesis 
(Bonner-Weir et al. 2008; Inada et al. 2008). These cells were found in all 
animals, either within the exocrine pancreas or associated to pancreatic ducts 
(Figure 4.17). 
 
  
Figure 4.17: Immunohistochemistry of pancreas sections for insulin. Isolated β-cells in 
the pancreas of 160-day-old mice 
Single isolated β-cells associated to a pancreatic duct (A) or within the exocrine pancreas (B) 
are found in all investigation groups. 
Bar: 50 μm 
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4.1.12 Quantitative-stereological findings of the pancreas 
4.1.12.1 Total pancreas volume 
At the age of 160 days, insulin-treated mutants, wild-type and placebo-treated 
mutant mice showed a similar total volume of the pancreas (Vpan) (308 mm3 ± 
34 mm3 vs. 328 ± 62 mm3 vs. 326 ± 37 mm3; Figure 4.18). 
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Figure 4.18: Total pancreas volume (Vpan) at the age of 160 days 
The Vpan in insulin-treated mutants (mt, ins), wild-type (wt, pl) and placebo-treated mutant mice 
(mt, pl) is equal. 
Data are means ± SEM; (n): number of animals investigated 
 
4.1.12.2 Volume density of islets in the pancreas 
The Vv(islets/pan) of insulin-treated mutant mice was lower than that of wild-type 
mice (p=0.051), but higher compared to placebo-treated mutants (0.23 ± 
0.03% vs. 0.34 ± 0.07% vs. 0.18 ± 0.02%; Figure 4.19). 
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Figure 4.19: Volume density of islets in the pancreas (Vv(islets/pan)) at the age of 160 days 
The Vv(islets/pan) is 32% lower in insulin-treated mutant (mt, ins) versus wild-type mice (wt, pl), 
and 28% higher compared to placebo-treated mutants (mt, pl). Placebo-treated mutant mice 
demonstrate a 47% lower Vv(islets/pan) than wild-type mice. 
Data are means ± SEM; b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl; p<0.05; 
(n): number of animals investigated 
 
4.1.12.3 Total islet volume  
Insulin-treated mutant mice presented a significantly lower total volume of 
islets in the pancreas (V(islets,pan)) than wild-type mice, and a significantly higher 
V(islets,pan) compared to placebo-treated mutants (0.71 ± 0.06 mm3 vs. 1.09 ± 
0.19 mm3 vs. 0.58 ± 0.03 mm3; Figure 4.20).  
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Figure 4.20: Total islet volume (V(islets,pan)) of 160-day-old mice 
In insulin-treated mutant mice (mt, ins) the V(islets,pan) is 35% lower compared to wild-type  
(wt, pl), and 22% higher compared to placebo-treated mutant mice (mt, pl). The V(islets,pan) of 
placebo-treated mutants is 47% lower than that of wild-type mice. 
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl; 
p<0.05; (n): number of animals investigated 
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4.1.12.4 Volume density of β-cells in the endocrine compartment of the 
islets 
The proportion of insulin-producing β-cells in the endocrine compartment of 
the islets was slightly lower in insulin-treated mutant than in wild-type mice, but 
higher compared to placebo-treated mutants (72 ± 4% vs. 81 ± 3% vs. 46 ± 
6%; Figure 4.21). 
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Figure 4.21: Volume density of β-cells in the endocrine compartment of the islets 
(Vv(β-cells/endo)) at the age of 160 days 
Insulin-treated mutant mice (mt, ins) exhibit a 11% lower Vv(β-cells/endo) versus wild-type mice 
(wt, pl), and a 57% higher Vv(β-cells/endo) compared to placebo-treated mutants (mt, pl). In 
placebo-treated mutants the Vv(β-cells/endo) is 43% lower than in wild-type mice.  
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl;  
p<0.05; (n): number of animals investigated 
 
4.1.12.5 Total volume of β-cells in the islets 
The total volume of β-cells in the islets (V(β-cells,islets)) of mutants treated with 
insulin was significantly lower than that of wild-type mice, but significantly 
higher than that of placebo-treated mutants (0.37 ± 0.04 mm3 vs. 0.65 ± 0.14 
mm3 vs. 0.21 ± 0.03 mm3 ; Figure 4.22). 
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Figure 4.22: Total volume of β-cells in the islets (V (β-cells,islets) ) at 160 days of age 
Insulin-treated mutant mice (mt, ins) feature a 43% lower V(β-cells,islets) than wild-type mice  
(wt, pl) and a 76% higher V(β-cells,islets)  compared to placebo-treated mutants (mt, pl). The  
V(β-cells,islets) of placebo-treated mutants is 68% lower than that of wild-type mice. 
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl;  c) mt, ins vs. mt, pl;  
p<0.05; (n): number of animals investigated 
4.1.12.6 Volume density of non-β-cells in the endocrine compartment of 
the islets 
The volume density of glucagon producing α-, somatostatin secreting δ-, and 
pancreatic polypeptide expressing PP-cells in the endocrine compartment of 
the islets (Vv(non-β-cells/endo)) was significantly higher in insulin-treated mutant 
compared to wild-type mice, but significantly lower compared to placebo-
treated mutants (28 ± 4% vs. 19 ± 3% vs. 54 ± 6%; Figure 4.23). 
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Figure 4.23: Volume density of non-β-cells in the endocrine compartment of the islets 
(Vv(non-β-cells/endo)) at the age of 160 days 
Insulin-treated mutant mice (mt, ins) feature a 47% higher Vv(non-β-cells/endo) than wild-type mice 
(wt, pl), and a 48% lower Vv(non-β-cells/endo) than placebo-treated mutants (mt, pl). Compared to 
wild-type mice the Vv (non-β-cells/endo) of placebo-treated mutants is 184% higher. 
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl;  c) mt, ins vs. mt, pl;  
p<0.05; (n): number of animals investigated 
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4.1.12.7 Total volume of non-β-cells in the islets 
The total volume of α-, δ-, and PP-cells in the islets (V(non-β-cells,islets)) was  
equal in insulin-treated mutants and wild-type mice (0.15 ± 0.02 mm3 vs. 0.15 
± 0.02 mm3). Placebo-treated mutant mice showed a significantly higher  
V(non-β-cells,islets) compared to wild-type mice (0.25 ± 0.03 mm3 vs. 0.15 ± 0.02 
mm3) and insulin-treated mutants (Figure 4.24). 
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Figure 4.24: Total volume of non-β-cells in the islets (V(non-β-cells,islets)) at 160 days of age 
Placebo-treated mutant mice (mt, pl) exhibit a 67% higher V(non-β-cells,islets) compared to wild-type 
(wt, pl) and insulin-treated mutant mice (mt, ins). 
Data are means ± SEM; b,c: b) wt, pl vs. mt, pl; c) mt, ins vs. mt, pl; p<0.05; 
(n): number of animals investigated 
 
4.1.12.8 Volume density of capillaries in the islets 
The volume density of capillaries in the islets (Vv(capillaries/islets)) of insulin-treated 
mutant mice was equal compared to wild-type mice, and higher compared to 
placebo-treated mutants (27 ± 4% vs. 27 ± 3% vs. 21 ± 4%; n.s.; Figure 4.25).  
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Figure 4.25: Volume density of capillaries in the islets (Vv(capillaries/islets)) at the age of 160 
days 
Insulin-treated mutant (mt, ins) and wild-type mice (wt, pl) present a 29% higher Vv(capillaries/islets) 
than placebo-treated mutants (mt, pl). 
Data are means ± SEM; (n): number of animals investigated 
 
4.1.12.9 Total volume of capillaries in the islets 
Insulin-treated mutant mice featured a significantly lower total capillary volume 
in the islets (V(capillaries,islets)) than wild-type mice, but a significantly higher 
V(capillaries,islets) than placebo-treated mutants (0.19 ± 0.04 mm3 vs. 0.29 ± 0.05 
mm3 vs. 0.12 ± 0.03 mm3; Figure 4.26). 
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Figure 4.26: Total volume of capillaries in the islets (V(capillaries,islets)) at 160 days of age 
The V(capillaries,islets) of insulin-treated mutants (mt, ins) is 34% lower versus wild-type mice  
(wt, pl), and 58% higher versus placebo-treated mutant mice (mt, pl). Placebo-treated mutants 
present a 59% lower V(capillaries,islets) than wild-type mice. 
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl;  c) mt, ins vs. mt, pl;  
p<0.05; (n): number of animals investigated 
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4.1.12.10 Volume density of isolated β-cells in the pancreas 
The volume density of isolated β-cells in the pancreas (Vv(isolated β-cells/pan)) of 
insulin-treated mice was significantly lower than that of wild-type mice, but 
significantly higher than that of placebo-treated mutants (0.0009 ± 0.0001% 
vs. 0.0013 ± 0.0002% vs. 0.0004 ± 0.0001%; Figure 4.27).  
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Figure 4.27: Volume density of isolated β-cells in the pancreas (Vv(isolated β-cells/pan)) at the 
age of 160 days 
Insulin-treated mutants (mt, ins) present a 31% lower Vv(isolated β-cells/pan) versus wild-type mice 
(wt, pl). Placebo-treated mutants (mt, pl) exhibit a 69% and 56% lower Vv(isolated β-cells/pan) than 
wild-type and insulin-treated mutant mice, respectively. 
Data are means ± SEM; a,b,c: a) wt, pl vs. mt, ins; b) wt, pl vs. mt, pl;  c) mt, ins vs. mt, pl;  
p<0.05; (n): number of animals investigated 
 
4.1.12.11 Total volume of isolated β-cells in the pancreas 
The total volume of isolated β-cells in the pancreas (V(isolated β-cells,pan)) of 
insulin-treated mutants was lower (p=0.053) than that of wild-type mice, but 
significantly higher than that of placebo-treated mutant mice (0.0026 ± 0.0005 
mm3 vs. 0.0042 ± 0.0011 mm3 vs. 0.0014 ± 0.0004 mm3; Figure 4.28). 
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Figure 4.28: Total volume of isolated β-cells in the pancreas (V(isolated β-cells,pan)) at the age 
of 160 days  
The V(isolated β-cells,pan) of insulin-treated mutant mice (mt, ins) is 37% lower than that of wild-type 
mice (wt, pl), and 83% higher than that of placebo-treated mutants (mt, pl). Placebo-treated 
mutant mice feature a 66% lower V(isolated β-cells,pan)  compared to wild-type mice. 
Data are means ± SEM; b,c: b) wt, pl vs. mt, pl;  c) mt, ins vs. mt, pl; p<0.05; 
(n): number of animals investigated 
 
4.1.12.12 β-cell replication 
In order to examine the rate of replicating β-cells in the islets of 160-day-old 
mice, BrdU positive β-cells per 100,000 β-cells were analysed. Insulin-treated 
mutant mice presented a similar amount of BrdU positive β-cells per 100,000 
β-cells as wild-type mice (80 ± 23 vs. 83 ± 34). In placebo-treated mutants the 
number of BrdU positive β-cells per 100,000 β-cells was higher compared to 
wild-type mice (122 ± 25 vs. 83 ± 34; Figure 4.29). 
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Figure 4.29: β-cell replication at the age of 160 days  
Insulin-treated mutants (mt, ins) demonstrate a similar amount of BrdU positive β-cells per 
100,000 β-cells compared to wild-type mice (wt, pl) and a 34% lower number of BrdU positive 
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β-cells compared to placebo-treated mutant mice (mt, pl). In placebo-treated mutants, the 
amount of BrdU positive β-cells is 47% higher than in wild-type mice. 
Data are means ± SEM; c: mt, ins vs. mt, pl; p<0.05; (n): number of animals investigated 
 
4.1.12.13 β-cell apoptosis 
The numerical fraction of apoptotic β-cells in the islets of 160-day-old mice 
was determined via TUNEL immunohistochemistry. No significant differences 
among the investigated groups concerning the number of TUNEL positive  
β-cells per 100,000 β-cells were detected. The amount of apoptotic β-cells 
varied substantially among the individual animals (Figure 4.30). 
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Figure 4.30: β-cell apoptosis at 160 days of age 
Insulin-treated mutant (mt, ins), placebo-treated mutant (mt, pl) and wild-type mice (wt, pl) 
exhibit similar amounts of TUNEL positive β-cells per 100,000 β-cells. 
Data are means ± SEM; (n): number of animals investigated 
 
4.1.13 Transmisson electron microscopy (TEM) 
Ultra-thin pancreas sections of 160-day-old mice were produced and 
examined using electron microscopy.  
Concerning the amount and distribution of the distinct endocrine cells within 
the islets, electron-microscopical observations were identical to qualitative-
histological and immunohistochemical findings (4.1.11 Qualitative-histological 
findings of the pancreas; Figure 4.31). 
The cytoplasm of β-cells of wild-type mice was densely packed with typical 
insulin secretory granules, characterised by an electron-dense core, 
surrounded by an electron lucent halo (Figures 4.31 (A); 4.32 (A)). 
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In placebo-treated mutant mice, most β-cells exhibited very few and small 
secretory granules. Many of the granules presented a tiny core and a 
broadened halo compared to wild-type mice. Other granules exhibited a 
narrowed and obscured halo (Figures 4.31 (B); 4.32 (C), (D); 4.33).  
The structure of granules in insulin-treated mutants was similar to that of wild-
type mice. The size of granule profiles seemed to be slightly smaller than that 
of wild-type mice, but definitely bigger than that of placebo-treated mutants. 
The amount of secretory granules in β-cells varied substantially within an islet. 
In general, there were fewer insulin granules in β-cells of insulin-treated 
mutants than in those of wild-type mice and more than in β-cells of placebo-
treated mutants (Figures 4.31 (C), (D); 4.32 (B)). 
These differences in the amount and size of secretory granules are mirrored 
by the various immunohistochemical staining intensities of β-cells described 
above (4.1.11 Qualitative-histological findings of the pancreas). 
In placebo- and insulin-treated mutant mice the rough endoplasmic reticulum 
(rER) appeared dilated as compared to wild-type mice (Figure 4.32). Due to 
perfusion artefacts, the width of Golgi lamellae could not be compared.  
A few β-cells of placebo-treated mutant mice featured enlarged mitochondria 
(Figures 4.32 (D); 4.33). In the β-cells of all examination groups, the crests of 
some mitochondria were disrupted, probably an artefact due to the perfusion 
(hypoxia) or, despite perfusion fixation, beginning autolysis. 
In contrast to wild-type and insulin-treated mutant mice, placebo-treated 
mutant mice regularly exhibited glycogen deposits in β-cells (Figure 4.32 (D)).  
Residual bodies could be found in all groups. Placebo-and insulin-treated 
mutant mice appeared to demonstrate a few more residual bodies than wild-
type mice (Figures 4.31 (B),(D); 4.33). 
No apoptotic bodies were found in β-cells of the mice examined. 
In all investigation groups, widened intercellular spaces could be found in 
some islets, which are interpreted as an artefact due to the perfusion.  
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Figure 4.31 Transmisson electron microscopy (TEM) of islet-cell profiles of 160-day-old 
mice 
Wild-type mice (A) demonstrate a typical murine islet structure with basically β-cells (β) in the 
centre. Non-β-cells (nβ) are located mainly at the border of the islets. The β-cells exhibit 
numerous secretory granules. In placebo-treated mutants (B) the amount of non-β-cells, 
particulary α-cells, is increased, and non-β-cells are distributed all over the islet profile. In the 
β-cells, there are very few and small secretory granules. Insulin-treated mutant mice (C, D) 
exhibit β-cells of varying amount of secretory granules within an islet. The number of residual 
bodies (? r) seems to be increased in insulin- and placebo-treated mutants, compared to wild-
type mice. In all examined groups, artefacts (e.g. dilated intercellular spaces (? ai) and Golgi 
lamellae (? aG)) are found, created by the perfusion 
Bar: 5 μm 
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Figure 4.32 TEM of β-cell profiles at the age of 160 days 
In some β-cells of placebo- (C, D) and insulin-treated mutant mice (B), the rough endoplasmic 
reticulum (? rER) appears dilated, compared to wild-type mice (A), and is filled with electron-
dense material. Secretory granules of insulin-treated mutants show a similar structure as wild-
type mice. They are marginally smaller than those of wild-type mice, but clearly bigger than 
those of placebo-treated mutants. Placebo-treated mutants exhibit only few and small 
secretory granules (? sg). In some granules, the halo is narrowed and obscured. Glycogen 
deposits (? gd) can be found in some β-cells of placebo-treated mutants. 
The size of mitochondria (m) in insulin-treated mutants is similar to that of wild-type mice (B 
vs. A). In placebo-treated mutants some mitochondria profiles are unchanged vs. wild-type 
mice (C vs. A), some are swollen (D).  
Bar: 1 μm 
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Figure 4.33 Details of β-cells of a placebo-treated mutant at the age of 160 days. TEM  
In some β-cells of placebo-treated mutants several mitochondria (m) are swollen (left β-cell), 
in others, mitochondria appear unchanged (right β-cell). Placebo-treated mutant mice show 
secretory granules (? sg) of different appearance. Some exhibit a tiny core and a broadened, 
clear halo compared to wild-type mice. Others present a narrowed and obscured halo  
r: residual body; aG: dilated Golgi lamellae, probably an artefact; 
Bar: 2 μm 
4.2 C-peptide II concentration in serum and pancreas of 
untreated male and female Munich Ins2C95S mutant and wild-
type mice 
4.2.1 Blood glucose concentration 
At the age of 21 days, heterozygous mutant mice of both genders 
demonstrated slightly higher randomly fed blood glucose concentrations 
compared to sex-matched wild-type mice. Blood glucose concentrations of 
male and female homozygous mutants were severely higher versus sex-
matched wild-type mice and heterozygous mutants (Table 4.5). 
 
 blood glucose (mg/dl) 
group (n) male female 
wt (4/5)* 112 ± 7 115 ± 4 
het (6) 138 ± 15 a 127 ± 11 d 
hom (5) 294 ± 42 b,c 271 ± 66 e,f 
Table 4.5 Randomly fed blood glucose concentrations at the age of 21 days 
Randomly fed blood glucose levels of male (m) and female (f) heterozygous mutants (het) are 
slightly higher compared to sex-matched wild-type (wt) mice, but lower versus homozygous 
mutants (hom). 
Data are means ± SD; a, b, c, d, e, f: a) m, wt vs. m, het; b) m, wt vs. m, hom; c) m, het vs. 
m, hom; d) f, wt vs. f, het; e) f, wt vs. f, hom; f) f, het vs. f, hom; p<0.05;  
(n): number of animals investigated; * n=4 (m), n=5 (f) 
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4.2.2 Serum C-peptide II concentration 
Twenty-one-day-old homozygous mutant mice featured 0.53 ng/ml (male) and 
0.43 ng/ml (female) C-peptide II concentrations in the serum. Thus, the mutant 
insulin 2 may be expressed and secreted. 
Heterozygous mutant mice of both genders showed lower C-peptide II levels 
than sex-matched wild-type mice (male: 0.97 ± 0.64 ng/ml vs. 1.22 ± 0.77 
ng/ml, n.s.; female: 0.86 ± 0.29 ng/ml vs. 1.41 ± 0.14 ng/ml; Figure 4.34).  
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Figure 4.34 C-peptide II concentrations of 21-day-old mice 
The serum C-peptide II levels of female (f) heterozygous mutants (het) are significantly lower 
versus female wild-type (wt) mice, but significantly higher than those of homozygous mutants 
(hom). In male (m) mice these differences are similar, but not significant.  
Data are means ± SEM; d, e, f: d) f, wt vs. f, het; e) f, wt vs. f, hom; f) f, het vs. f, hom; p<0.05; 
(n): number of animals investigated 
 
4.2.3 C-peptide II content in the pancreas 
The C-peptide II/protein content in the pancreas of male heterozygous 
mutants was about 1/3 that of sex-matched wild-type mice (5.0 ± 1.1 ng/mg 
vs. 16.0 ± 2.5 ng/mg), and 4.5-fold higher versus homozygous mutants (5.0 ± 
1.1 ng/mg vs. 1.1 ± 0.3 ng/mg). Female heterozgous mutant mice exhibited a 
4.4-fold higher pancreatic C-peptide II/protein content than female 
homozygous mutants (6.1 ± 1.7 ng/mg vs. 1.4 ± 0.5 ng/mg). The C-peptide 
II/protein content of female heterozygous mutants was less than ½ that of 
female wild-type mice (6.1 ± 1.7 ng/mg vs. 13.4 ± 2.9 ng/mg; Figure 4.35). 
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Figure 4.35: C-peptide II/protein concentrations in the pancreas of 21-day-old mice 
The C-peptide II/protein content in male (m) and female (f) heterozygous mutants (het) is 
significantly lower compared to sex-matched wild-type (wt) mice, but significantly higher 
versus homozygous mutants (hom).  
Data are means ± SEM; a, b, c, d, e, f: a) m, wt vs. m, het; b) m, wt vs. m, hom; c) m, het vs. 
m, hom; d) f, wt vs. f, het; e) f, wt vs. f, hom; f) f, het vs. f, hom; p<0.05;  
(n): number of animals investigated 
4.3 Additional investigations of untreated male and female 
Munich Ins2C95S  mutant and wild-type mice 
4.3.1 Body weight 
Male Munich Ins2C95S mutant mice exhibited significantly lower randomly fed 
body weights at the age of 30, 90 and 180 days versus age- and sex-matched 
wild-type mice. Female mutant and wild-type mice showed a similar body 
weight, irrespective of age at sampling (Table 4.6). 
 
 age (days) 
group (n) 21 30 90 180 
m, wt (10) 8.8 ± 0.7 16.1± 0.8  26.1 ± 1.3  29.9 ± 1.5  
m, mt (≥8) 8.4 ± 0.6 15.2± 1.0 a  24.9 ± 0.9 a 27.8 ± 0.8 a  
f, wt (10) 9.1 ± 1.1 14.0± 1.1 23.8 ± 1.6 26.8 ± 1.4 
f, mt (8) 8.7 ± 0.8 13.9± 0.7 23.4 ± 0.9 26.4 ± 0.8 
Table 4.6: Randomly fed body weights (g) 
Female (f) mutant (mt) mice demonstrate similar body weights as female wild-type (wt) mice 
during the investigation period. From 30 days of age onwards, body weights of male (m) 
mutants are significantly lower than those of sex-matched wild-type mice.  
Data are means ± SD; a: m, wt vs. m, mt; p<0.05; (n): number of animals investigated 
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4.3.2 Blood glucose concentration 
From 30 days of age onwards, male and female Munich Ins2C95S mutant mice 
featured significantly elevated randomly fed blood glucose concentrations 
compared to sex- and age-matched wild-type mice. The blood glucose levels 
of male mutant mice rose continuously, reaching 587 ± 88 mg/dl at the age of 
180 days. Blood glucose concentrations of female mutants were below 185 
mg/dl (182 ± 24 mg/dl). In male and female wild-type mice, the blood glucose 
levels remained stable (range 105 - 125 mg/dl (m, wt); 101 - 117 mg/dl (f, wt); 
Figure 4.36). 
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Figure 4.36: Randomly fed blood glucose concentrations 
Male (m) and female (f) mutant (mt) mice exhibit significantly higher blood glucose levels than 
sex-matched wild-type (wt) mice from 30 days of age onwards. Blood glucose concentrations 
of wild-type mice of both genders remain stable. In contrast to female mutant mice, male 
mutants show a progressive diabetic phenotype. 
Data are means ± SEM; a, b: a) m, wt vs. m, mt; b) f, wt vs. f, mt; p<0.05; 
(n): number of animals investigated 
 
4.3.3 Intraperitoneal insulin tolerance test (ipITT) 
Intraperitoneal insulin tolerance tests (ipITT) were carried out with 21-, 30-, 90- 
and 180-day-old mice. 
After insulin injection, 21- and 180-day-old female mutant and female wild-type 
mice exhibited a similar percentaged decrease of blood glucose levels from 
basal value (T0=100%) at all time points of the test. At the age of 30 and 90 
days, blood glucose decrease was slightly delayed in female mutants vs. wild-
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type mice (Figure 4.37) but there were no differences in the corresponding 
area under the curve (AUCblood glucose) comparing female mutants and female 
wild-type mice (Figure 4.38).  
Male mutants exhibited a similar course of percentaged blood glucose 
decrease as male wild-type mice at the age of 21 days, and at 30 days, blood 
glucose decrease was slightly delayed vs. wild-type males. The percentaged 
blood glucose decrease was lower in 90- and 180-day-old male mutants as 
compared to age and sex-matched wild-type mice at all time points of the 
ipITT (Figure 4.37). The AUCblood glucose of male mutants was similar to male 
wild-type mice at the age of 21 and 30 days. Ninety- and 180-day-old male 
mutants featured an elevated AUCblood glucose compared to male wild-type mice 
(Figure 4.38). These results reveal that male Munich Ins2C95S became insulin 
resistant. 
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 (C) 90 days of age (D) 180 days of age 
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Figure 4.37 (A)-(D): Intraperitoneal insulin tolerance tests (ipITT) at the age of 21 (A), 30 
(B), 90 (C) and 180 (D) days 
During the entire test, the percentaged decrease of blood glucose levels from the basal value 
(T0=100%) after insulin application was equal in female (f) wild-type (wt) versus female mutant 
(mt) mice at the age of 21 and 180 days, as well as in male (m) wild-type versus male mutant 
mice at the age of 21 days. In 30- and 90-day-old female mutant as well as in 30-day-old male 
mutant mice, blood glucose decrease was delayed. At the age of 90 and 180 days, male 
mutants present lower percentaged blood glucose decrease compared to male wild-type mice 
during the entire ipITT.  
Data are means ± SEM; a, b: a) m, wt vs. m, mt; b) f, wt vs. f, mt; p<0.05; 
(n): number of animals investigated 
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Figure 4.38: Area under the curve of the percentaged blood glucose decrease from 
basal values (AUCblood glucose) of the ipITT 
The AUCblood glucose of female (f) wild-type (wt) and female mutant (mt) mice are equal, 
irrespective of age at testing. Male (m) mutants show similar AUCblood glucose as male wild-type 
mice at 21 and 30 days of age but feature elevated AUCblood glucose compared to male wild-type 
mice at the age of 90 and 180 days. 
Data are means ± SEM; a: m, wt vs. m, mt; p<0.05; (n): number of animals investigated 
 
4.3.4 Serum glucagon and corresponding blood glucose concentration 
4.3.4.1 Randomly fed serum glucagon and glucagon concentration  
10 minutes after insulin injection 
At the age of 200 days, male mutant mice presented 2.3-fold (basal, randomly 
fed) and 1.5-fold (10 minutes after insulin application) elevated glucagon 
concentrations compared to sex- and age-matched wild-type mice, in spite of 
increased blood glucose values. Female mutant and female wild-type mice 
exhibited similar glucagon levels, randomly fed and after insulin injection 
(Figure 4.39, Table 4.7). 
Glucagon concentrations of male mutant mice slightly decreased (-11 ± 30 
pg/dl) after insulin injection, whereas those of wild-type mice of both genders 
and those of female mutant mice increased (m, wt: 35 ± 34 pg/ml; f, wt: 10 ± 
53 pg/ml, f, mt: 35 ± 69 pg/ml; Figure 4.40). 
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Figure 4.39 (A)/(B): Serum glucagon concentrations, randomly fed (T0; (A)) and 10 
minutes after insulin injection (T10; (B)) at the age of 200 days 
Male (m) mutants (mt) feature significantly higher serum glucagon levels than male wild-type 
(wt) mice at T0 and T10. The glucagon concentrations of female (f) mutants are equal to those 
of female wild-type mice. 
Data are means ± SEM; a: m, wt vs. m, mt; p<0.05; (n): number of animals investigated 
 
 
 blood glucose (mg/dl) 
group (n) T0 T10 
m, wt (5) 119 ± 15  097 ± 13  
m, mt (5) 652 ± 110 a 674 ± 74 a 
f, wt (5) 120 ± 5  106 ± 28 
f, mt (5) 161 ± 30 b 130 ± 28 
Table 4.7: Corresponding blood glucose levels to glucagon concentrations in Fig. 4.39 
Male (m) mutant (mt) mice demonstrate 5.4-fold (T0) and 6.9-fold (T10) higher blood glucose 
levels than male wild-type (wt) mice. In female (f) wild-type and mutant mice these differences 
aren’t as distinct (f, mt vs. f, wt: 1.3-fold (T0) and 1.2-fold (T10) increased).  
Data are means ± SD; a, b: a) m, wt vs. m, mt; b) f, wt vs. f, mt; p<0.05; 
(n): number of animals investigated 
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Figure 4.40: Changes in serum glucagon levels 10 minutes after intraperitoneal insulin 
application 
Female (f) wild-type (wt), female mutant (mt) and male (m) wild-type mice show an increase in 
glucagon secretion after insulin injection, whereas glucagon levels in male mutants decrease.  
Data are means ± SEM; a: m, wt vs. m, mt; p<0.05; (n): number of animals investigated 
 
4.3.4.2 Fasting serum glucagon and glucagon concentration 10 minutes 
after oral glucose application 
Fasting glucagon concentrations of male and female mutant mice at the age of 
230 days didn’t differ from those of sex- and age-matched littermate controls. 
Female mutants exhibited significantly higher glucagon levels than female 
wild-type mice 10 minutes after glucose administration (Figure 4.41). 
Glucagon concentrations of male and female wild-type mice decreased after 
glucose challenge (m, wt: -26 ± 40 pg/dl ; f, wt: -21 ± 34 pg/dl). In mutant mice 
of both genders, glucagon concentrations increased (m, mt: 25 ± 30 pg/dl;  
f, mt: 11 ± 20 pg/dl) in spite of rising blood glucose levels (Figure 4.42,  
Table 4.8). 
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Figure 4.41 (A)/(B): Serum glucagon concentrations, fasting (T0; (A)) and 10 minutes 
after oral glucose administration (T10; (B)) at 230 days of age 
Fasting glucagon concentrations are similar in male (m) mutant (mt) and wild-type (wt) mice as 
well as in female (f) mutant and wild-type mice. Ten minutes after glucose application, the 
glucagon levels of male and female mutants are higher than those of sex- and age-matched 
wild-type mice. 
Data are means ± SEM; b: f, wt vs. f, mt; p<0.05; (n): number of animals investigated 
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Figure 4.42: Changes in serum glucagon levels 10 minutes after oral glucose 
application 
Glucagon concentrations of male (m) and female (f) mutant (mt) mice rise in spite of 
increasing blood glucose values 10 minutes after glucose administration. In wild-type (wt) mice 
of both sexes, glucagon levels decrease after glucose challenge. 
Data are means ± SEM; a: m, wt vs. m, mt; (n): number of animals investigated 
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 blood glucose (mg/dl) 
group (n) T0 T10 
m, wt (5) 120 ± 16  296 ± 38  
m, mt (5) 339 ± 173 a 635 ± 238 a 
f, wt (5) 103 ± 9  304 ± 46  
f, mt (5/4) 166 ± 15 b 477 ± 76 b 
Table 4.8: Corresponding blood glucose concentrations to glucagon levels in Fig. 4.41 
Male (m) mutant (mt) mice show 2.8-fold (T0) and 2.1-fold (T10) elevated blood glucose 
concentrations compared to male wild-type (wt) mice. In female (f) mutants blood glucose 
levels are 1.6-fold (T0 and T10) higher than in sex-matched wild-type mice.  
Data are means ± SD; a, b: a) m, wt vs. m, mt; b) f, wt vs. f, mt; p<0.05; 
(n): number of animals investigated 
 
- 132 - 
5 Discussion 
Male Munich Ins2C95S mutant mice exhibit a progressive diabetic phenotype 
with severe reduction of pancreatic β-cell mass (Herbach et al. 2007). 
The present study was performed to analyse the mechanisms of β-cell loss in 
male Munich Ins2C95S mutant mice. Since homozygous male and female 
mutants died at a mean age of 46 and 52 days, respectively, and female 
heterozygous mutant mice demonstrated a mild diabetic phenotype (Herbach 
et al. 2007), male heterozygous mutants were used in this study. In order to 
investigate the influence of hyperglycaemia on β-cell loss in the pancreas of 
mutant mice, one group of mutants was treated with subcutaneous insulin-
pellets to normalise blood glucose concentration. Placebo-treated wild-type 
and mutant mice served as controls.  
5.1  Treated male Munich Ins2C95S mutant and wild-type mice 
5.1.1 Glucose homeostasis 
At weaning, mutant mice exhibited slightly higher randomly fed blood glucose 
concentrations compared to wild-type mice, but soon became hyperglycaemic, 
reaching blood glucose levels over 200 mg/dl at the age of 32 days. In 
heterozygous Akita mice, which also exhibit a mutation in the Ins2 gene, blood 
glucose concentrations were similar compared to wild-type mice up to 21 days 
of age. Like male Munich Ins2C95S mutant mice, male Akita mice became 
hyperglycaemic soon after weaning, showing randomly fed blood glucose 
levels of over 250 mg/dl at the age of 28 days (Yoshioka et al. 1997). In 
contrast, Ins2 knockout mice stay normoglycaemic, most likely due to 
compensation by increased Ins1 expression (Leroux et al. 2001). Since 
Munich Ins2C95S mutant mice become diabetic despite possessing one intact 
Ins2 allele and 2 intact Ins1 alleles, the mutant Ins2 seems to exert dominant 
negative effects on β-cell function and viability (Herbach et al. 2007). A similar 
dominant negative effect of one mutated Ins2 allele was found in Akita mice 
(Wang et al. 1999; Izumi et al. 2003). 
In general, insulin treatment normalised blood glucose levels of mutant mice. 
To avoid hypoglycaemia due to additive effects of the old and the new insulin-
pellet, it was accepted that insulin-treated mutants demonstrated higher blood 
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glucose levels compared to wild-type mice shortly before the next pellet 
injection. In placebo-treated mutants, blood glucose levels rose continuously. 
The progressive diabetic phenotype of placebo-treated mutants can be 
explained by impaired insulin secretion, development of insulin resistance and 
increasing loss of total β-cell volume (Herbach et al. 2007; this study). In  
type 1 diabetes, autoimmune destruction of β-cells results in gradual loss of 
functional β-cell mass, leading to hyperglycaemia (Al-Mutairi et al. 2007).  
Type 2 diabetes normally becomes overt when insulin secretion is insufficient 
to compensate for the elevated insulin demand, resulting from reduced insulin 
action (Ahren 2005).  
 
In oral glucose tolerance tests, insulin-treated mutants showed similar or even 
lower areas under the blood glucose curve (AUCblood glucose) compared to wild-
type mice, which can be explained by the insulin released from the pellets. 
Placebo-treated mutant mice demonstrated a significantly elevated AUCblood 
glucose compared to wild-type mice, irrespective of age at sampling, confirming 
the diabetic phenotype described above and in an earlier study (Herbach et al. 
2007). 
In insulin-treated mutants, the decrease of blood glucose concentrations after 
glucose application was delayed compared to wild-type mice. Blood glucose 
concentrations of placebo-treated mutant mice declined even later than those 
of insulin-treated mutants. The delayed decline of blood glucose levels after 
glucose challenge in insulin- and placebo-treated mutant mice was most likely 
due to disturbed insulin secretion 10 minutes after glucose application 
(Herbach et al. 2007; this study). The earlier blood glucose decrease in 
insulin- versus placebo-treated mutants probably resulted from the insulin 
delivered by the pellets. In older mice, the higher insulin sensitivity in insulin- 
compared to placebo-treated mutant mice (see below) could have further 
contributed to the earlier decline of the blood glucose curves.  
These findings demonstrate that glucose tolerance in insulin-treated mutants 
is almost normalised, whereas placebo-treated mutant mice exhibit an 
impaired glucose tolerance. 
 
Since C-peptide is secreted concomitant and in equimolar amounts with 
insulin (Caumo and Luzi 2004; Luzi et al. 2007), C-peptide levels were 
- 134 - 
measured, in order to examine the endogenous randomly fed and glucose-
stimulated insulin secretion (GSIS). 
Randomly fed, C-peptide concentrations of insulin-treated mutants were 
largely reduced compared to those of both, wild-type and placebo-treated 
mutant mice. Likewise, intensive insulin treatment led to the decrease of 
fasting C-peptide levels in type 2 diabetics (Kärvestedt et al. 2002). In another 
study, insulin application in combination with oral anti-diabetic agents also 
resulted in reduced fasting C-peptide levels compared to treatment with oral 
anti-diabetic agents alone (Yki-Järvinen et al. 2000).  
The effect of insulin on β-cells concerning insulin secretion is unclear. Earlier 
studies postulated a negative feedback of insulin on insulin secretion (Argoud 
et al. 1987; Ammon et al. 1991), whereas more recent studies demonstrated 
that insulin stimulates its own secretion by binding to the insulin receptor of  
β-cells (Aspinwall et al. 1999; Melloul et al. 2002; Borelli et al. 2004). However, 
other studies indicated that insulin has neither stimulatory nor inhibitory effects 
on insulin secretion (Wicksteed et al. 2003; Persaud et al. 2008). When insulin 
is secreted by β-cells, the insulin concentration within the islet capillaries is 
much higher compared to the insulin concentration in the whole circulation, 
since islet blood flow is less than 1% of total portal venous blood (Bonner-Weir 
1991; Meier et al. 2006). Therefore, if insulin has auto- and paracrine effects 
on β-cells, these effects would be lower in insulin-treated mutants compared to 
wild-type mice and placebo-treated mutants, due to lower endogenous insulin 
secretion and consequently lower insulin levels in the intra-islet capillaries of 
insulin-treated mutants. The reduced potential positive feedback of insulin on 
insulin secretion could therefore contribute to the reduced C-peptide levels of 
randomly fed insulin-treated mutants compared to wild-type mice and placebo-
treated mutants. 
However, since glucose is the main stimulus for insulin secretion (Melloul et al. 
2002; Kaiser et al. 2003; Li et al. 2006), reduced auto- or paracrine effects of 
insulin in insulin-treated mutants might probably be less important. 
 
Placebo-treated mutants exhibited an approximately 50% reduction of 
randomly fed C-peptide concentrations compared to wild-type mice. In patients 
with INS mutations, exhibiting permanent neonatal diabetes mellitus,  
C-peptide levels were also very low or not detectable (Støy et al. 2007). The 
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randomly fed insulin levels in Akita mice were also largely reduced compared 
to those of wild-type mice (Yoshioka et al. 1997). The reduced C-peptide 
secretion of randomly fed placebo-treated Munich Ins2C95S mutant mice might 
be due to dominant negative effects of mutant proinsulin on secretory 
pathways (Izumi et al. 2003) and/or due to severely decreased pancreatic  
C-peptide content (described below).  
The structure and secretion of different mutant proinsulins were analysed, 
including those with a disrupted A6-A11 intrachain disulfide bond (CA6Y), 
similar to the mutation of Munich Ins2C95S mutant mice (CA6S), and with a 
disrupted A7-B7 interchain disulfide bond (CA7Y) as in the Akita mouse. In 
HEK293 cells expressing one of these mutant proinsulins (CA6Y or CA7Y), the 
fraction of non-native proinsulin was increased compared to HEK293 cells 
expressing wild-type proinsulin, indicating defects in proinsulin folding. 
Furthermore, the secretion of mutant proinsulin was severely disturbed in 
these cells, and non-secreted proinsulin was probably intracellularly degraded 
(Colombo et al. 2008). In vitro studies demonstrated that the disruption of the 
A6-A11 intrachain disulfide bond has less influence on insulin conformation 
and stability than the disruption of the A7-B7 or A20-B19 interchain disulfide 
bond (Dai and Tang 1996; Chang et al. 2003). Further, it was shown that 
mutant proinsulin bearing the Akita mutation (CA7Y) could virtually not be 
secreted from 293T cells, whereas CA11S mutant proinsulin was at least 
partially secreted (Liu et al. 2005). It was also demonstrated that the Akita 
mutation leads to a disturbed secretion of proinsulin in transfected CHO cells. 
The mutant proinsulin was described to form complexes with BiP and to be 
eventually degraded (Wang et al. 1999). The secretion of mutant insulin 2 of 
Akita mice was also impaired in transfected insulinoma cells (Nozaki et al. 
2004). Furthermore, it was stated that the early secretory pathway in β-cells of 
Akita mice is nonspecifically impaired due to intracellular accumulation  
of misfolded proinsulin, leading to disturbed secretion of both, wild-type  
and mutant insulin (Izumi et al. 2003). However, determination of serum  
C-peptide II levels could show that mutant insulin 2 is effectively secreted in 
21-day-old male heterozygous Munich Ins2C95S mutant mice. Further, fasting 
serum insulin levels and serum insulin after 2h refeeding did not differ 
comparing untreated mutants and wild-type mice of both genders (Herbach et 
al. 2007). This could lead to the assumption that there is no general defect in 
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insulin secretion in mutant mice. Alternatively, the clearance of mutant  
insulin 2 may be reduced due to decreased receptor binding to the insulin 
receptor, leading to reduced uptake and degradation, for example in 
hepatocytes or myocytes. Liver-specific insulin receptor knockout mice 
showed severe hyperinsulinaemia due to increased insulin secretion, but also 
due to reduced receptor-mediated insulin uptake and degradation in the liver 
(Michael et al. 2000). Point mutations in the INS gene in humans were 
described to result in reduced insulin receptor binding affinity and therefore 
decreased degradation, even leading to hyperinsulinaemia and an increased 
insulin to C-peptide ratio (Haneda et al. 1983; Nanjo et al. 1986; Nanjo et al. 
1987; Steiner et al. 1990). Further, the disruption of the A6-A11 intrachain 
disulfide bond resulted in a largely reduced receptor binding activity of insulin 
in vitro (Dai and Tang 1996; Chang et al. 2003).  
 
In conclusion, insulin treatment seems to lead to reduced randomly fed 
endogenous insulin secretion and therefore decreased serum C-peptide 
concentrations versus placebo-treated mutant mice. In male placebo-treated 
mutants the decreased insulin secretion probably results from partial 
misfolding of the mutant (pro-)insulin, thereby disturbing secretory pathways.  
 
Ten minutes after oral glucose challenge, the insulin secretion of insulin- and 
placebo-treated mutant mice didn’t increase, irrespective of age at sampling, 
whereas C-peptide levels of wild-type mice rose 1.5- to 3.6-fold. These results 
demonstrate that mutant mice suffer from a disturbed glucose-stimulated 
insulin secretion (GSIS). It has been described that GSIS is often impaired in 
type 1 and type 2 diabetics (Weir et al. 2001; Steele et al. 2004; Kahn et al. 
2009), and in vivo and in vitro studies demonstrated that chronically high 
glucose concentrations cause an impaired GSIS (Zhang et al. 2005; Tsuboi et 
al. 2006), which could explain the disturbed GSIS of placebo-treated mutants. 
Since not only hyperglycaemic placebo-treated mutants, but also 
normoglycaemic insulin-treated mutant mice and female heterozygous 
mutants with a mild diabetic phenotype (Herbach et al. 2007) showed severely 
impaired GSIS, high blood glucose levels cannot be the main reason for the 
disturbed GSIS. Further, insulin-treated mutants demonstrated a higher 
pancreatic C-peptide content than placebo-treated mutants (see below), and 
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female mutant mice showed a higher pancreatic insulin content than male 
mutants (Herbach et al. 2007), which argues against depletion of insulin stores 
as a cause of disturbed GSIS. As described above, partial misfolding of 
mutant proinsulin may lead to disturbed insulin secretion (Izumi et al. 2003; Liu 
et al. 2005; Colombo et al. 2008). Further, isolated islets of 4-week-old male 
Akita mice demonstrated a disturbed GSIS compared to islets of sex-matched 
wild-type mice (Yoshioka et al. 1997).  
Physiologically, glucose uptake causes an increase of the ATP/ADP ratio, 
leading to the closure of specific KATP channels, resulting in membrane 
depolarisation and opening of voltage-dependent calcium channels, and 
therefore in increasing intracellular Ca2+ concentrations. Finally mature insulin 
granules fuse with the plasma membrane, and insulin and C-peptide are 
secreted (Kaiser et al. 2003). Reduced increase of the ATP/ADP ratio due to 
energy consumption by chaperones upon ER stress or elevated intracellular 
Ca2+ levels due to Ca2+ release from the ER upon ER stress may be involved 
in the disturbed GSIS (Xu et al. 2005; Szegezdi et al. 2006; Scheuner and 
Kaufman 2008). It was stated that chronically elevated cytoplasmic Ca2+ 
concentrations might inhibit glucose-stimulated insulin secretion (Björklund et 
al. 2000; Grill and Björklund 2001). Therefore, mutant insulin may lead to ER 
stress and thereby disturbed GSIS in both Munich Ins2C95S and Akita mutant 
mice. 
 
Taken together, since insulin- and placebo-treated mutants and untreated 
mutants of both genders demonstrated a severely disturbed glucose-
stimulated insulin secretion, it is likely that misfolded (pro-)insulin 2 and ER 
stress lead to impaired GSIS. The exact mechanism of the disturbed GSIS 
remains to be investigated.  
 
The C-peptide content in the pancreas of 100-day-old insulin-treated mutants 
was about 1/3 that of wild-type mice but over 4-fold higher compared to 
placebo-treated mutants, which demonstrated less than 1/10 of pancreatic  
C-peptide content versus wild-type mice. Morphological investigations of the 
pancreas demonstrated that the reduced pancreatic C-peptide content in  
3-month-old untreated male mutant mice results from a decreased density of 
secretory granules within the β-cells and not from a reduction in β-cell mass 
- 138 - 
(Herbach et al. personal communication). These findings lead to the 
assumption that insulin production is largely decreased in Munich Ins2C95S 
mutant mice, and that normalisation of blood glucose levels improves  
C-peptide/insulin production. However, the reduced insulin secretion in insulin-
treated mutants (see above), could also lead to less depletion of insulin stores 
and therefore to increased pancreatic C-peptide levels versus placebo-treated 
mutants. The findings of reduced pancreatic C-peptide content in placebo-
treated mutants and of reduced pancreatic insulin content in untreated male 
and female mutant mice (Herbach et al. 2007) indicate disturbed insulin 
production and/or increased intracellular degradation. In the Akita mouse, the 
insulin and C-peptide content in the islets was also largely reduced (Wang et 
al. 1999; Zuber et al. 2004). Insulin production was shown to be unchanged in 
Akita islets, whereas intracellular degradation of mutant proinsulin was found 
to be increased (Izumi et al. 2003; Allen et al. 2004).  
 
Randomly fed serum glucagon levels were similar in normoglycaemic insulin-
treated mutant and wild-type mice, whereas in placebo-treated mutants, 
glucagon concentrations were elevated, despite higher blood glucose levels.  
Glucagon is produced and secreted by pancreatic α-cells. Physiologically, high 
blood glucose concentrations inhibit glucagon secretion via direct effects on  
α-cells and most likely also in an indirect manner, for example via increasing 
insulin secretion (Dunning et al. 2005; Franklin et al. 2005; Jacobson et al. 
2009; Quoix et al. 2009). However, in diabetic patients glucose sensing of  
α-cells is disturbed, leading to elevated glucagon secretion, which further 
contributes to hyperglycaemia (Quesada et al. 2008; Jacobson et al. 2009). 
Therefore, increased randomly fed glucagon levels in placebo-treated mutants 
can be explained by defective glucose sensing of α-cells due to chronic 
hyperglycaemia. Insulin treatment of mutant mice normalised blood glucose 
concentrations, leading to physiological randomly fed serum glucagon levels.  
 
Intraperitoneal insulin tolerance tests (ipITT) and a placebo-ipITT were 
performed to analyse insulin sensitivity. The percentaged decrease of blood 
glucose concentrations from basal value after intraperitoneal insulin or NaCl 
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0.9% injection was measured at distinct time points, and the corresponding 
area under the curve was calculated (AUCblood glucose).  
In the ipITT the AUCblood glucose of insulin-treated mutant mice was similar or 
even significantly lower compared to wild-type mice, which can be explained 
by the additional insulin, released from the pellets of insulin-treated mutants. 
At the age of 50 days, placebo-treated mutants showed a similar AUCblood 
glucose in the ipITT as wild-type mice, whereas the AUCblood glucose of 100- and 
150-day-old placebo-treated mutant mice was significantly higher compared to 
wild-type mice, indicating reduced insulin sensitivity.  
In order to examine the influence of the insulin delivered from the pellets on 
the ipITT of insulin-treated mutants, a placebo-ipITT with 150-day-old mice 
was performed. In contrast to wild-type and placebo-treated mutant mice, 
blood glucose concentrations of insulin-treated mutants decreased 
continuously during the placebo-ipITT, due to the insulin released from the 
pellets. However, blood glucose levels during the placebo-ipITT did not decline 
as much as during the ipITT, suggesting preserved sensitivity to 
intraperitoneally injected insulin in insulin-treated mutants.  
A comparison of the AUCblood glucose of the ipITT and placebo-ipITT confirmed 
this assumption and showed that insulin administration significantly lowers the 
AUCblood glucose of both, insulin-treated mutant and wild-type mice as compared 
to 0.9% NaCl injection, indicating physiological insulin sensitivity. Since the 
relative differences between AUCblood glucose of the placebo-ipITT and the ipITT 
were similar in insulin-treated mutant and wild-type mice, insulin-therapy 
completely preserved insulin sensitivity in mutant mice. 
In placebo-treated mutants, the AUCblood glucose during the ipITT was equal to 
that during the placebo-ipITT, demonstrating insulin resistance. Additionally 
performed ipITTs with untreated heterozygous mutant mice at different ages 
confirmed these results (see 5.3). 
Since normoglycaemic insulin-treated mutants and female mutant mice with 
slightly elevated blood glucose concentrations showed similar insulin 
sensitivity compared to sex-matched wild-type mice, the development of 
insulin resistance in placebo-treated mutants is likely to be the consequence of 
chronic hyperglycaemia. Long-term high blood glucose concentrations lead to 
oxidative stress (Robertson 2004), which reduces insulin sensitivity, for 
example, in myocytes and adipocytes (Maddux et al. 2001; Houstis et al. 
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2006). The Akita mouse was also shown to exhibit severe peripheral and 
hepatic insulin resistance, and peripheral insulin resistance could be 
ameliorated by lowering blood glucose concentrations, using phloridzin (Hong 
et al. 2007). Ninety per cent pancreactomised (Px) male Sprague-Dawley rats 
developed diabetes mellitus including disturbed insulin sensitivity compared to 
shamPx rats (Park et al. 2007). In humans, insulin resistance is often 
associated with obesity and contributes to the development of diabetes type 2 
(Ahren 2005). However, type 1 diabetics also develop insulin resistance, 
especially when blood glucose concentrations are poorly controlled 
(Greenbaum 2002; Heptulla et al. 2003). These studies and the findings in 
Munich Ins2C95S mutant mice underline the assumption that hyperglycaemia 
leads to insulin resistance. Developing insulin resistance contributes to the 
progressive diabetic phenotype of placebo-treated mutants. 
5.1.2 Lipid peroxidation 
Thiobarbituric acid reactive substances (TBARS) reveal the degree of lipid 
peroxidation and are often used as marker for oxidative stress in diabetic 
animal models and humans (Maritim et al. 2003; Ramakrishna and Jailkhani 
2007). Serum TBARS levels were significantly higher in placebo-treated 
mutants, but were unchanged in insulin-treated mutants as compared to wild-
type mice at 100 and 140 days of age. Further, blood glucose levels of the 
investigated groups correlated with lipid peroxidation in the serum. Therefore 
hyperglycaemia seems to have caused oxidative stress in placebo-treated 
mutants, whereas insulin-treatment prevented lipid peroxidation and probably 
oxidative stress in mutant mice. Elevated levels of TBARS can also be found 
in the serum of type 1 and type 2 diabetics (Kalaivanam et al. 2006; 
Ramakrishna and Jailkhani 2007; Song et al. 2007) and, for example, in the 
serum of STZ-induced diabetic Wistar rats (Ozansoy et al. 2001) and diabetic 
Zucker diabetic fatty (ZDF) rats (Coppey et al. 2002). 
5.1.3 Islet isolation and ER stress 
Isolation of islets, especially of placebo-treated mutants but also of insulin-
treated mutant mice was very difficult. Due to the low insulin content in the 
islets, the colour of islets appeared different than that of wild-type mice. 
Further, islets of mutant mice were very fragile which led to deformation and 
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fragmentation of islets, resulting in irregularly shaped islet clusters that were 
hardly distinguishable from exocrine pancreas clusters. Therefore, the purity of 
islet isolates of mutant mice, particularly of placebo-treated mutants, was 
lower than that of wild-type mice. Similar difficulties were faced during islet 
isolation of Akita mice, leading to a considerable contamination of islet 
samples with non-endocrine tissue (around 30%) (Izumi et al. 2003). The 
accumulation of misfolded proinsulin in Akita islets was thought to non-
specifically affect secretory pathways and might interfere with the transport of 
other cargo, including membrane proteins (Izumi et al. 2003). For example, the 
reduced transport of collagens, especially collagen type IV α1 and α2, which 
are components of the peri-insular capsule (Irving-Rodgers et al. 2008), may 
reduce islet resistance to collagenase digestion. Thus, the reduced integrity of 
isolated islets of Munich Ins2C95S mutants after collagenase digestion might be 
due to an altered collagen composition of the peri-insular capsule, resulting 
from a non-specific block in protein transport. Furthermore, hyperglycaemia 
leads to the generation of free radicals, which can directly interact with 
proteins and other macromolecules (Maritim et al. 2003; Robertson 2004). 
Determining the carbonyl content of proteins, it was demonstrated that 
hyperglycaemia-induced oxidative stress leads to oxidation of proteins in the 
serum of type 1 diabetics (Ramakrishna and Jailkhani 2007) and in the 
pancreata of hyperglycaemic Cohen diabetic rats (Ryu et al. 2008). Therefore, 
reactive oxygen species might interact with proteins within the peri-insular 
capsule of hyperglycaemic mice, reducing the stability of these islets. This 
assumption is in coincidence with the higher integrity of isolated islets of 
normoglycaemic insulin-treated mutant mice compared to hyperglycaemic 
placebo-treated mutants.  
 
Isolated islets of 100-day-old insulin-treated mutants showed an increased 
abundance of CHOP and PeIF2α compared to wild-type mice. Placebo-treated 
mutants demonstrated similar amounts of BiP and PeIF2α, and a slightly 
higher abundance of CHOP compared to wild-type mice. However, the 
reduced sample purity (up to 40% contamination with exocrine pancreas 
tissue) results in decreased islet-protein content in samples of mutant mice, 
especially of placebo-treated mutants. Therefore, the abundance of ER stress 
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associated proteins in β-cells is likely to be underestimated, and Western blot 
analyses have to be interpreted carefully.  
CHOP is involved in ER stress-induced apoptosis (Oyadomari and Mori 2003; 
Scheuner and Kaufman 2008), and Chop disruption in heterozygous Akita 
mice reduced β-cell apoptosis compared to Akita mice with intact Chop genes 
(Oyadomari et al. 2002b). Chop null mutation in Leprdb/db mice resulted in 
largely increased β-cell mass and reduced β-cell apoptosis compared to 
diabetic Leprdb/db mice with intact Chop (Song et al. 2008).  
Therefore it is likely that CHOP-induced apoptosis also occurs in Munich 
Ins2C95S mutants.  
ER stress leads to the phosphorylation of eucaryotic initiation factor 2α, which 
results in reduced translation of many mRNAs, thereby reducing protein 
biosynthesis (Harding et al. 1999; Oyadomari et al. 2002a). In islets of diabetic 
db/db mice for example, expression of various genes of the unfolded protein 
response (UPR) was increased including that of PeIF2α compared to non-
diabetic controls (Laybutt et al. 2007). However, in CHO cells expressing 
proinsulin with the Akita mutation, neither proinsulin nor overall protein 
synthesis rates were decreased compared to CHO cells expressing wild-type 
proinsulin. Further, in isolated islets of 16-week-old male Akita mice, the 
overall protein synthesis was similar compared to wild-type islets. The authors 
concluded that mutant proinsulin does not profoundly reduce protein synthesis 
in Akita mice (Izumi et al. 2003). However, the finding of increased PeIF2α in 
islets of insulin-treated mutants argues for translational attenuation in Munich 
Ins2C95S mutant mice. 
Misfolded proinsulin 2 accumulates in the β-cells of Akita mice and leads to 
the induction of several ER stress markers like BiP, HRD1, spliced XBP-1 and 
ATF6 in islets of Akita mice or in cell lines expressing the mutant insulin 
(Wang et al. 1999; Allen et al. 2004; Nozaki et al. 2004; Zuber et al. 2004). 
The ER stress markers BiP, CHOP and spliced XBP-1 were also increased in 
isolated islets of transgenic mice overexpressing human islet amyloid 
polypeptide, which aggregates in the β-cell, leading to increased β-cell 
apoptosis (Huang et al. 2007). 
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These findings indicate that misfolded (pro-)insulin induces ER stress in  
β-cells of insulin- and placebo-treated mutants, probably resulting in β-cell 
apoptosis and possibly in reduced insulin mRNA translation.  
5.1.4 Qualitative-histological and quantitative-stereological analysis of 
the endocrine pancreas 
Qualitative-histological analyses were performed, using sections 
immunostained for insulin or simultaneously stained for glucagon, 
somatostatin and pancreatic polypeptide (non-β-cells). Mutant mice exhibited 
fewer large islet profiles than wild-type mice. Immunostaining for non-β-cells, 
demonstrated an altered islet composition in mutant mice, especially in 
placebo-treated mutants. Normally islets are composed of a core of mainly  
β-cells, surrounded by a small rim of non-β-cells. In mutant mice, the 
proportion of non-β-cells was increased and non-β-cells were found distributed 
all over the islet profile. Further, immunostaining for insulin revealed a weak 
staining of β-cells of mutant mice, whereas insulin-treated mutants exhibited a 
stronger staining for insulin than placebo-treated mutants. 
 
Quantitative-stereological investigations were performed using state-of-the-art 
unbiased model-independent stereological methods (Gundersen et al. 1988; 
Wanke et al. 1994).  
Due to perfusion fixation, capillaries didn’t collapse and accounted for about 
25% of the total islet volume. The volume density of capillaries within the islets 
of insulin-treated mutants was similar to that of wild-type mice, whereas 
placebo-treated mutants demonstrated a slightly lower volume density of 
capillaries within the islets compared to wild-type mice and insulin-treated 
mutants. Chronically high blood glucose concentrations lead to structural 
changes in vessels, like increased basement membrane width, due to 
enhanced matrix deposition, and therefore to less elasticity of blood vessels, 
which could explain the lower Vv(capillaries/islets) of hyperglycaemic mutants (Di 
Mario and Pugliese 2001). Usually pancreata are not fixed via vascular 
perfusion, and therefore, the capillaries are collapsed. In order to generate 
data that can be compared to results of studies with non-perfused pancreata, 
the volume densities of β-cells and non-β-cells were referred to the endocrine 
compartment of the islet and not to the whole islet profile in this study.  
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The volume density of β-cells in the endocrine compartment of the pancreas 
was only slightly decreased in insulin-treated mutants compared to wild-type 
mice, representing almost 75% of all endocrine cells, whereas in placebo-
treated mutants, the volume density of β-cells was reduced to less than 50% 
of the endocrine compartment, resulting in a large increase of the volume 
density of non-β-cells. It was shown previously, that most of the non-β-cells 
represent α-cells (Herbach et al. 2007). Other diabetic animal models also 
show a disturbed islet composition, irrespective of the causative genetic 
manipulation (e.g. GIPRdn transgenic mice (Herbach et al. 2005), GLP-1R 
knockout mice (Ling et al. 2001), MafA knockout mice (Zhang et al. 2005), 
PERK knockout mice (Harding et al. 2001) and dominant negative HNF-1α 
transgenic mice (Hagenfeldt-Johansson et al. 2001)). In addition, 
morphometric analyses of type 2 diabetic humans revealed an increased  
α-cell fraction in the islets (Yoon et al. 2003).  
In islets of Akita mice, the proportion of insulin positive cells was also reduced 
compared to wild-type mice (Yoshioka et al. 1997). However, the insulin 
antibody used in other studies only detects wild-type, but not mutant insulin of 
Akita mice (Wang et al. 1999; Izumi et al. 2003), which leads to the 
assumption that the insulin antibody used in the study of Yoshioka et al. 
(1997) probably does not react with mutant insulin 2. Therefore, and due to 
severe degranulation of β-cells (Wang et al. 1999; Izumi et al. 2003), insulin 
staining might be insufficient to identify largely degranulated β-cells, leading to 
an underestimation of the proportion of β-cells in the islets of Akita mice. It was 
described that around 20% and 25% of the islet area of 4-week-old male Akita 
mice exhibited immunoreactivity for insulin and glucagon, respectively 
(Yoshioka et al. 1997). Since δ- and PP-cells account for a minor proportion in 
pancreatic islets (together less than ~10% (Brissova et al. 2005; Cabrera et al. 
2006; Herbach et al. 2007)), it seems likely that many of the endocrine cells 
without detectable immunoreactivity for insulin were β-cells (almost 50%). The 
immunoreactivity for insulin was also severely reduced in β-cells of placebo-
treated Munich Ins2C95S mutant mice. In order to avoid an underestimation of 
the volume density of β-cells, this parameter was determined in sections 
immunostained for non-β-cells in this study. 
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The total volume of non-β-cells of insulin-treated mutants, was similar to that 
of wild-type mice. In placebo-treated mutants, the total volume of non-β-cells 
was largely increased versus wild-type and insulin-treated mutant mice. 
Chronic hyperglycaemia of placebo-treated mutants may therefore lead to 
increased differentiation and development of non-β-cells, especially α-cells. 
Long-term hyperglycaemia reduces PDX-1 mRNA concentrations and PDX-1 
DNA binding activity in pancreatic β-cells, which is essential for β-cell 
development and maintenance (Tanaka et al. 1999; Holland et al. 2002; 
Melloul et al. 2002; Miyazaki et al. 2004; Robertson and Harmon 2006; Andrali 
et al. 2008). It was demonstrated that inhibition of Pdx-1 expression in adult 
transgenic mice using the tet regulatory system, which allows tissue-specific 
and doxycycline-inducible control of Pdx-1 expression, results in increased 
volume density of glucagon positive cells in the islets. Further, the glucagon 
expressing cells were distributed homogeneously throughout the islets, similar 
as in placebo-treated mutants of the present study (Lottmann et al. 2001). 
Ahlgren et al. (1998) suggested that PDX-1 would suppress glucagon 
expression in β-cells and is necessary to maintain the β-cell phenotype. 
Physiologically, the proportion of insulin- to glucagon-expressing cells in 
pancreatic islets is 5:1, and these endocrine cells express either insulin or 
glucagon. Tissue specific reduction of Pdx-1 expression, using the Cre-IoxP 
technology, led to a 1:1 ratio of glucagon- to insulin-positive cells, and 22% of 
the endocrine cells co-expressed glucagon and insulin (Ahlgren et al. 1998). 
These findings were confirmed by a more recent study, which used the tet 
regulatory system to inhibit Pdx-1 expression in rat insulinoma cells. 
Impairment of Pdx-1 expression in INSrβ cells, which normally express insulin 
and show only an undetectable background of glucagon mRNA, severely 
increased glucagon mRNA levels and largely reduced Ins transcription. These 
results demonstrate that suppression of Pdx-1 expression leads to the 
differentiation of an insulin-predominant β-cell lineage to a glucagon-
predominant α-cell phenotype (Wang et al. 2001). 
The findings of the different studies lead to the assumption that chronic 
hyperglycaemia in placebo-treated mutant mice suppresses the development 
of β-cells and might increase the differentiation of glucagon expressing α-cells 
from common progenitor cells and possibly from existing β-cells via trans-
differentiation, which contributes to the altered ratio of β- to α-cells within the 
- 146 - 
endocrine compartment of the islets and results in the higher total volume of 
glucagon positive cells in the islets of placebo-treated mutants.  
 
The total volume of β-cells in insulin-treated mutants was about half that of 
wild-type mice and approximately twice that of placebo-treated mutants. It was 
demonstrated that long-term exposure to high glucose concentrations leads to 
β-cell apoptosis in isolated human islets (Federici et al. 2001; Maedler et al. 
2008), and studies in autopsies showed that type 2 diabetics exhibit a reduced 
volume density of β-cells in the pancreas and a decreased total β-cell mass 
compared to non-diabetic controls (Sakuraba et al. 2002; Butler et al. 2003; 
Cnop et al. 2005). Quantitative-stereological investigations of the pancreata of 
3-month-old (Herbach et al. personal communication) and 6-month-old mice 
(Herbach et al. 2007, this study) demonstrated a severe reduction of total  
β-cell volume in male heterozygous mutant mice with age, which suggests that 
duration and increase of hyperglycaemia lead to β-cell loss. Since in insulin-
treated mutants the total β-cell volume was higher compared to placebo-
treated mutants, but lower versus wild-type mice, chronically elevated blood 
glucose levels seem to be only one reason for the reduced β-cell mass in 
placebo-treated mutants. Long-term ER stress is probably another essential 
factor, leading to reduced total β-cell volume in insulin- and placebo-treated 
mutant mice, via programmed cell death. As described above, the transcription 
factor CHOP, which is associated with ER stress-induced apoptosis 
(Oyadomari et al. 2002b; Oyadomari and Mori 2003), was elevated in isolated 
islets of 100-day-old insulin- and placebo-treated mutant mice. In the Akita 
mouse it was shown that CHOP is involved in β-cell apoptosis of heterozygous 
Akita mice (Oyadomari et al. 2002b).  
Additionally to ER stress, reduced endogenous insulin secretion in insulin-
treated mutants might possibly contribute to the reduced total β-cell volume in 
the islets compared to wild-type mice. Insulin-treated mutants demonstrated 
reduced randomly fed and glucose-stimulated insulin secretion, probably 
leading to decreased auto- and paracrine effects of insulin on β-cells, as 
described above. Different studies demonstrated that insulin has anti-apoptotic 
and proliferative effects on MIN6 β-cells (Muller et al. 2006; Beith et al. 2008). 
Furthermore, knockout of the insulin receptor of pancreatic β-cells in mice 
(βIRKO mice), using the Cre-IoxP system, resulted in the development of 
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disturbed glucose tolerance, and some βIRKO mice became diabetic. Since 
not only diabetic but also non-diabetic βIRKO mice exhibited reduced β-cell 
mass at the age of 26 - 30 weeks, insulin-mediated signalling pathways seem 
to be essential to maintain pancreatic β-cell mass (Otani 2004).  
 
The total volume of β-cells within the pancreas of adult mice depends on the 
balance between β-cell apoptosis and regeneration of β-cells either by 
replication of β-cells within an existing islet or by differentiation of new β-cells 
from progenitor cells within pancreatic ducts (Butler et al. 2003; Bonner-Weir 
et al. 2008; Xia et al. 2009). It was stated that progenitor cells in the epithelium 
of pancreatic ducts can differentiate into insulin-producing β-cells and bud 
from the duct to form new islets, not only in neonatal, but also in adult mice 
(Bonner-Weir et al. 2008; Inada et al. 2008).  
The volume density and the total volume of isolated β-cells in the pancreas of 
insulin-treated mutant mice, were lower compared to wild-type mice and 
higher versus placebo-treated mutants, which leads to the assumption that 
reduced islet neogenesis might be one reason for the lower total islet and  
β-cell volumes of mutant mice.  
As described above, in placebo-treated mutants reduced Pdx-1 expression 
due to chronic and severe hyperglycaemia might be involved in the reduced 
differentiation of progenitor cells to β-cells, and therefore in the reduced total 
volume of isolated β-cells in the pancreas. In contrast to chronically elevated 
blood glucose levels, induction of severe hyperglycaemia for 48 hours via 
glucose infusion resulted in increased islet neogenesis in Wistar rats (Paris et 
al. 2003). Further, mild glucose infusion of male Sprague-Dawley rats for 96 
hours led to slightly elevated blood glucose levels and increased islet 
neogenesis versus rats infused with saline (Jetton et al. 2008). These findings 
lead to the assumption that positive or negative effects of glucose concerning 
islet neogenesis are dependent on the duration and severity of 
hyperglycaemia. Physiological short-term increase of blood glucose 
concentrations, for example after meal intake, is essential for DNA binding of 
the transcription factors PDX-1, MafA and NeuroD1 in β-cells (Andrali et al. 
2008), whereas long-term hyperglycaemia reduces PDX-1 DNA binding 
(Melloul 2004). Since PDX-1 plays an important role for the differentiation of 
progenitor cells to β-cells (Bonner-Weir et al. 2008), it seems likely that short-
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term elevation of blood glucose levels results in increased islet neogenesis, 
whereas long-term hyperglycaemia has contrary effects. In the prediabetic 
state and at the beginning of hyperglycaemia in humans, compensatory 
mechanisms result in increased β-cell mass, whereas long-term elevated 
blood glucose concentrations lead to reduced β-cell mass in diabetics (Weir et 
al. 2001; Butler et al. 2003; Cnop et al. 2005). These findings confirm that 
short-term elevated blood glucose levels increase β-cell mass and possibly 
islet neogenesis, whereas long-term hyperglycaemia has contrary effects. 
In insulin-treated mutants improved glucose control may therefore be 
responsible for the significantly higher total volume of isolated β-cells as 
compared to placebo-treated mutants. However, the total volume of isolated  
β-cells in insulin-treated mutants was reduced compared to wild-type mice. It 
was stated that increased insulin demand, for example due to reduced insulin 
action in obese humans and animal models, during pregnancy, and in the 
prediabetic period, results in compensatory increase of β-cell mass, via 
neogenesis, replication or hypertrophy (Weir et al. 2001; Yoon et al. 2003; 
Ahren 2005; Bouwens and Rooman 2005). In type 2 diabetics, in which the 
area density of islet β-cells in the pancreas was still unchanged, the area 
density of ductular β-cells in the pancreas was increased, indicating elevated 
islet neogenesis (Clark et al. 2001). This possibly suggests that the opposite, 
namely reduced insulin demand due to insulin treatment might contribute to 
lower islet neogenesis compared to wild-type mice.  
 
The replication rate of β-cells in placebo-treated mutants was higher compared 
to insulin-treated mutants and wild-type mice. The influence of glucose and 
insulin on β-cell replication is discussed controversially (Bouwens and 
Rooman 2005). In in vitro studies, it was demonstrated that exogenous insulin 
has proliferative effects on mouse β-cells (Beith et al. 2008) and insulin-
secreting MIN6 cells (Muller et al. 2006). In contrast, insulin infusion for 48 
hours resulted in over 60-fold increased plasma insulin levels and drastically 
reduced β-cell proliferation in Wistar rats (Paris et al. 2003). 
As described above, in the prediabetic period and at the beginning of 
hyperglycaemia compensatory mechanisms can lead to elevation of β-cell 
mass. However, mild glucose infusion of rats resulted in increased β-cell 
mass, whereas β-cell proliferation was unchanged for the first 36 hours and 
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afterwards was even lower compared to saline infused rats (Jetton et al. 
2008). Glucose infusion of Wistar rats for 48 hours led to largely increased 
blood glucose concentrations and reduced β-cell replication (Paris et al. 2003). 
Further, β-cell replication was demonstrated to be reduced after prolonged 
exposure of isolated islets to high glucose concentrations (Maedler et al. 2001; 
Maedler et al. 2002).  
Therefore, it seems surprising that β-cell replication was increased in placebo-
treated mutants compared to wild-type mice, especially since the total β-cell 
volume of placebo-treated mutants was largely decreased compared to wild-
type mice and insulin-treated mutants. 
However, since only about 0.1% of the β-cells were BrdU-positive and the 
replication rate was analysed at a single time point in the present study, it is 
difficult to accurately quantify replication rates (Donath and Halban 2004). 
 
The numerical fraction of TUNEL-positive β-cells was similar in the examined 
groups. However, the number of apoptotic β-cells was very low and showed 
substantial variation between the investigated mice. In the Akita mouse, whole 
islets were examined for apoptotic cells, using serial sections, and the number 
of TUNEL-positive β-cells was very low at the age of 4, 8 and 13 weeks (Izumi 
et al. 2003). The low number of TUNEL-positive cells results from the short 
duration of apoptotic events, and rapid clearance by macrophages, which 
makes it difficult to quantify programmed cell death (Weir et al. 2001; Izumi et 
al. 2003). Furthermore, the determination of apoptotic β-cells at a single time 
point can be an inaccurate representation of the real rate of programmed cell 
death in the analysed tissues (Donath and Halban 2004; Huerta et al. 2007). 
Thus, despite similar number of TUNEL-positive β-cells in the islets of insulin- 
and placebo-treated male Munich Ins2C95S mutants and wild-type mice, 
apoptosis may still account for the reduced total β-cell volume in mutant mice.  
At 90 days of age, the total β-cell volume was still similar in mutants versus 
wild-type mice (Herbach et al. unpublished data), therefore, β-cell loss occurs 
between 90 and 180 days of age in male Munich Ins2C95S mutants (Herbach et 
al. 2007). Thus, the determination of apoptotic cells at 160 days of age may be 
too late, since the total β-cell volume is already reduced up to ~70% compared 
to wild-type mice. 
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In conclusion, in placebo-treated mutants chronic hyperglycaemia and  
ER stress lead to the reduced total β-cell volume, most likely due to increased 
β-cell apoptosis, decreased β-cell differentiation and reduced islet neogenesis. 
Insulin treatment prevented hyperglycaemia-induced β-cell apoptosis and 
partially preserved β-cell regeneration in mutant mice. Since glucose levels 
are generally normalised in insulin-treated mutants, ER stress seems to be a 
main reason for the reduced total β-cell volume in the pancreas of insulin-
treated mutants compared to wild-type mice.  
5.1.5 Electron microscopic findings in β-cells 
Electron microscopy revealed that the different staining intensities of β-cells in 
the islets of the investigated groups, which were observed in sections 
immunostained for insulin, resulted from different densities of secretory 
granules within the β-cells. 
In placebo-treated mutants most of the β-cells were almost completely 
degranulated, whereas in β-cells of insulin-treated mutants the density of 
secretory granules was in general higher compared to placebo-treated 
mutants, but lower than in wild-type β-cells. The reduced density of secretory 
granules is in coincidence with the reduced pancreatic C-peptide content of 
mutant mice (see 5.1.1). 
The density of secretory granules within the β-cells depends on the rate of Ins 
transcription, insulin mRNA translation, (pro-)insulin processing and 
intracellular degradation of (pro-)insulin. Furthermore the relation between 
insulin production and insulin secretion must be considered. Since insulin-
treated mutants demonstrated significantly lower randomly fed and glucose-
stimulated C-peptide levels compared to placebo-treated mutants, lower 
insulin secretion seems to largely contribute to the higher density of secretory 
granules in insulin-treated mutants versus placebo-treated mutants.  
It is unknown if insulin-treated mutants exhibit a lower, equal or higher insulin 
biosynthesis compared to placebo-treated mutant mice. A reduced insulin 
production in insulin-treated mutants would lead to decreased protein folding 
load and to decreased biosynthesis of mutant (pro-)insulin 2, and therefore to 
reduced ER stress versus placebo-treated mutants. However, determination of 
ER stress markers in isolated islets (see 5.1.3) and electron microscopic 
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findings (see below) indicate that β-cells of insulin-treated mutants suffer from 
as much ER stress as those of placebo-treated mutant mice. 
In placebo-treated mutants, chronically high blood glucose concentrations and 
therefore oxidative stress may result in reduced Ins expression due to 
decreased insulin promoter binding activity of PDX-1 and other transcription 
factors, like MafA (Melloul et al. 2002; Melloul 2004; Andrali et al. 2008). Long-
term incubation of HIT-T15 cells in 11.1 mM glucose resulted in reduced  
PDX-1 and MafA DNA binding activity and in reduced insulin mRNA content 
as well as decreased insulin concentrations, which was partially prevented by 
co-incubation with antioxidants (Tanaka et al. 1999). Exposure of isolated rat 
islets to H2O2 for 48 hours led also to decreased PDX-1 binding activity and 
reduced insulin mRNA levels (Kaneto et al. 2002). In isolated islets of 8- to  
12-week-old Akita mice, total insulin mRNA levels were approximately 85 - 
90% that of wild-type mice, and mutant insulin was transcribed in similar 
degree as wild-type insulin (Wang et al. 1999).  
It was demonstrated that insulin stimulates its own expression via insulin 
receptor signalling (Leibiger et al. 1998; Melloul et al. 2002). In vitro studies 
with isolated pancreatic islets showed that exogenous insulin leads to 
increased proinsulin synthesis. Stimulation of insulin secretion via KCl also 
resulted in elevated proinsulin biosynthesis, and inhibition of insulin secretion 
via nifedipine reduced glucose-stimulated proinsulin biosynthesis. It was 
suggested that both, glucose and endogenous insulin secretion exert 
stimulatory effects on insulin biosynthesis, in an additive manner (Leibiger et 
al. 2000). Therefore, it seems possible that reduced endogenous insulin 
secretion in insulin-treated mutants contributes to decreased insulin 
biosynthesis. However, decreased insulin secretion in insulin-treated mutants 
has probably more effects on the density of secretory granules than a reduced 
insulin biosynthesis. 
In addition to the influence of glucose on Ins transcription, ER stress in islets 
of insulin- and placebo-treated mutants possibly leads to reduced insulin 
mRNA translation. It is known that ER stress can reduce mRNA translation via 
phosphorylation of eIF2α (Rajan et al. 2007), and in isolated islets of insulin-
treated mutants PeIF2α abundance was slightly increased compared to wild-
type mice. As described above, it was stated that mutant proinsulin 2 does not 
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seem to severely reduce protein synthesis in islets of Akita mice or CHO cells 
(Izumi et al. 2003), but PeIF2α was not analysed. 
In Akita mice it was demonstrated that misfolded and accumulated proinsulin 
was partially degraded via ERADI (Allen et al. 2004). Therefore it seems 
possible that, at least in part, misfolded (pro-)insulin might be also degraded in 
β-cells of insulin- and placebo-treated mutants, contributing to the reduced 
density of secretory granules. 
 
In some β-cells of placebo- and insulin-treated mutant mice, the ER seemed to 
be dilated and filled with electron dense material, as described in Akita mice 
(Wang et al. 1999; Zuber et al. 2004). The denotation of structures between 
the perinuclear ER and the Golgi apparatus varies substantially, including 
rough ER, transitional ER and pre-Golgi intermediates (Ghadially 1988; Fan et 
al. 2003; Zuber et al. 2004; Riggs et al. 2005). The dilated structures in the 
Akita mouse were denoted transitional ER  (Wang et al. 1999), ER-like 
structures (Izumi et al. 2003), and dilated rough ER and pre-Golgi 
intermediates (Zuber et al. 2004). The dilated structures of placebo- and 
insulin-treated Munich Ins2C95S mutant mice mostly represent dilated rough ER 
that is found throughout the cytoplasm and, to a lower degree, pre-Golgi 
intermediates, that are located in close association to the Golgi complex. The 
electron-dense material in the lumen may represent the accumulation of 
secretory proteins. In Akita mice it was shown by immunogold labelling that 
this electron dense material is composed of proinsulin (Zuber et al. 2004), and 
it is likely that proinsulin accumulation also occurs in ER-like structures of 
Munich Ins2C95S mutant mice. Dilated rough ER is thought to be an indicator of 
impairment of secretory pathways in the Akita mouse (Izumi et al. 2003) and 
ER distension was stated to be a characteristic of ER dysfunction (Scheuner 
and Kaufman 2008). Further, expansion of the ER was denominated as a 
characteristic of ER stress (Cnop et al. 2008; Malhotra et al. 2008). Dilated ER 
was also seen in other mouse models, exhibiting elevated ER stress markers, 
a disturbed ER stress response and/or intracellular accumulation of proteins, 
e.g. PERK knockout mice (Harding et al. 2001), βWfs knockout mice (Riggs et 
al. 2005), C57BL/6 mice overexpressing coagulation factor VIII, (Malhotra et 
al. 2008), Hsp47 knockout mice (Marutani et al. 2004). 
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In conclusion, the decreased density of secretory granules in β-cells of 
placebo-treated mutants compared to wild-type mice probably results from 
reduced Ins expression due to chronic hyperglycaemia and from the misfolded 
proinsulin 2, which probably accumulates in the ER and causes ER stress. In 
insulin-treated mutants, misfolded proinsulin 2 and ER stress may be mainly 
responsible for the lower density of secretory granules versus wild-type mice, 
and lower insulin secretion mainly accounts for higher granule density than in 
placebo-treated mutants.  
 
Electron microscopy demonstrated that in some β-cells of placebo-treated 
mutants the mitochondria appeared swollen, versus wild-type and insulin-
treated mutant mice. Oxidative stress can increase mitochondrial membrane 
permeability and alter the potential of the inner mitochondrial membrane 
(Kanwar et al. 2007). It was stated that altered membrane permeability leads 
to mitochondrial swelling and to cytochrome c release, thereby activating 
apoptotic mitochondrial pathways (Jiang et al. 2001; Zhang et al. 2008). 
Mitochondrial swelling was associated with oxidative stress e.g. in the retina 
(Kanwar et al. 2007) and the heart of of diabetic mice (Shen et al. 2004).  
ER stress can also alter the mitochondrial membrane permeability, lead to 
cytochrome c release and to apoptosis (Jimbo et al. 2003; Zhang et al. 2008). 
Swollen mitochondria were found in β-cells of different diabetic rodent models 
with β-cell loss, like the Akita mouse (Izumi et al. 2003), STZ-induced diabetic 
Wistar rats (Zhou et al. 2009) and diabetic Goto Kakizaki rats (Mizukami et al. 
2008).  
The lack of enlarged mitochondria in β-cells of insulin-treated mutants argues 
for chronic hyperglycaemia as main reason for mitochondrial swelling. Swollen 
mitochondria may be an early sign for apoptosis of the affected β-cells in 
placebo-treated mutants. 
 
Glycogen deposits, which appear as small rosettes of dark granules 
(Bendayan et al. 2007), were only found in β-cells of placebo-treated mutant 
mice. Glycogen accumulation in β-cells was also found in other diabetic 
animals, e.g. Psammomys obesus (Bendayan et al. 1995), dogs (Hoenig 
2002), or in glucose infused cats (Zini et al. 2009), and is associated with 
hyperglycaemia. 
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5.1.6 Body and organ weights 
Body weights of 160-day-old randomly fed placebo-treated mutants were 
significantly lower compared to wild-type mice. Due to increased food intake, 
the gastrointestinal contents were heavier in diabetic placebo-treated mutant 
mice compared to wild-type mice and insulin-treated mutants. Experiments 
with mice lacking insulin receptors in the brain (Brüning et al. 2000) or in the 
hypothalamus (Obici et al. 2002) showed that missing insulin signalling in the 
brain, especially in the hypothalamus can lead to hyperphagia, a symptom 
sometimes observed in diabetics (ADA 2006). The increased food intake in 
placebo-treated mutant mice is assumed to be also the reason for the elevated 
weight of the emptied GIT of placebo-treated mutants compared to wild-type 
mice and insulin-treated mutants. It was described that enteral nutrients lead 
to adaption of the intestine, especially in the mucosal layer (Tappenden 2006). 
Diabetic polyphagic Wistar rats, for example, exhibited elevated weight of the 
intestine despite lower body weight compared to non-diabetic Wistar rats, 
which was mainly due to increased mucosa thickness of the intestine (Zhao et 
al. 2003). 
When the GIT content was subtracted from the body weight, insulin-treated 
mutant mice were as heavy as wild-type mice and significantly heavier 
compared to placebo-treated mutants. Furthermore, insulin-treated mutants 
featured more fatty tissue compared to placebo-treated mutants, but less than 
wild-type mice.  
These findings mirror the anabolic effects of insulin. Insulin promotes glucose 
uptake, increases lipogenesis and reduces lipolysis in adipocytes (Blüher et al. 
2002; Nishino et al. 2007). In muscle cells, insulin mediates uptake of glucose 
and amino acids, increases glycogen synthesis, reduces proteolysis and 
increases protein synthesis (Kim et al. 2000; Fujita et al. 2006). Therefore, 
insulin treatment of mutant mice resulted in more fatty tissue and probably 
muscle mass, and consequently in higher body weight compared to placebo-
treated mutants. The reason for the reduced fatty tissue of insulin-treated 
mutants compared to wild-type mice is unclear, since insulin normally leads to 
increased lipogenesis (Blüher et al. 2002; Nishino et al. 2007) and insulin 
treatment in humans is often associated with weight gain (Hollander et al. 
2007; Raslova et al. 2007). 
- 155 - 
Testes weights of insulin-treated mutants and wild-type mice were similar, but 
higher as compared to placebo-treated mutants, which can be explained by 
insulin effects on the reproductive system. Male NIRKO mice, which 
demonstrate a knockout of the insulin receptor in the brain, featured reduced 
epididymal sperm content and decreased amounts of Leydig cells, which was 
associated with reduced plasma levels of luteinising hormone (LH) (Brüning et 
al. 2000). Hypogonadism, which is predominantly defined by reduced levels of 
testosterone, is also often observed in older men with type 2 diabetes (Corona 
et al. 2005; Kapoor et al. 2007). 
Liver weights of insulin-treated mutants and wild-type mice were similar, 
whereas placebo-treated mutant mice featured elevated liver weights. In 
patients with type 1 or type 2 diabetes, increased contents of triglycerides 
(liver steatosis) and glycogen deposits in hepatocytes (hepatic glycogenosis) 
can lead to hepatomegaly. Since hepatic glycogenosis is often seen in type 1 
diabetics with poorly controlled hyperglycaemia (Tomihira et al. 2004; Sayuk et 
al. 2007; Martocchia et al. 2008) and liver steatosis is absent in many lean 
type 1 diabetics (Torbenson et al. 2006), high blood glucose levels seem to be 
the main reason for hepatocellular glycogen deposits. Liver steatosis and 
hypertriglyceridaemia are frequently observed in obese type 2 diabetics 
(Toledo et al. 2006), and can be found in overweight patients with type 1 
diabetes (Sayuk et al. 2007). These findings indicate that liver steatosis is 
mainly associated with obesity and dyslipidaemia, and hepatic glycogenosis 
results predominantly from hyperglycaemia. Since glycogen deposits were 
found in the β-cells of placebo-treated mutants and these mice are non-obese, 
it is likely that hepatic glycogenosis is the main reason for hepatomegaly in 
placebo-treated mutants. Glycogen and fat staining of liver tissue would be 
necessary to confirm this assumption and to show if liver steatosis is present 
in placebo-treated mutants. 
Kidney weights of placebo-treated mutants were elevated compared to insulin-
treated mutants and wild-type mice. Renal hypertrophy is an early pathological 
manifestation of diabetic kidney disease, and chronic hyperglycaemia plays a 
major role in the development of diabetic nephropathy (Mahimainathan et al. 
2006; Forbes et al. 2007). Therefore it is possible that chronically elevated 
blood glucose concentrations lead to renal hypertrophy of placebo-treated 
mutants. Further analyses are necessary to investigate other possible 
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diabetes-associated kidney lesions, like glomerular hypertrophy and 
glomerulosclerosis, in placebo-treated mutants. 
 
In summary, the clinical investigations showed that insulin treatment of mutant 
mice in general normalised blood glucose concentrations, and improved oral 
glucose tolerance compared to placebo-treated mutants. Further, insulin 
treatment preserved insulin sensitivity, but did not ameliorate the disturbed 
glucose-stimulated insulin secretion. Insulin therapy of mutants led to 
increased pancreatic C-peptide content versus placebo-treated mutants and 
prevented changes in body and organ weights, which were detected in 
placebo-treated mutant mice.  
5.2 C-peptide II concentration in serum and pancreas of 
untreated male and female Munich Ins2C95S mutant and wild-
type mice 
Twenty-one-day-old homozygous mutant mice of both genders demonstrated 
severe randomly fed hyperglycaemia, whereas blood glucose concentrations 
of male and female heterozygous mutant mice were only slightly elevated 
compared to wild-type mice. The elevated blood glucose levels in mutant mice 
might be due to reduced insulin secretion and/or due to reduced receptor 
binding and biological activity of mutant insulin, as discussed above (5.1.1). 
The secretion of mutant insulin 2 was analysed by determining C-peptide II 
concentrations in the serum of 21-day-old male and female homozygous 
Munich Ins2C95S mutant mice. Randomly fed C-peptide II concentrations in the 
serum of heterozygous mutants of both genders were higher compared to 
those of sex-matched homozygous mutants and lower compared to those of 
wild-type mice. The reduced serum C-peptide II concentrations in mutant mice 
may be due to disturbed secretory pathways in β-cells of Munich Ins2C95S 
mutant mice (see 5.1.1) and/or due to the significantly reduced pancreatic  
C-peptide II content.  
The C-peptide II content in the pancreas of male and female heterozygous 
mutant mice was significantly reduced compared to sex-matched wild-type 
mice, but significantly higher than that of homozygous mutants. Similar 
observations were made in 14-day-old Akita mice (Kayo and Koizumi 1998). 
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Since 3-month-old heterozygous mutants exhibited a reduced density of 
secretory granules within the β-cells compared to wild-type mice, but an 
unchanged total volume of β-cells in the pancreas (Herbach et al. personal 
communication), it is likely that the reduced pancreatic C-peptide II content in 
21-day-old heterozygous mutants also results from a decreased density of 
insulin secretory granules, but not from a reduced total β-cell volume. In  
14-day-old homozygous Akita mice the total islet volume and the density of  
β-cells within the islets were largely reduced compared to heterozygous Akita 
and wild-type mice, leading to a reduced total β-cell volume (Kayo and 
Koizumi 1998). Therefore, the severely decreased C-peptide II content in the 
pancreas of homozygous Munich Ins2C95S mutant mice might be due to a 
decreased density of secretory granules within the β-cells and due to a 
reduced total volume of β-cells. 
The more severe diabetic phenotype in homozygous Munich Ins2C95S mutant 
mice versus heterozygous mutants, with largely reduced pancreatic and serum 
C-peptide II content, severe hyperglycaemia and reduced lifespan (Herbach et 
al. 2007; this study) mirror the dosage effect of mutant insulin, which is also 
found in Akita mice (Kayo and Koizumi 1998). 
Male and female homozygous mutants, as well as heterozygous mutant mice 
of both genders, demonstrated similar serum and pancreatic C-peptide II 
levels and similar blood glucose concentrations. These findings suggest that 
before sexual maturity, female mutants are as prone to become diabetic as 
male mutants, in contrast to adult animals. In several diabetic rodent models 
adult male mutants show a more severe diabetic phenotype than females, 
which seems to be associated with antidiabetic and antioxidative effects of 
estrogen (Louet et al. 2004; Le May et al. 2006). However, since sexual 
maturity in female mice does not occur before 28 days of age (Belle 2004) and 
the ovary is the major site for estrogen production (Lundholm et al. 2008),  
21-day-old females might have estrogen levels comparable to those of male 
mutants. Therefore, 21-day-old female mutants probably don’t demonstrate 
higher antioxidative defence mechanisms than male mutants, leading to the 
similar diabetic phenotype. In 14-day-old heterozygous and homozygous Akita 
mice pancreatic insulin content and morphological findings did not 
demonstrate gender differences, either (Kayo and Koizumi 1998), but female 
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heterozygous adult Akita mice exhibited a milder diabetic phenotype 
compared to male heterozygous Akita mice (Yoshioka et al. 1997).  
 
In conclusion, the secretion of mutant insulin 2 is possible, thereby confirming 
previous in vitro observations (Liu et al. 2005). The homozygous mutation of 
Ins2 results in a more severe diabetic phenotype compared to the 
heterozygous genotype, with earlier onset of diabetes and lower pancreatic 
and serum C-peptide II concentrations. Male and female mutants are affected 
in a similar manner, probably due to missing antidiabetic and antioxidative 
effects of estrogen in premature females. 
5.3 Additional investigations of untreated male and female 
Munich Ins2C95S mutant and wild-type mice 
In contrast to female heterozygous mutants, which demonstrated similar 
randomly fed body weights and only slightly elevated blood glucose 
concentrations compared to female wild-type mice, male heterozygous 
mutants developed reduced randomly fed body weights versus sex-matched 
wild-type mice and showed a progressive diabetic phenotype. These findings 
confirm the observations described in an earlier study (Herbach et al. 2007). 
The mild diabetic phenotype of female heterozygous mutant mice is probably 
due to antioxidative and antidiabetic effects of female sexual hormones, 
especially estrogen. Several tissues of female rats demonstrated higher 
antioxidant capacity compared to those of male rats (Katalinic et al. 2005). It 
was shown that induction of oxidative stress via streptozotocin injection 
caused loss of β-cells and reduced pancreatic insulin content in male wild-type 
mice, and estradiol deficient ArKO-/- mice of both genders, but not in female 
wild-type mice. Treatment with estradiol at physiological doses prevented  
β-cell loss in male wild-type and estradiol deficient ArKO-/- mice (Le May et al. 
2006). Further, in the Akita mouse, heterozygous male mutants exhibit a more 
severe diabetic phenotype than heterozygous female mutants (Yoshioka et al. 
1997), and this phenomenon was also described in other mouse models 
(Louet et al. 2004). The findings of the different studies confirm the 
assumption that antioxidative and antidiabetic effects of estrogen are the main 
reasons for the mild form of diabetes in female Munich Ins2C95S mutant mice. 
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Intraperitoneal insulin tolerance tests at different ages showed that only male 
heterozygous mutants develop insulin resistance, thereby confirming the 
results of the homeostasis model assessment of insulin resistance index 
(HOMA IR (%)) (Herbach et al. 2007). The HOMA indices were developed to 
assess β-cell function in human beings (Wallace et al. 2004; Lee et al. 2008). 
However, a linear correlation between insulin sensitivity, determined during 
hyperinsulinaemic euglycaemic clamp studies in insulin resistant mice, and the 
surrogate index HOMA IR was proven (Lee et al. 2008) and is also confirmed 
in this study. As described above (5.1.1), heterozygous male mutants 
developed insulin resistance due to chronically elevated blood glucose 
concentrations. The preserved insulin sensitivity of female mutant mice might 
be due to the mild hyperglycaemia compared to male mutants, and probably 
due to antioxidative effects of estrogen. It was demonstrated that estrogen 
exerts antioxidative effects in vivo by upregulating the expression of 
mitochondrial superoxide dismutase and glutathione peroxidase via binding to 
the estrogen receptor and activation of the MAPK pathway (Viña et al. 2005). 
Oxidative stress leads to insulin resistance, for example in myocytes and 
adipocytes, probably via phosphorylation of IRS on threonine or serine 
residues (Maddux et al. 2001; Evans et al. 2002; Houstis et al. 2006). 
Therefore, estrogen might contribute to the preserved insulin sensitivity in 
female mutants via its antioxidative effects. Estradiol treatment of 
ovariectomised STZ-induced diabetic rats, for example, improved insulin 
sensitivity compared to non-treated ovariectomised diabetic rats (Ordónez et 
al. 2007). The preserved insulin sensitivity in female Munich Ins2C95S mutant 
mice contributes to the mild and stable diabetic phenotype, compared to male 
mutants. 
 
Serum glucagon concentrations were determined randomly fed and after 
insulin injection at the age of 200 days, as well as fasted and after glucose 
challenge at the age of 230 days. 
Male heterozygous mutants demonstrated elevated randomly fed serum 
glucagon levels compared to sex-matched wild-type mice, whereas randomly 
fed glucagon levels of female heterozygous mutant and female wild-type mice 
were similar. Under physiological conditions, high blood glucose levels 
suppress glucagon secretion from α-cells (Quoix et al. 2009). However, α-cells 
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of both, type 1 and type 2 diabetics have a defective glucose sensing, leading 
to increased glucagon secretion despite elevated blood glucose levels 
(Dunning et al. 2005; Jacobson et al. 2009). The mechanisms contributing to 
the α-cell pathology are still largely unknown (Quesada et al. 2008). A 
disturbed glucose sensing in α-cells of male mutants explains the elevated 
glucagon levels compared to sex-matched wild-type mice, despite drastically 
increased blood glucose levels. Female mutants exhibited a mild diabetic 
phenotype which can explain unaltered α-cell sensing and glucagon secretion. 
The same is true for insulin-treated male heterozygous mutant mice (see 
5.1.1). 
Ten minutes after insulin injection, serum glucagon levels of male mutants 
decreased, whereas those of wild-type mice and female mutants increased. In 
wild-type mice and female mutants, which demonstrated unchanged insulin 
sensitivity, insulin injection resulted in decreasing blood glucose levels, in 
contrast to insulin resistant male mutants. Decreasing blood glucose 
concentrations physiologically stimulate glucagon secretion in α-cells (Dunning 
and Gerich 2007), whereas in type 1 diabetics and patients with advanced 
type 2 diabetes, this counter-regulation of α-cells is impaired (Cryer and Cryer 
2002). Therefore, decreasing blood glucose levels of wild-type mice and mild 
diabetic female mutants resulted in increasing glucagon secretion, whereas 
glucagon concentrations of male mutants didn’t increase.  
Fasted glucagon concentrations in mutant mice of both genders were similar 
to those of sex-matched wild-type mice. Diabetic patients regularly 
demonstrate elevated randomly fed serum glucagon levels and increased 
glucagon secretion after glucose challenge compared to healthy subjects 
(Dunning and Gerich 2007; Quesada et al. 2008). However, fasted glucagon 
concentrations may be similar or elevated versus non-diabetics (Gastaldelli et 
al. 2000; Bock et al. 2006; Abdul-Ghani and DeFronzo 2007). In the study of 
Abdul-Ghani and DeFronzo (2007), for example, the suppression of glucagon 
secretion in the oral glucose tolerance test was severely reduced in diabetics 
compared to non-diabetics, whereas the fasting glucagon levels were not 
significantly different.  
Ten minutes after glucose challenge, glucagon concentrations of wild-type 
mice decreased, whereas those of male and female mutant mice increased. 
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The decreasing glucagon secretion in wild-type mice is in coincidence with the 
inhibition of glucagon secretion by increasing blood glucose levels (Dunning et 
al. 2005; Quoix et al. 2009). Type 2 diabetics with severe hyperglycaemia also 
demonstrated a paradoxical stimulation of glucagon secretion in the OGTT 
(Ohneda et al. 1978; Dunning et al. 2005), which explains the increased 
glucagon secretion in male Munich Ins2C95S mutants.  
It was demonstrated that glucagon secretion is not only regulated by glucose, 
but also by paracrine factors like insulin. Physiologically increased blood 
glucose concentrations directly inhibit glucagon secretion of α-cells (Quoix et 
al. 2009), and stimulate insulin secretion (Andrali et al. 2008). Products of 
insulin secretion, like insulin and zinc, also inhibit glucagon secretion from  
α-cells in a paracrine manner (Dunning and Gerich 2007; Gromada et al. 
2007; Quesada et al. 2008). Treatment of isolated islets and isolated α-cells 
with insulin or zinc, reduced glucagon secretion independent of glucose 
(Franklin et al. 2005). Therefore, the defective glucose-stimulated insulin 
secretion 10 minutes after glucose challenge in female and male mutants 
(Herbach et al. 2007), might contribute to the missing inhibition of glucagon 
secretion in mutant mice despite increasing blood glucose levels. This could 
explain the increasing glucagon secretion after glucose challenge in female 
mutants, despite unchanged randomly fed glucagon concentrations.  
 
In conclusion, wild-type mice of both genders demonstrated physiological 
glucose sensing and glucagon secretion of α-cells, whereas severe 
hyperglycaemia in male mutants resulted in defective glucose sensing of  
α-cells, leading to randomly fed hyperglucagonaemia and increasing glucagon 
secretion after glucose challenge. Although female mutants featured 
unchanged randomly fed glucagon concentrations, glucagon secretion 
increased after glucose application, probably due to disturbed insulin 
secretion. 
5.4 Summary  
The present study demonstrated that hyperglycaemia-induced oxidative stress 
and ER stress are main reasons for the reduced total β-cell volume in male 
Munich Ins2C95S mutant mice. Furthermore, glycaemic control via insulin 
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treatment preserved insulin sensitivity and partially prevented β-cell loss. 
Therefore insulin resistance is most likely a mere consequence of 
hyperglycaemia, whereas β-cell loss is caused by both hyperglycaemia and 
ER stress in Munich Ins2C95S mutant mice. 
Both, development of insulin resistance and β-cell loss are involved in the 
development of type 2 diabetes in humans, and contribute to the progressive 
diabetic phenotype in Munich Ins2C95S mutant mice. 
Recently INS mutations in humans were described to cause permanent 
neonatal diabetes mellitus. Therefore, Munich Ins2C95S mutant mice provide an 
essential tool to further investigate the involvement of INS mutations in the 
development of diabetes mellitus, and to establish new treatment protocols. 
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6 Perspective 
The involvement of oxidative stress in the loss of functional β-cell mass and in 
the development of insulin resistance in heterozygous male Munich Ins2C95S 
mutant mice may be further analysed, via treatment of heterozygous male 
mutants with antioxidants, like N-acetyl cysteine, lipoic acid and/or vitamins E 
and C. 
In order to get more insights into the role of ER stress in the pathogenesis of 
diabetes mellitus and in the reduced total β-cell volume in male Munich 
Ins2C95S mutant mice, treatment of male heterozygous mutants with chemical 
chaperones, like 4-phenyl butyric acid or tauroursodeoxycholic acid, which 
increase ER folding capacity, would be useful. 
In contrast to male Munich Ins2C95S mutant mice, female heterozygous 
mutants show a mild diabetic phenotype and preserved β-cell mass (Herbach 
et al. 2007). Therefore, investigations with ovariectomised mutants would be a 
helpful approach to investigate the antidiabetic and antioxidative effects of 
female sexual hormones, especially estrogen. 
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7 Summary 
Mechanisms of β-cell loss in male Munich Ins2C95S mutant mice 
Loss of functional β-cell mass is one major factor contributing to the 
development of diabetes mellitus in humans. Recently, mutations in the insulin 
gene were described in patients exhibiting early onset diabetes with severe 
hyperglycaemia. Munich Ins2C95S mutant mice exhibit a point mutation in the 
insulin 2 gene, leading to diabetes mellitus and a profound loss of β-cells in 
male mutants. Aim of the present study was to investigate the mechanisms 
resulting in the reduced total β-cell volume of heterozygous male Munich 
Ins2C95S mutant mice. In order to analyse the involvement of chronic 
hyperglycaemia and oxidative stress in the pathogenesis of β-cell loss, blood 
glucose concentrations of one group of male mutants were normalised via 
subcutaneous insulin-pellets. Placebo-treated mutants and wild-type mice 
served as controls. Several clinical parameters were examined, including 
randomly fed blood glucose concentration, oral glucose tolerance, insulin 
sensitivity, as well as serum and pancreatic C-peptide levels. Furthermore, 
oxidative stress was analysed in the serum, and ER stress markers were 
investigated in isolated pancreatic islets. Qualitative-histological and 
quantitative-stereological analyses of the pancreas were performed, and β-cell 
apoptosis as well as β-cell replication were determined. Additionally, secretion 
of mutant insulin 2 was investigated in untreated homozygous and 
heterozygous mutants of both genders, and compared to sex-matched wild-
type mice.  
Insulin treatment generally normalised blood glucose concentrations of mutant 
mice, whereas placebo-treated mutants exhibited a progressive and severe 
diabetic phenotype. Insulin-treated mutant mice demonstrated improved oral 
glucose tolerance, preserved insulin sensitivity and increased pancreatic  
C-peptide content compared to placebo-treated mutant mice, whereas insulin 
treatment did not ameliorate the disturbed glucose-stimulated insulin secretion 
in mutant mice. Normalising blood glucose concentrations of insulin-treated 
mutants inhibited oxidative stress, and resulted in higher total islet and β-cell 
volume as well as higher volume density of β-cells in the endocrine 
compartment of the islets as compared to placebo-treated mutants. 
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Furthermore, the total volume of isolated β-cells, which indicate islet 
neogenesis, was increased in insulin-treated mutants compared to placebo-
treated mutant mice. However, insulin-treated mutants demonstrated a lower 
volume density of β-cells in the endocrine compartment of the islets, as well as 
lower total islet, β-cell, and isolated β-cell volumes than wild-type mice, 
showing that insulin treatment reduced, but did not completely prevent β-cell 
loss in mutant mice. Ultrastructural changes in the β-cells of mutant mice were 
less distinct in insulin-treated mutants than in placebo-treated mutants. In 
both, insulin- and placebo-treated mutant mice, the abundance of the ER 
stress marker CHOP was increased compared to wild-type mice. Furthermore, 
electron dense material accumulated in the dilated endoplasmic reticulum of 
mutant mice, suggesting ER stress.  
In conclusion, insulin treatment prevented hyperglycaemia-induced loss of 
functional β-cell mass in male Munich Ins2C95S mutant mice, but did not 
completely preserve total β-cell volume, suggesting that β-cell loss is in part 
caused by ER stress. 
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8 Zusammenfassung 
Mechanismen des β-Zell-Verlustes bei männlichen Munich Ins2C95S 
Mausmutanten 
Der Verlust funktioneller β-Zell-Masse ist einer der Hauptfaktoren, die zur 
Entstehung von Diabetes mellitus beim Menschen beitragen. Vor kurzem 
wurden Mutationen im Insulin-Gen von Patienten beschrieben, die einen früh 
einsetzenden Diabetes mellitus mit starker Hyperglykämie zeigten. Munich 
Ins2C95S Mausmutanten weisen eine Punktmutation im Insulin 2 Gen auf, die 
zu Diabetes mellitus und bei männlichen Mutanten zu schwerwiegendem 
Verlust von β-Zellen führt. Ziel dieser Studie war es, die Mechanismen zu 
untersuchen, die zum verminderten Gesamt-β-Zell-Volumen von 
heterozygoten männlichen Munich Ins2C95S Mausmutanten führen. Um die 
Beteiligung von chronischer Hyperglykämie und oxidativem Stress an der 
Pathogenese des β-Zell-Verlustes zu analysieren, wurde bei einem Teil der 
männlichen Mutanten der Blutzuckerspiegel mittels subkutaner Insulin-Pellets 
normalisiert. Placebo-behandelte Mausmutanten und Wild-Typ-Mäuse dienten 
als Kontrolle. 
Verschiedene klinische Parameter wurden untersucht, einschließlich der 
freigefütterten Blutglukosekonzentration, der oralen Glukosetoleranz, der 
Insulinsensitivität, sowie der C-Peptidkonzentrationen im Serum und im 
Pankreas. Des Weiteren wurden das Serum bezüglich oxidativem Stress 
untersucht und ER-Stress Marker in isolierten pankreatischen Inseln 
analysiert. Qualitativ-histologische und quantitativ-stereologische 
Untersuchungen der Bauchspeicheldrüse wurden durchgeführt und β-Zell-
Apoptose sowie β-Zell-Replikation bestimmt. Zusätzlich wurde die Sekretion 
des mutierten Insulin 2 an unbehandelten homozygoten und heterozygoten 
Mutanten beiderlei Geschlechtes untersucht und mit gleichgeschlechtlichen 
Wild-Typ-Mäusen verglichen. 
Die Insulinbehandlung hat die Blutglukosekonzentrationen von Mausmutanten 
im Allgemeinen normalisiert, wohingegen Placebo-behandelte Mutanten einen 
progressiven und scherwiegenden diabetischen Phänotyp aufwiesen. Insulin-
behandelte Mausmutanten zeigten eine verbesserte orale Glukosetoleranz, 
eine erhaltene Insulinsensitivität und einen höheren C-Peptidgehalt im 
- 167 - 
Pankreas als Placebo-behandelte Mausmutanten, wohingegen die 
Insulinbehandlung die Glukose-stimulierte Insulinsekretion in Munich Ins2C95S 
Mausmutanten nicht verbessert hat. Die Normalisierung der 
Blutglukosekonzentrationen von Insulin-behandelten Mausmutanten 
verhinderte die Entstehung von oxidativem Stress und führte zu einem 
höheren Gesamt-Insel- und Gesamt-β-Zell-Volumen sowie zu einer höheren 
Volumendichte von β-Zellen im endokrinen Teil der Inseln verglichen mit 
Placebo-behandelten Mausmutanten. Darüber hinaus war das 
Gesamtvolumen an isolierten β-Zellen, welche auf Inselneogenese hinweisen, 
in Insulin-behandelten Mutanten höher im Vergleich zu Placebo-behandelten 
Mausmutanten. Allerdings wiesen Insulin-behandelte Mutanten eine geringere 
Volumendichte an β-Zellen im endokrinen Teil der Inseln sowie geringere 
Gesamtvolumina an Inseln, β-Zellen und isolierten β-Zellen als Wild-Typ-
Mäuse auf. Dies zeigt, dass die Insulinbehandlung den β-Zell-Verlust in 
Mausmutanten reduzierte, aber nicht vollständig verhinderte. Ultrastrukturelle 
Veränderungen in den β-Zellen von Mausmutanten waren in Insulin-
behandelten Mutanten weniger deutlich ausgeprägt als in Placebo-
behandelten Mutanten. Sowohl in Insulin- als auch in Placebo-behandelten 
Mausmutanten war die Abundanz des ER-Stress Markers CHOP im Vergleich 
zu Wild-Typ-Mäusen erhöht. Des Weiteren akkumulierte elektronendichtes 
Material im dilatierten Endoplasmatischen Retikulum von Mausmutanten, was 
auf ER-Stress hindeutet.  
Schlussfolgerung: Die Insulinbehandlung verhinderte den Hyperglykämie-
induzierten Verlust der funktionellen β-Zell-Masse in männlichen Munich 
Ins2C95S Mausmutanten, konnte aber den β-Zell-Verlust nicht vollständig 
aufhalten. Dies deutet darauf hin, dass der β-Zell-Verlust zum Teil durch  
ER-Stress verursacht wurde. 
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10 Appendix 
10.1 List of abbreviations 
ATF activating transcription factor 
BiP binding Ig protein  
C/EBP CCAAT/enhancer binding protein 
CAT catalase 
CHO Chinese hamster ovarian  
CHOP C/EBP homologous protein 
CoQ10 coenzyme Q10 
eIF2 eucaryotic initiation factor 2  
ENU N-ethyl-N-nitrosourea 
ER endoplasmic reticulum  
ERAD ER-associated degradation 
ERO1 ER oxidoreductase 1 
ERSE ER stress response element  
FFA free fatty acid  
GADD growth arrest and DNA damage 
GR glutathione reductase 
GRP glucose regulated protein  
Grx glutaredoxin 
GSH reduced glutathione  
GSH-Px glutathione peroxidase  
GSSG oxidised glutathione  
IFNγ interferon-γ 
IL interleukine 
IPF insulin promoter factor 
ipITT intraperitoneal insulin tolerance test 
IR insulin receptor  
IRE1 inositol requiring 1  
IRS insulin receptor substrate  
JNK C-Jun NH2 terminal kinase 
LA α-lipoic acid  
MAPK mitogen-activated protein kinase  
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MEF mouse embryo fibroblast  
MnSOD manganese superoxide dismutase  
MODY maturity-onset diabetes of the young 
NAC N-acetyl cysteine  
NDM neonatal diabetes mellitus 
NF-κB nuclear factor-κB 
Nrf nuclear respiratory factor 
OGTT oral glucose tolerance test 
PDI protein disulfide isomerase 
PeIF2α phosphorylated eIF2  
PERK double-stranded RNA-activated protein kinase like endoplasmic 
reticulum kinase 
PKC protein kinase C 
PNDM permanent neonatal diabetes mellitus 
ROS reactive oxygen species 
SOD superoxide dismutase 
STZ streptozotocin 
TBARS thiobarbituric acid reactive substances 
UPR unfolded protein response 
UPRE unfolded protein response element 
XBP-1  X-box binding protein-1 
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10.2 Assay procedures 
10.2.1 Radioimmunoassay (RIA) 
10.2.1.1 C-peptide 
C-peptide concentrations in the serum and pancreas were determined by a 
Rat C-Peptide RIA Kit (Linco Research, USA). The assay was performed 
using half amount of sample and assay reagents as denoted in the instruction 
sheet. Pancreas homogenate was diluted 1:1,000 (wild-type mice), 1:400 
(insulin-treated mutant mice) and 1:100 ( placebo-treated mutant mice ) in 
PBS. 
 
On the first day, 150 µl of assay buffer were filled into the non-specific binding 
tubes (tube 3, 4) and 100 µl into the reference tubes (tube 5, 6). The remaining 
tubes (tube 7 onwards) were loaded with 50 µl assay buffer. Fifty µl of 
standards and quality controls were pipetted in duplicate into tube 7-24. The 
same amount of sample was added to the rest of the tubes. After adding 50 µl 
of rat C-peptide antibody into tube 5 onwards, the tubes were vortexed, 
covered with parafilm and incubated overnight (4°C, 22 hours). 
The next day 50 µl of 125I-rat C-peptide tracer were added to all tubes. 
Subsequently, the tubes were vortexed, covered with parafilm and incubated 
overnight (4°C, 22 hours). 
Half a ml of cold precipitating reagent (4°C) was pipetted into all tubes, except 
total count tubes (tube 1, 2) on the third day. After vortexing, covering and 
incubating (20 minutes, 4°C) the tubes, they were centrifuged (Megafuge 1.0 
R, HERAEUS Sepatech, Germany; 20 minutes, 3,000 x g, 4°C). The 
supernatant was decanted from tube 3 onwards by inverting them and draining 
them for 60 seconds. Serum C-peptide concentrations were determined by a 
gamma counter (LB 2111, BERTHOLD TECHNOLOGIES, Germany) within  
1 minute. Calculation was run by the program Berthold-MULTI-WELL 
(BERTHOLD TECHNOLOGIES, Germany). 
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Materials: 
Materials were components of the assay kit. 
 
Assay buffer:
 Phosphosaline 0.05 M, pH 7.4 
 EDTA 0.025 M 
 Sodium azide 0.08% 
 RIA grade BSA 1% 
 
Guinea pig anti-rat C-peptide antibody: 
 diluted in assay buffer 
 
125I-rat C-peptide tracer: 
 HPLC purified, lyophilised 
Hydrate with label hydrating buffer 30 minutes before use while mixing gently 
once in a while. 
 
Label hydrating buffer:  
 Assay buffer containing normal guinea pig serum as carrier 
 
Rat C-peptide standards: 
 purified recombinant rat C-peptide diluted in assay buffer 
 25, 50, 100, 200, 400, 800 and 1,600 pM 
 
Quality controls 1 and 2: 
 purified recombinant rat C-peptide  diluted in assay buffer 
 
Precipitating reagent:  
 Goat anti-guinea pig IgG 
 PEG 3%  
 Triton X-100 0.05% 
 Phosphosaline 0.05 M 
 EDTA 0.025 M 
 Sodium azide 0.08% 
 
10.2.1.2 Glucagon 
Serum glucagon levels were analysed by a Glucagon RIA KIT (Linco 
Research, USA), using half the reaction batch volumes.  
The procedure of this RIA is similar to the one of the Rat C-Peptide RIA Kit 
(Linco Research, USA; 10.2.1.1 C-peptide). Compared to the C-Peptide RIA 
the Glucagon RIA comprises two standards less. It utilises Glucagon Antibody 
and 125I-Glucagon tracer to analyse serum glucagon concentration. 
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Materials: 
Materials were components of the assay kit. 
 
Assay buffer: 
 Glycine 0.2 M, pH 8.8 
 EDTA 0.03 M 
 Sodium azide 0.08% 
 RIA grade BSA 1% 
 
Guinea pig anti-glucagon antibody: 
 diluted in assay buffer 
 
125I-glucagon tracer: 
 HPLC purified, lyophilised 
hydrate with label hydrating buffer 30 minutes before use while mixing 
gently once in a while 
 
Label hydrating buffer: 
 Assay buffer containing glycine as carrier 
 
Glucagon standards: 
 Glucagon diluted in assay buffer  
 20, 50, 100, 200 and 400 pg/ml 
 
Quality controls 1 and 2: 
 purified recombinant glucagon diluted in assay buffer 
 
Precipitating reagent: 
 Goat anti-guinea pig IgG   
 PEG 3%  
 Triton X-100 0.05% 
 Phosphosaline 0.05 M 
 EDTA 0.025 M 
 Sodium azide 0.08% 
 
10.2.2 C-peptide II ELISA 
A Mouse C-Peptide II ELISA (KAMIYA, USA) was used to determine the  
C-peptid II concentrations in serum and pancreas. Pancreas homogenates 
were diluted 1:20 (wild-type mice) and 1:10 (heterozygous and homozygous 
mutants) with distilled water. 
 
The C-peptide II calibrator solutions were prepared by diluting the 100 ng/ml 
calibrator solution 1 to 3 with buffer solution. The serial dilution was repeated 5 
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times attaining the following standards: 100, 33.33, 11.11, 3.704, 1.235, 0.412 
and 0 ng/ml. Twenty-five µl of the particular standard or sample were filled into 
the wells of a goat anti-rabbit IgG antibody-coated plate. Afterwards, 100 µl of 
labelled antigen and 50 µl of C-peptide II antibody were added. The plate was 
covered with a plate seal and incubated for 17 hours at 4°C.  
The next day, the plate was placed on a plate rotator for 1 hour at room 
temperature. After removing the seal and washing the wells 3 times with wash 
solution (320 µl per well), 100 µl of SA-HRP solution were pipetted into each 
well. The plate was covered with a plate seal and incubated on a plate rotator 
(1 hour, room temperature). After washing 5 times with wash solution, 100 µl 
of substrate solution were added, the plate was covered with a seal and 
incubated for 30 minutes at room temperature. Finally, 100 µl of stop solution 
were filled into the wells to stop the colour reaction. The optical absorbance 
was determined at 492 nm, using the microplate reader SUNRISE (Tecan, 
Germany). C-peptide II concentrations were calculated via the computer 
program Magellan 2 (Tecan, Germany). 
Materials: 
Materials were components of the assay kit. 
 
Antibody-coated plate: 
 96 well microtiter plate, ready to use 
 
C-peptide II calibrator (lyophilised):  
 add 1 ml buffer solution to the vial and vortex to obtain 100 ng/ml  
 calibrator solution 
 
Labelled antigen (lyophilised): 
 Biotinylated mouse C-peptide II 
 add 12 ml Buffer Solution to the vial, vortex 
 
Buffer solution: 
 Phosphate buffer, ready to use 
 
C-peptide II antibody: 
 Rabbit anti-mouse C-peptide II, ready to use 
 
SA-HRP solution: 
 HRP (horse radish peroxidase) labelled streptavidin, ready to use 
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OPD tablet: 
 o-Phenylenediamine dihydrochloride 
 
Substrate buffer: 
 Hydrogen peroxide 0.015% 
 
Substrate solution: 
 dissolve one OPD tablet in 12 ml substrate buffer  
 (immediately before use) 
 
Stop solution: 
 H2SO4 1 M, ready to use 
 
Wash solution concentrate: 
 Concentrated saline 
 add 50 ml wash solution concentrate to 1,000 ml distilled water 
 
Plate seal: 3 sheets 
10.2.3 Thiobarbituric Acid Reactive Substances (TBARS) 
Lipid peroxidation in the serum was analysed using a TBARS Assay Kit® 
(Cayman, USA). Serum was diluted 1:1 with HPLC grade water. 
 
The 8 Malondialdehyde (MDA) standards (0-50 pM) were obtained pipetting 
the adequate amount of MDA and HPLC grade water into glass tubes. One 
hundred µl of standard or sample were filled into labelled 12 ml polypropylene 
screw-cap centrifuge tubes. Subsequently, 100 µl of the SDS solution were 
pipetted into each tube, tubes were vortexed, and 4 ml of colour reagent were 
added. After boiling in a water bath (GFL, Germany; 1 hour), the tubes were 
incubated for 10 minutes on ice in order to stop the reaction. The tubes were 
centrifuged (4K15C centrifuge, Sigma, Germany; 10 minutes, 1,600 x g, 4°C), 
and 150 µl supernatant were pipetted into a 96 well plate. Standards were 
pipetted in duplicate. The absorbance was read by a microplate reader 
(SUNRISE, Tecan, Germany) at 532 nm. Concentrations of TBARS expressed 
as MDA equivalents were calculated, using the program Magellan 2 (Tecan, 
Germany). 
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Materials: 
Materials were components of the assay kit, except for HPLC grade water 
 
Colour reagent: for each standard or sample: 
 Acetic acid: 2 ml 
 Thiobarbituric acid powder: 21.2 mg 
 Sodium hydroxide: 2 ml 
 
Acetic acid: 
 Acetic Acid, stock solution: 40 ml 
 HPLC grade water: 160 ml 
 
Sodium hydroxide : 
 Sodium hydroxide, stock solution (x10): 20 ml 
 HPLC grade water: 180 ml 
 
Thiobarbituric acid powder (2 g) 
 
SDS solution, ready to use 
 
Malondialdehyde standard (500 µM): 
 Standard solutions (0.000, 0.625, 1.25, 2.5, 5, 10, 25, 50 pM) were 
 prepared according to the manufacturer’s manual 
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